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 Genome-wide association studies (GWAS) have identified thousands of genetic loci associated 
with cardiometabolic traits including type 2 diabetes (T2D), lipid levels, body fat distribution, and adiposity, 
although most causal genes remain unknown. We used subcutaneous adipose tissue RNA-seq data from 
434 Finnish men from the Metabolic Syndrome in Men (METSIM) study to identify 9,687 primary and 
2,785 secondary cis-expression quantitative trait loci (eQTL; <1 Mb from transcription start site, false 
discovery rate FDR<1%). Compared to primary eQTL signals, secondary eQTL signals were located 
further from transcription start sites, had smaller effect sizes, and were less enriched in adipose tissue 
regulatory elements compared to primary signals. Among 2,843 cardiometabolic GWAS signals, 262 
colocalized by linkage disequilibrium (LD) and conditional analysis with 318 transcripts as primary and 
conditionally distinct secondary eQTLs, including some across ancestries. Of cardiometabolic traits 
examined for adipose tissue eQTL colocalizations, waist-hip ratio (WHR) and circulating lipid traits had 
the highest percentage of colocalized eQTLs (15% and 14%, respectively). Among alleles associated with 
increased cardiometabolic GWAS risk, approximately half (53%) were associated with decreased gene 
expression level. Mediation analyses of colocalized genes and cardiometabolic traits within the 434 
individuals provided further evidence that gene expression influences variant-trait associations. We 
further quantified exons and splice junctions to identify cis-exon-level eQTLs and cis-splice eQTLs 
(sQTLs). Using pathway analysis, we identified 46 pathways that potentially affect the transcriptional 
program of adipose tissue, including several that impact mRNA splicing, lipid droplet formation, and 
inflammation. Among the sQTLs, we identified 104 variants associated with 132 splice junctions found in 
74 genes colocalized with cardiometabolic GWAS loci. Further, we highlighted plausible mechanisms for 
two novel splice junctions in ALDH3A2 and NR1H3 that may impact oxidative stress and cholesterol 
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homeostasis. These results identify hundreds of candidate genes and mechanisms that may act in 
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CHAPTER 1: INTRODUCTION 
 
Cardiometabolic traits and GWAS 
Cardiovascular disease (CVD) and type 2 diabetes (T2D) present a substantial cost and public 
health burden in the US and worldwide1,2. In the United States, cardiovascular disease affects about 
121.5M people and will cost the US an estimated 680 billion dollars in 20203. An estimated 26M 
Americans are living with Type 2 diabetes and about 101.2M are undiagnosed or have prediabetes3. 
Cardiovascular disease and T2D share a cluster of risk factors, sometimes called metabolic syndrome, 
that are thought to contribute to disease progression4,5. These risk factors include obesity and body fat 
distribution, measured by body mass index (BMI) and waist-to-hip ration (WHR), circulating lipid levels, 
such as high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and 
triglycerides, and clinical measures of glycemic traits, such as fasting insulin, proinsulin, and glucose6. 
Risk factors for cardiometabolic diseases are heritable7–9 and are themselves complex traits, meaning that 
numerous genes are involved in the development of these clinical phenotypes. The complexity of these 
diseases and traits requires genome-wide efforts to detect the many genetic loci that contribute to 
disease etiology and progression.  
Genome wide association studies (GWAS) provide an unbiased approach to identify variants that 
are associated with clinical traits and diseases10. To date, GWAS have identified thousands of variant-trait 
associations for cardiometabolic diseases and risk factors, such as CVD, T2D, WHR, circulating lipid 
levels and others11–15. Many of these GWAS associations include multiple distinct associations within a 
region16, henceforth referred to as signals. These signals can be separated from each other using 
statistical methods like step-wise conditional analysis or GCTA17 but are not necessarily fully 
independent. In a recent T2D GWAS meta-analysis, variants at 243 loci were associated with disease, 




European ancestry GWAS studies have had the largest sample sizes for complex traits, but GWAS of 
other ancestries, particularly East Asian ancestry, are rapidly increasing in sample size. This expansion is 
critical, because allele frequency can differ substantially between populations with different ancestries, 
resulting in changes in the lead variant(s) or even novel signals18.  
While GWAS have identified regions of the genome that may influence the trait of interest, they 
do not provide evidence for which gene or genes are altered by the signal, or identify the mechanism of 
action. The identity of the putative genes and mechanisms at these loci is valuable because candidate 
genes could be analyzed biochemically to assess their effects on traits and disease and could eventually 
be used as potential targets for pharmaceutical interventions. To name these loci, some GWAS 
investigators attempt to identify a plausible biological candidate gene in the surrounding region but many 
simply name the locus after the nearest gene due to the high volume of signals detected genome-wide.  
While a fraction of GWAS variants change the coding sequence of proteins, the majority of 
variants found in these analyses are non-coding and have unknown function10. One common hypothesis 
is that noncoding variants may influence clinical traits by altering the expression of nearby genes. Since 
gene expression levels have been found to be highly heritable19,20, one of the many methods have been 
proposed to focus on the plausible candidate genes is mapping expression quantitative trait loci 
(eQTLs)21. This method uses the gene expression, assayed via microarray or RNA-sequencing, and 
genotypes from the same samples to perform association testing, ordinarily using linear regression, and 
identify eQTLs.  
 
Expression Quantitative Trait Loci (eQTLs) and RNA-sequencing 
An eQTL signal consists of one or more variants and a gene. For ease of use, eQTLs are 
sometimes counted by the number of genes significantly associated with at least one variant. Genetic 
variants that are significantly associated with genes are sometimes called eSNPs and their counterpart 
genes are sometimes called eGenes. eQTLs are detected locally (termed cis-eQTLs and which we define 
as within 1Mb of the transcription start site [TSS] of the gene) and distally (termed trans-eQTLs and 
defined as either >1 Mb or >5 Mb away from the TSS). Distal eQTLs identify genetic variants which 
influence the expression level of transcripts that are located distally on the same chromosome or on other 
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chromosomes. Distal eQTLs also commonly have a local association between the lead variant and a 
transcript encoding a transcription factor or other molecule that may modulate the expression level of 
other genes. Power to detect trans-eQTLs is still limited given current sample sizes due to multiple testing 
burden and modest effect sizes, especially when compared with model organisms22. Both cis- and trans-
eQTL associations have been reported across many tissue types23. Like GWAS associations, eQTL 
studies can identify multiple distinct associations in a region, by conditional analysis. Primary eQTLs are 
the associations identified without any conditional analysis, and all subsequent signals are called 
conditional eQTLs. Studies have shown that conditional eQTL signals are common genome-wide23 and 
their associated lead variants are farther away from the TSS than primary eQTL signals24. Allelic 
heterogeneity, a process by which multiple variants act through a gene on a trait, may account for the 
‘missing heritability’ observed at GWAS loci25, rendering the inclusion of conditional eQTL in current and 
future studies vital. 
 Since changes in exon usage have been linked to important biological processes26–28, identifying 
the exons and splices present in tissue is critical to understanding the active pathways. RNA-sequencing 
provides the opportunity to capture differences in exon usage by estimating the read counts on the splice 
junction and exon level in addition to gene-level counts (Figure 1.1).  Gene-level counts combine all reads 
that map to the gene of interest based on outside gene annotation, such as GENCODE29 or RefSeq30. 
These gene-level annotations frequently include different transcript types, such as protein-coding, long 
non-coding RNAs, pseudogenes, and others. By contrast, exon counts estimate the proportion of reads 
that fall within a specific exon31,32. Notably, Odhams et al. identified more genes involved in eQTL 
associations on the exon-level than on the gene-level33. Splice junction counts are based on the number 
of reads that span the exon junction, providing specific evidence of skipped exons34. Splice junction 
counts can then be adjusted for gene-level expression to mitigate the effect of gene level variation from 
splice junction eQTL (sQTL) detection34. Previous studies have identified and evaluated sQTLs or exon-
level eQTLs in lymphoblastoid cell lines33 and cultured fetal retinal pigment epithelium cells35 as well as 
whole blood36,37, adipose38, and brain tissue from the dorsolateral prefrontal cortex39,40. The Genotype-
Tissue Expression (GTEx) project has also detected sQTLs across 9 tissue types41. Further application of 




Adipose tissue and gene expression 
Adipose tissue is involved in a wide variety of cardiovascular and metabolic processes, including 
angiogenesis42 and blood pressure43, body weight homeostasis and appetite regulation44, and insulin 
sensitivity and glucose homeostasis45,46. Adipocytes expand to store excess lipids, buffer lipid energy 
balance45,47, and release adipokines to regulate energy levels48. Subcutaneous adipose tissue in 
particular has been suggested to play a protective role in metabolic risk49. Adipose tissue can also buffer 
energy balance by expanding either the size of individual adipocytes or by forming new adipocytes; larger 
adipocytes have been linked to insulin resistance45,46, while proliferation of adipocytes confers lower risk. 
While an estimated 94% eQTLs are shared across two or more tissues50, some are tissue-specific due to 
the expression pattern of the gene, necessitating the study of tissues closely connected to disease 
etiology and progression. 
 Prior efforts have been made to identify the expression profile of subcutaneous adipose tissue 
and the variants that alter expression of genes and splices. Many studies have identified cis-eQTLs in 
adipose tissue51–55. Among these, several have compared adipose tissue with other metabolically active 
tissues such as liver and skeletal muscle53–55. Gamazon et al. identified adipose-specific eQTLs by 
comparing with other tissues within GTEx55. Studies have also mapped trans- eQTLs in adipose tissue, 
discovering several potential master regulators51–53,56,57. Small et al. identified a trans-eQTL signal 
originating at the KLF14 locus on chromosome seven in subcutaneous adipose tissue from the MuTHER 
cohort (n=776 healthy female twins)57. Civelek et al. extended the gene network of KLF14 to 55 genes, 
identified a novel trans-eQTL at ZNF800, using subcutaneous adipose tissue from 770 Finnish men from 
the METSIM study52. Recently, Small et al. expanded the set of genes associated with KLF14 to 385, 
including a subnetwork regulated by SREBF157. The GTEx Consortium found that subcutaneous adipose 
shared the most sQTL signals with whole blood and the least with lung and ventricular heart. Ma et al., 
used six tissues from GTEx, including subcutaneous adipose, to identify sQTLs affecting the FTO locus.  
Differences in sample size, participant characteristics such as population and sex, data collection, and 
analysis methods between these studies have led to some differences between the discovery of cis- and 
trans-eQTLs on the gene-level as well as sQTLs.  
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Deconvolution and cell-type heterogeneity 
 Bulk tissue expression analysis presents a unique set of challenges to isolating gene expression 
profiles, such as contamination from other tissues or heterogeneity of expression between different cell-
types native to the tissue of interest. Subcutaneous adipose tissue itself is heterogeneous and contains 
native cell-types, such as adipocytes, preadipocytes, and endothelial cells, as well as infiltrating 
macrophages, which enter adipose tissue as part of the inflammatory processes surrounding obesity58,59. 
Additionally, the type of biopsy can contribute heterogeneity to the sample, with needle biopsies providing 
more potential for blood cell contamination than other methods60. Due to these challenges, deconvolution 
methods have been proposed to detect and remove contaminated samples to improve data quality or to 
attempt to isolate the signals of specific sub-populations of cells61–63. Deconvolution analyses can also be 
used to adjust for the cell-type component of the signal to allow more heterogeneous samples to be 
compared. Recently, Glastonbury et al. noted that adjustment for known and unknown factors that 
influence gene expression, using PEER or similar software, is sufficient to reduce the variability for 
reliable detection of gene-level cis-eQTLs64. However, studies with the goal of ascertaining a signal’s cell-
type of origin require more careful deconvolution methods.  
 
Colocalization of GWAS and eQTL signals  
 The mere presence of an eQTL within a GWAS region does not necessarily indicate that the 
eQTL gene is implicated as a potential candidate gene for the effect of this genomic region on a clinical 
trait. An estimated 78% of genes genome-wide have at least one variant associated with their expression 
level36, suggesting genetic variants affect expression level of essentially all genes. GWAS variants may 
be associated with eQTL genes, sometimes called eGenes, due to low or moderate linkage disequilibrium 
(LD) with the lead eQTL variant. Linkage disequilibrium is a pattern of inheritance in which the observed 
frequency of genetic variants being inherited together differs from the expected frequency at which the 
variants would be inherited together at random. Due to LD, a GWAS variant may be significantly 
associated with expression level of the eQTL gene, but not among the variants that have the strongest 
effect on gene expression (Figure 1.2). To ensure that GWAS and eQTL signals do not coincide by 
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chance alone, colocalization methods are applied to formally test whether the GWAS and eQTL represent 
the same signal. 
Numerous colocalization methods have been proposed, using both Bayesian and frequentist 
statistical models65–71. Some colocalization methods require access to primary genotypes and gene 
expression levels, while others require only summary-level data from both the GWAS and eQTL studies, 
that are often made publicly available. All of these methods are somewhat sensitive to the priors and 
assumptions 65,72, thresholds for significance, or to the presence of multiple signals66. Colocalization is 
further complicated due to changes in allele frequency when comparing eQTL studies of smaller sample 
size to large GWAS meta-analyses with heterogeneity of sample size from variant to variant and by 
comparing eQTLs of one ancestry to GWAS in another.  
Several studies have identified cis-eQTLs that colocalize with GWAS loci for T2D, WHR, BMI, 
and other cardiometabolic traits51–54. Civelek et al. found evidence of 140 eQTLs colocalized with 109 
cardiometabolic GWAS traits52. The STARNET study compared cardiometabolic disease GWAS loci to 
eQTLs from seven vascular and metabolic tissues, including subcutaneous and visceral adipose tissue 
(n=600 patients with coronary artery disease) and found substantial overlap between adipose tissue and 
blood lipid phenotypes54. Sajuthi et al. mapped eQTLs in adipose and muscle tissue from 260 non-
diabetic African Americans and found cis-eQTL associations with more than 54 genes at GWAS loci for 
T2D and obesity53. Gamazon et al. found enrichment of adipose-specific cis-eQTLs for diastolic blood 
pressure GWAS signals in GTEx (version 6)55. Additional GWAS-eQTL colocalizations may be detected 
by using larger eQTL sample sizes and different methods of measuring gene expression, as well as by 
analyzing additional GWAS loci. 
 
Expression-trait associations and mediation analysis 
 Measured clinical traits within the eQTL study population present the opportunity to detect 
associations between gene expression and cardiometabolic risk factors. These relationships can be 
detected by applying linear regression to the gene and trait levels. For cardiometabolic traits, however, 
inclusion of BMI as a covariate presents a challenge, since the levels of approximately half of all genes 
expressed in adipose tissue are associated with BMI52. This may introduce the potential for collider bias, 
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because BMI is also associated with other clinical traits and included as a covariate for traits like WHR, 
fasting glucose, and fasting insulin. Collider bias occurs when an artificial association is introduced due to 
both the exposure (gene) and the outcome (trait) associating with a third variable, in this case, BMI73. 
When interpreted with appropriate consideration of collider bias, gene-trait association can help to 
elucidate the genes that are associated with clinical traits. 
Mediation analyses incorporate genetic variants to perform a more sophisticated test for the effect 
of a variant on a trait level through gene expression level. Mediation analyses with individual level data for 
variant, trait and expression level is rare, because very few eQTL studies have been performed with 
tissue from individuals that have extensive clinical traits measured. Evidence of mediation can provide 
additional statistical support for the involvement of candidate genes in the modulation of traits, particularly 
at colocalized GWAS and eQTL signals.  
 
METabolic Syndrome in Men (METSIM) Study 
 The METSIM cohort is a population study of 10,197 Finnish men (ages 45-73) with the goal of 
examining the genetic and nongenetic factors that influence T2D, CVD, and related risk factors74. To 
address these goals, the METSIM investigators collected whole blood for genotyping and exome-
sequencing, subcutaneous adipose tissue for RNA-sequencing and DNA methylation, and extensive 
clinical phenotypes, including body fat distribution, CVD risk factors, glycemic, and lipid traits. 
Subcutaneous adipose tissue was collected via needle-biopsy from near the umbilicus within three 
months of the initial clinical phenotyping. A previous microarray study has been conducted with a subset 
of the METSIM cohort (n=770) to measure expression in adipose tissue52. The RNA-sequencing study of 
434 Finnish men presented here is also a subset of METSIM, with 331 samples shared with the prior 
microarray study. RNA-sequencing provides a greater dynamic range than microarray expression 
measurements, allowing for finer resolution of relative expression level among very lowly and highly 
expressed transcripts75, and the ability to quantify transcripts or portions of transcripts that are not yet 
annotated, such as novel splice junctions34.  
In the following chapters, I describe the analysis of subcutaneous adipose tissue gene expression 
levels from 434 participants in the METSIM study. In Chapter 2, I describe primary and secondary eQTLs 
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and characterize these different sets for transcript types, distance to TSS, and enrichment in promoters 
and enhancers. I describe colocalizations between cardiometabolic GWAS loci and gene-level eQTL 
signals, including cross-ancestry analysis and complex loci that consist of multiple GWAS and eQTL 
signals. I also incorporate clinical trait data from the same samples to assess the potential for these 
candidate genes to mediate the relationship between genetic variants and cardiometabolic traits. In 
Chapter 3, I describe many of the same analyses using splice junctions to define sQTLs. In that chapter, I 
describe an example of a complex locus that includes nine GWAS signals for four traits, two eQTL 
signals, and an sQTL. The sQTL is for a novel splice junction, not previously annotated in GENCODE, 
and I demonstrate the validity of this mapping and predict the functional consequence of the splicing 
event on HDL cholesterol levels. In Chapter 4, I summarize and compare the findings from both studies, 





Figure 1.1: Assignment of reads for different quantification methods: Read counts in RNA-
sequencing can be quantified on different levels.  For each model (gene-, exon-, and splice-level), the 
reads overlapping different features are shown (left) and the resulting read counts are shown (right).  
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Exon-level Expression
Exon 3 counts: 5
Exon 4 counts: 3
Exon 5 counts: 6
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Figure 1.2: Colocalization between GWAS and eQTL signals: This is a model of colocalization at a 
GWAS signal (top, dark blue). The lead GWAS variant has a significant association with expression level 
of both Gene D (center) and Gene C (bottom). However, the eQTL signal for Gene D does not match the 
pattern of association at the GWAS signal, and the GWAS variant is not among the peak of variants with 
the strongest association with Gene D’s expression level. By contrast, the eQTL signal for Gene C does 
match the pattern of association at the GWAS signal, and the eQTL peak variants align with the GWAS 




CHAPTER 2: ADIPOSE TISSUE GENE EXPRESSION ASSOCIATIONS REVEAL 
HUNDREDS OF CANDIDATE GENES FOR CARDIOMETABOLIC TRAITS1 
 
Introduction 
Excess adipose tissue, especially in central abdominal depots, is associated with increased 
cardiometabolic risk76,77 and mortality78. Subcutaneous adipose tissue expands to store additional lipids 
and serves as a buffering system for lipid energy balance, especially for fatty acids45,47, providing a 
protective role in metabolic risk49. However, expansion of adipocyte size, rather than formation of new 
adipocytes has also been linked to insulin resistance45,46. 
Genome-wide association studies (GWAS) have identified thousands of loci for hundreds of 
human traits, but most functional variants, genes affected by variants, and mechanisms remain elusive. 
Identification of genetic variants associated with gene expression level (eQTLs) in relevant tissues has 
proven useful to link non-coding GWAS variants to plausible candidate genes that may influence complex 
traits50. While 94% of eQTLs are shared across at least two tissues50, some are specific to one tissue or a 
subset of tissues, necessitating the study of tissues that potentially contribute to GWAS traits to identify 
candidate genes. 
Recently, eQTL studies have begun to identify additional eQTL signals through conditional 
analysis23,24,79 in addition to the more commonly reported primary eQTLs. These additional conditionally 
distinct secondary eQTL signals are widespread and located more distal than primary signals from the 
transcription start sites of the associated genes23,24. The additional eQTL signals have also been shown 
to colocalize with GWAS loci24, suggesting that they can detect additional candidate genes.  
                                                   
1 This chapter previously appeared in the American Journal of Human Genetics. The original citation is as 
follows: Raulerson, C. K. et al. Adipose Tissue Gene Expression Associations Reveal Hundreds of 




Previous studies have identified adipose tissue cis-eQTLs and tested for colocalizations of eQTL 
signals with cardiometabolic GWAS loci52,54,80,81. Additionally, GWAS have reported colocalized 
subcutaneous adipose cis-eQTLs with loci for body mass index (BMI), waist-hip ratio (WHR), WHR 
adjusted for BMI (WHRadjBMI), type 2 diabetes (T2D), circulating lipid levels, and adiponectin, a hormone 
produced by adipocytes that regulates glucose levels and fatty acid breakdown12,15,82–84. However, 
colocalization presents its own challenges, particularly when the GWAS and eQTL studies are from 
different ancestries or when multiple, conditionally distinct signals exist.  
Here, we describe the analysis of subcutaneous adipose tissue gene expression levels from 434 
participants in the METabolic Syndrome in Men (METSIM) study. METSIM participants have been well 
characterized for detailed clinical phenotypes, including metabolic and cardiovascular traits such as 
plasma lipids, anthropometric, and glycemic traits74. We identified and characterized primary and 
secondary cis-eQTL genes that colocalize with GWAS loci for BMI, cholesterol and triglyceride levels, 
WHR and WHRadjBMI, T2D, adiponectin, cardiovascular endpoints, and other cardiometabolic traits. We 
further associated gene expression level with cardiometabolic trait levels in the METSIM cohort and 
identify the genes that show the strongest evidence of mediating the variant to trait associations. 
 
Methods 
METSIM study participants and sample characteristics 
METSIM is a population-based cohort composed of 10,197 males of Finnish ancestry from 
Kuopio, Finland74. For this analysis, we used a subset of 550 participants from whom subcutaneous 
adipose tissue had been collected near the umbilicus by needle biopsy. The METSIM study was 
approved by the Ethics Committee of the University of Eastern Finland and Kuopio University Hospital in 
Kuopio, Finland and carried out in accordance with the Helsinki Declaration. Written informed consent 
was obtained from all participants. 
Genotypes were measured using the Illumina OmniExpress BeadChip array and the Illumina 
HumanCoreExome at the Center for Inherited Disease Research (Baltimore, MD). Genotyping quality 
control (QC) and imputation to the Haplotype Reference Consortium (HRC) panel85 have been previously 
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described52. For this study, we filtered HRC-imputed genotypes to retain 7.8 million variants with minor 
allele frequency (MAF)>0.01 and imputation quality, r2>0.3. 
 
RNA extraction and sequencing 
Following the adipose tissue biopsies, total mRNA was isolated using the Qiagen miRNeasy kit 
(Qiagen, Hilden, Germany), following the manufacturer’s instructions. mRNA was isolated with a polyA+ 
selection protocol (Illumina TruSeq RNA Sample Preparation Kit v2) and sequenced on the Illumina 
HiSeq 2000 platform at the University of California Los Angeles Neuroscience Genomics Core (UNGC) to 
an average sequencing depth of 45 million paired-end 50 bp reads.  
Reads were filtered using the Fastx-toolkit requiring 80% of bases to have phred quality > 20. 
Reads containing linker and adapter sequences were removed using TagDust (see URLs). We 
implemented STAR (version 2.4.2a)86 to align reads to the hg19/GRCh37 human genome reference 
sequence87, using GENCODE v19 (July 2013 freeze) as the annotation. Duplicate reads were retained. 
Read pairs with unpaired alignments were removed. The average uniquely mapped reads across all 
samples was 82.2%.  
To ensure RNA samples were matched with the correct genotypes, we applied MixupMapper88, 
verifyBamID89, and GATK best practice guidelines (see URLs) to call variants from RNA-seq data and 
assign best matches between the RNA-seq and genotype data. We retained samples that matched DNA 
genotypes corresponding to the expected self-sample for at least one method.  
 
Expression quantification and sample level QC  
To identify fragments mapping to transcript isoforms, we used Salmon (version 0.7.2)90 and 
provided GENCODE v19 as annotation; to correct for bias in isoform abundance estimates due to 
technical biases resulting from GC content, we used the --gcBias option. Isoform abundances were 
collapsed to the gene-level, and transcript per million (TPM) values were calculated using tximport 
(version 1.0.3)91. To remove genes with limited evidence of expression, we retained genes with ³ 5 reads 
in > 25% of samples, resulting in using 21,735 genes of 57,821 for cis-eQTL analysis.  
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To assess the tissue heterogeneity of tissue samples, we used the unmix function in DESeq263 to 
estimate the percent composition of whole blood, Epstein Barr virus (EBV)-transformed lymphocytes, 
skeletal muscle, and subcutaneous adipose, using Genotype-Tissue Expression (GTEx) v7 median TPM 
values per tissue as reference55. We examined the expression of adipose-specific genes in three sample 
sets: all samples (n = 550) and the subsets comprised of samples with approximately >50% adipose 
composition (n = 434) and > 75% adipose composition (n = 387). 
 
eQTL mapping 
To adjust for the known and unknown technical factors that influence gene expression estimates, 
we inverse normal transformed gene-level TPMs and implemented probabilistic estimation of expression 
residuals (PEER)92 and inverse normal transformed again, since both PEER and eQTL detection require 
data in a normal distribution. To optimize for cis-eQTL discovery, we performed PEER analysis including 
differing numbers of factors (k = 10 to 90) at intervals of 10. We next performed cis-eQTL detection using 
FastQTL (v2.184)93 on all variants within 1Mb of the TSS of each gene and assessed the total number of 
cis-eQTLs and the number of genes associated with ³ 1 variant with various PEER factor values. We 
selected 60 PEER factors to maximize the number of cis-eQTLs identified. We next implemented 
FastQTL permutation testing to estimate adjusted p-values and calculated the P-value corresponding to 
1% FDR using the qvalue package in R (P < 9.6 ´ 10-6) to account for genome-wide eQTL testing of 
variants within 1Mb of each transcript and determine the significance threshold. 
To identify conditionally distinct cis-eQTLs, we first identified all genes with ³ 1 significantly 
associated variant at FDR < 1% and the lead variant for each of these genes. We then included the 
dosage values of the lead variant for each gene as a covariate for eQTL mapping using FastQTL. 
Conditional secondary eQTLs were considered significant at FDR < 1% for primary cis-eQTLs (P < 9.6 ´ 
10-6). 
To identify trans-eQTLs, we removed 3,182 pseudogenes94 and genes with low mappability as 
these have been observed to increase false positives in distal eQTL analyses36. We implemented 
RSeQC95 to calculate transcript integrity number (TIN)96, the distribution of deletions across reads, and 
the distribution of inserted nucleotides across reads from BAM files. We inverse normal transformed the 
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gene expression for 18,553 remaining genes and adjusted for TIN, batch, age, insert size, deletion 
distribution, and either 0 or 3 PEER factors prior to analysis. To avoid collider bias, we used limited PEER 
factors in trans-eQTL mapping. Using QTLtools (v1.1)32, we performed association tests for variants > 1 
Mb away from the transcription start site (TSS); the significance threshold for identifying trans-eQTLs was 
calculated using the Bonferroni correction (P < 3.4 ´ 10-13).  
 
eQTL validation 
For validation, we compared eQTLs with the significant eQTLs from the GTEx Project V7 release 
for both subcutaneous (n = 385) and visceral adipose tissue (n = 313). For variant-gene pairs available in 
both files, we matched the effect alleles to compare the of direction of effect. To ensure that groups of 
variants associated with the same gene did not inflate replication estimates, we limited this analysis to the 
lead variants for each gene in either METSIM or GTEx. We used the lead variant for each gene from one 
study and assessed whether that variant was significant for the same gene in the other study. We then 
counted the number of variant-gene pairs that showed a consistent direction of effect and met several 
different P-value thresholds between 5 ´ 10-3 and 5 ´ 10-8 in both studies.  
 
eQTL enrichment in adipose tissue open chromatin and Roadmap adipose nuclei chromatin states 
We compiled a set of adipose tissue transcriptional regulatory elements from tissue-derived adipose 
nuclei chromatin states from the Roadmap Epigenomics Consortium97 and METSIM adipose tissue 
accessible chromatin regions98 generated using an Assay for Transposase-Accessible Chromatin (ATAC-
seq)99. For Roadmap chromatin states, we used the 18 state chromatin model and selected promoter 
states (1_TssA, 2_TssFlnk, 3_TssFlnkU, 4_TssFlnkD, 14_TssBiv) and enhancer states (7_EnhG1, 
8_EnhG2, 9_EnhA1, 10_EnhA2, 11_EnhWk, 15_EnhBiv).  We defined adipose tissue accessible 
chromatin regions as the union of ATAC-seq peaks across three METSIM subcutaneous adipose 
samples98. We also tested for enrichment among the subsets of ATAC-seq peaks that overlapped 
Roadmap adipose nuclei promoters and enhancers97, requiring that a peak be completely contained 
within the epigenomic region. We pruned eQTL variants based on linkage disequilibrium (LD, r2 > 0.2) 
using swiss to prevent variants in nominal LD with each other from inflating enrichment estimates. We 
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selected background variants using GREGOR100; variants were matched on allele frequency, distance to 
gene, and LD (r2 > 0.8 1000 Genomes phase 1, in a 1 Mb window). Background variants were then 
pruned with swiss using the same parameters as for significant eQTLs. We removed background variants 
that were themselves significant eQTLs at FDR < 1% (primary or secondary signals) or that were in high 
LD (r2 > 0.8) with an eQTL lead variant (primary or secondary signals). We tested for enrichment using 
logistic regression, regressing the eQTL status of a variant (1 = significant eQTL, 0 = not eQTL), against 
whether that variant overlapped a given genomic annotation (1 = overlapped, 0 = not overlapped). An 
eQTL or background variant was considered to overlap a genomic annotation if it or any of its LD proxies 
(r2 > 0.8, 1000 Genomes phase 1) overlapped the annotation. Enrichment was defined as the beta of the 
regression model, which is the log of the odds ratio that a variant is an eQTL if it overlaps the given 
genomic annotation.  
 To compare the effect sizes of eQTL signals that overlap various genomic annotations, we used 
the lead eQTL variant and all variants in high LD (r2 > 0.8) to identify overlaps with promoters, enhancers, 
and ATAC-seq peaks, stratified by primary and secondary eQTLs.  We then used the effect size of the 
lead variant of the overlapping eQTLs to test for differences in the strength of effect among different 
annotations using a Wilcoxon rank sum test. 
 
Selection of GWAS loci and GWAS-eQTL colocalization 
We downloaded the NHGRI-EBI GWAS catalog101 in December 2017 and extracted 4588 GWAS 
variants associated with one or more of 93 cardiometabolic traits (Table 2.8) at genome-wide significance 
(P < 5 ´ 10-8) and then added results from five additional large GWAS studies for cardiometabolic traits12–
15,102. To ensure that GWAS variants representing the same signal did not inflate colocalization estimates, 
we performed LD pruning using swiss (see URLs) across all traits; variants were ranked by P-value, and 
variants in LD r2 ³ 0.8 in METSIM with the lead variant at each locus were removed. We defined the 
GWAS risk allele as the variant associated with a disease state or with the higher quantitative trait level, 
except for adiponectin and high-density lipoprotein (HDL) cholesterol levels, for which we defined the risk 
effect allele as associated with a lower trait level as these indicate poorer health outcomes. 
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We performed initial colocalization analysis based on LD between a lead GWAS variant and a 
lead eQTL variant. We then performed conditional analysis in the eQTL data by providing genotypes for 
the lead GWAS variant to FastQTL as a covariate. We considered signals to be colocalized if: (i) the 
pairwise LD was high between the GWAS variant and eQTL variants (r2 ³ 0.8 in METSIM), and (ii) after 
conditioning on the GWAS variant, the lead eQTL variant no longer met the 1% FDR equivalent P-value 
(P > 9.6 ´ 10-6).  
For eQTLs that appeared colocalized with GWAS signals based on LD, we applied coloc224 to 
further assess evidence of colocalization. Coloc2 is a Bayesian method that uses summary statistics to 
test whether variants underlying a signal are shared between two studies. For each gene, we included all 
variants located within 1 Mb of the TSS for which summary statistics were available in both the GWAS 
and eQTL studies. Coloc2 estimates the posterior probabilities of five hypotheses concurrently (H0, no 
association signal in either the GWAS or eQTL; H1, only the GWAS has an association signal; H2, only 
the eQTL has an association signal; H3, both datasets have an association signal, but they are not the 
same; H4, the GWAS and eQTL associations signals are colocalized). To make our results more 
comparable with prior colocalization studies, we set prior probabilities for coloc2 to values comparable to 
coloc’s66 default settings, rather than allowing the software to generate its own priors. We used coloc’s 
default priors for p1 and p2, the prior probabilities that a variant is causal for either GWAS or eQTL 
respectively (p1 and p2 = 1 ´ 10-4) We set p12, the prior probability that a variant is causal to both GWAS 
and eQTL, to 1 ´ 10-6.  We selected this more conservative value than coloc’s default p12 prior (1 ´ 10-5) 
because we are using coloc to provide additional support for conditional analysis results based on LD and 
conditional analysis. We evaluated the posterior probabilities that correspond to H3 and H4, that both the 
GWAS and the eQTL have signals, but that they are not the same (PP3) and that the GWAS and eQTL 
signals colocalize (PP4), respectively. We considered the signals to have strong evidence of 
colocalization if PP4 > 0.8. 
 
Trait-gene expression association  
For 287 genes that showed evidence of GWAS signal colocalization with a primary eQTL signal 
based on LD and conditional analysis, we tested for association between gene expression level and each 
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of the 20 cardiometabolic traits measured in the 434 individuals (for a list of traits, see Tables 2.15 and 
2.16). We adjusted traits for age and gene expression level for TIN, sequencing batch, and age. 
Following inverse normal transformation of both trait and expression level residuals, we used linear 
regression to test for association between the gene expression levels and traits. Because adipose 
expression level of a large number of genes is associated with BMI, we also performed these analyses 
additionally adjusting both gene expression levels and traits for BMI. The P-value corresponding to 5% 
FDR was calculated using the qvalue package in R. 
 
Mediation analysis  
Mediation analyses were conducted in 434 METSIM individuals using a procedure described by 
Imai et. al103, similar to that of Huang et al.104, implemented in R and C++, assuming an additive effect 
and modified for a continuous outcome. We performed mediation analyses only when the eQTL and 
GWAS data were colocalized and trait data for the GWAS trait itself or a similar trait was available for 
METSIM individuals, specifically testing fasting glucose, fasting insulin, Matsuda index, and HOMA-β for 
T2D. We determined the effect of a variant on a trait through the mediator of gene expression, the effect 
of the variant on the trait when the mediator is held constant, and the combined effect, which is the sum 
of the mediation and variant-trait effects. This method uses two least squares regression models, where 
the first model uses the variant genotype, coded as 0, 1, or 2, as the predictor and the mediator of gene 
expression as the response, and the second model uses both gene expression level and variant 
genotype as predictors and the trait outcome as the response. The mediation effect was estimated by the 
product of coefficients from the two linear regression models. We assumed that the individual effects 
were linear and that there is not an interactive effect between the variant and mediator on the outcome. 
Confidence intervals for the mediating effect were calculated using Monte Carlo simulations. We set ! =
0.05 and calculated 95% confidence intervals corresponding to a possible range for the estimates of the 







Analysis of tissue heterogeneity 
To identify cis-eQTLs for subcutaneous adipose tissue, we performed RNA-seq on needle biopsy 
samples obtained from 550 Finnish men in the METSIM study (Table 2.1). Adipose tissue is comprised of 
adipocytes, pre-adipocytes, endothelial cells, and various immune cells58,59, and needle biopsies of 
adipose tissue can include whole blood and/or muscle. The resulting heterogeneity between samples can 
confound the analysis of bulk tissue transcriptomics105–107, but its effects can be mitigated by tissue 
deconvolution methods. We estimated tissue composition using tissue from GTEx as reference tissue 
profiles (Figure 2.1). We found wide variation in the estimated percentage of adipose tissue within our 
samples. To determine whether to limit the analysis to higher purity samples or to retain the larger sample 
size including lower quality samples, we compared eQTL results from the set of all 550 samples to 
subsets of samples with estimated adipose tissue percentage of approximately >50% (n=434) and >75% 
(n=387). For all three sample sets, we performed cis-eQTL analyses with a range of PEER factor 
corrections using 7.8M variants and 21,735 genes. We then compared the strength of association at three 
previously described adipose eQTL loci52,80 and counted the total number of variant-gene associations 
observed (Tables 2.2, 2.3). The known eQTLs showed the strongest associations within the >50% 
adipose subset (Table 2.3). The 50% adipose subset also had the most significant cis-eQTL variants 
(1.6M vs. 1.5M and 1.4M, 50%, all, and 75% sample sets, respectively) and the most variant-gene pairs 
(3.0M vs. 2.8M and 2.5M, 50%, all, and 75% sample sets, Table 2.2). These results suggest that the 
heterogeneity between samples in the full sample set of 550 samples and the smaller sample size of the 
387 samples with >75% adipose attenuated the association signals and that requiring samples to 
contain >50% adipose tissue (n=434) yielded a set of cis-eQTL results that best correspond to adipose 
tissue; thus, we performed all subsequent analyses using the subset of 434 samples. 
eQTL identification and characterization 
We performed genome-wide cis-eQTL analyses using ~7.8 million genetic variants (MAF > 0.01) 
from the 434 samples with >50% adipose tissue and 21,735 genes. Of these, 9,687 genes were 
associated with at least one variant located within 1 Mb of the TSS (FDR < 1%, P < 9.6 ´ 10-6). The first 
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and second PEER factors correlated with TIN96 and estimated percent adipose tissue, respectively 
(Figure 2.2).  
To examine the validity of our results, we compared the METSIM subcutaneous adipose tissue 
eQTL results to those from the GTEx project’s subcutaneous (n=385) and visceral (n=313) adipose eQTL 
analyses. Overall, GTEx detected fewer cis-eQTLs (FDR<5%) than METSIM (Table 2.4). At a 
significance threshold of P < 5 ´ 10-5, which meets the FDR <5% threshold in both studies, 4,442 (95.4%) 
and 3,370 (96.4%) of the lead eQTL variants identified in METSIM also showed significant associations 
with the same gene and in a consistent direction of effect in the GTEx subcutaneous and visceral adipose 
data, respectively. Combined, these results demonstrated consistency of the METSIM subcutaneous 
adipose tissue eQTLs with GTEx eQTLs.  
Secondary association signals are frequently identified at eQTL loci and may reflect more 
complex gene regulation23,24. Of 9,687 genes that exhibited primary eQTL signals, 2,785 genes (28.7%) 
showed a significant secondary cis-eQTL (FDR < 1%, P < 9.6 ´ 10-6). The proportions of transcript types 
with primary and secondary cis-eQTLs were not significantly different from each other (&2 P = 0.42, Figure 
2.3A). Secondary eQTLs have been reported to be located farther away from the TSS than primary 
eQTLs23,24. We also observed this pattern; the distribution of distances to TSS for secondary eQTLs 
(median=40.3 kb) was significantly higher than for primary eQTLs (median=26.7 kb, Mann Whitney U-
test, P < 2.2 ´ 10-16; Figure 2.3B). The identification of secondary eQTL signals in subcutaneous adipose 
tissue greatly expanded the set of cis-eQTL signals for available further investigation.  
To characterize the potential function of the primary and secondary eQTL signals, we evaluated 
the enrichment of and effect sizes of the lead variant and LD proxies compared to adipose nuclei 
chromatin states (promoters, enhancers) defined by the Roadmap Epigenomics Project97 and METSIM 
adipose tissue open chromatin as measured by ATAC-seq98. Lead variants of primary eQTL signals were 
more enriched in open chromatin, promoters, and enhancers than matched control variants, especially in 
open chromatin regions within promoters (P < 2 ´ 10-308; β = 2.83). Secondary eQTL variants showed a 
similar but weaker pattern of enrichment in all categories, even for a matched number of eQTL genes 
(Table 2.5; Figure 2.3C). Further, effect sizes for primary eQTL variants were significantly larger than 
those of secondary eQTL variants found within promoters and enhancers, (Wilcoxon rank sum test, P = 
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4.3 ´ 10-131; Figure 2.3D). Including both primary and secondary eQTL variants, effect sizes of variants 
within promoters were significantly larger than variants within enhancers (P = 8.1 ´ 10-12; Figure 2.4), and 
effect sizes of variants within open chromatin in promoters were significantly larger than promoter variants 
generally (P = 3.2 ´ 10-5). We observed no significant difference in the effect sizes between variants 
within open chromatin in enhancers and all enhancer variants. These results indicate that eQTL variants 
within promoters, particularly those in open chromatin, have larger effects on expression levels of nearby 
associated genes than those variants in enhancers.  
To identify variants that influence the expression of distal genes and contribute to regulatory 
networks in adipose tissue, we performed a trans-eQTL analysis using 7.8 M variants (MAF > 0.01) and 
18,553 protein-coding and lncRNA transcripts, requiring variants to be > 1 Mb away from the TSS. 
Accounting for the number of tests performed (Bonferroni, P < 3.4 ´ 10-13), we identified 4,432 target 
genes, and at a relaxed significance threshold (P < 5 ´ 10-8), we identified 13,953 target genes, 
representing 24 and 75% of genes tested, respectively (Table 2.6). At the known adipose-specific trans-
eQTL hub near KLF1452,57, which is also a known GWAS locus for HDL-cholesterol108 and type 2 diabetes 
(T2D)109, we identified rs4731702 as the lead KLF14 cis-eQTL variant and validated (P < 5 ´ 10-8) the 
distal association of this variant with expression level of one known target gene, PRMT2, and two 
additional target genes, SNX14 and RBBP7, not previously reported52,57 (Table 2.7). This male-only 
METSIM study detected fewer trans-eQTL associations for KLF14 than the larger female-only TwinsUK 
study57, consistent with power and the reported stronger effects in females at this locus110.  
 
Colocalization of eQTLs and cardiometabolic GWAS loci 
While thousands of cardiometabolic GWAS loci have been identified, many of the genes 
underlying these associations remain unknown. We evaluated cis-eQTLs for evidence of colocalization 
with 2,843 GWAS signals (variants clumped by LD r2 ³ 0.8) associated with one or more of 93 
cardiometabolic traits and available in our cis-eQTL data (Table 2.8). Of the 2,843 GWAS signals, 874 
(30.7%) were significantly associated with at least one nearby (<1 Mb) gene at FDR < 1% (Table 2.9). 
Using LD and conditional analysis (see Methods), we identified colocalizations of 231 GWAS variants 
with expression of 287 genes, described further below as GWAS-colocalized primary eQTLs. 
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Colocalized GWAS and eQTL signals suggest potential candidate genes for cardiometabolic risk. 
Among the 287 primary eQTL genes colocalized with a GWAS trait, eQTLs for 116 genes were identified 
at BMI loci, 62 genes for lipid traits, 57 genes for WHRadjBMI, 37 genes for T2D, and 10 genes for 
cardiovascular disease (Table 2.10). These colocalizations were based on differing numbers of GWAS 
signals per trait; to identify the proportion of GWAS signals with colocalized eQTLs for each trait, we 
compared the total number of signals reported by five recent GWAS publications for BMI, lipids, WHR, 
WHRadjBMI, and T2D, which reported between 79 to 851 conditionally distinct GWAS signals per trait, to 
the number of signals with a colocalized eQTL signal from those same studies. Across traits from five 
studies12–15,102, the proportion of signals found to be colocalized ranged from 8% for T2D and BMI to 12% 
for WHRadjBMI, 14% for all lipids, and 15% for WHR (Table 2.11). These results suggest that adipose 
tissue gene expression levels are relevant to a broad set of cardiometabolic and other GWAS traits, 
potentially reflecting the cell types present in adipose tissue.  
Genes may influence disease risk by downregulating or upregulating expression level or 
function111. To assess the direction of effect of GWAS signals on gene expression level, we matched the 
GWAS risk alleles to the gene expression effect alleles (see Methods). Across all primary colocalized loci, 
the GWAS trait risk allele corresponded to decreased gene expression for 53% of transcripts (Table 2.10; 
Figure 2.5; Figure 2.6), with a range from 44% for LDL loci to 65% for WHR loci. These results show that 
for common complex traits, disease risk is associated with decreased gene expression level for about half 
of all colocalized signals.  
We also evaluated secondary eQTL signals for colocalization with the initial 2,843 GWAS signals. 
Of 154 lead GWAS variants associated (FDR < 1%) with a secondary eQTL signal for at least one nearby 
gene (Table 2.12), 31 eQTL signals for 31 transcripts were colocalized at GWAS loci. Of these, 10 
(32.3%) variants showed evidence of colocalization with at least one primary eQTL gene and with a 
different secondary eQTL gene. The other 21 variants (67.7%) did not demonstrate any evidence of 
colocalization with a primary eQTL signal such that no gene would have been identified using primary 
eQTLs alone. We did not observe the same gene to be colocalized with a GWAS variant for both a 
primary and secondary eQTL. For example, the lead variant rs11724804 from a WHR and WHRadjBMI 
locus, is not colocalized with the primary eQTL signal for DGKQ via conditional analysis (rs11731377; LD 
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r2 = 0.26) but was colocalized with the secondary eQTL signal for DGKQ, rs13101828, based on LD and 
conditional analysis (r2 = 1.0; Figure 2.7). In hepatic cells, silencing DGKQ decreased the ability of 
synthetic FXR ligand to promote phosphorylation of mTOR, Akt and FoxO1112, and misregulation of the 
mTOR pathway has been shown to result in peripheral insulin resistance and to promote adipogenesis 
and lipogenesis in adipose tissue113. These results suggest that colocalization of secondary eQTLs can 
identify substantially more GWAS loci for which at least one potential candidate gene can provide insights 
into GWAS biology, than primary eQTL colocalizations alone.  
For a subset of the 287 GWAS-colocalized primary eQTLs for which GWAS summary statistics 
were available (n=173; BMI, WHR, WHRadjBMI, and T2D), we further investigated colocalization of 
primary eQTL signals by applying coloc2, a Bayesian colocalization test that uses summary statistics24,66 
(Table 2.13). Of 173 genes tested, 81 showed strong or moderate evidence of GWAS-eQTL 
colocalization (coloc2 posterior probability H4 > 0.8 and H4 > 0.5, respectively). An additional 82 genes 
showed strong or moderate posterior probabilities that did not support colocalized signals (coloc2 H3 > 
0.8 and H3 > 0.5, respectively), which was especially unexpected for nine signals with the same lead 
variant in both the GWAS and eQTL data and 31 signals with very strong pairwise LD (r2 > 0.95) between 
lead GWAS and eQTL variants. A comparison of GWAS and eQTL association plots (e.g. Figure 2.8; 
Table 2.13) showed the GWAS and eQTL signals are very similar and suggests that coloc2 is sensitive to 
additional nearby GWAS and eQTL signals. 
 
Cross-ancestry colocalization analysis 
Colocalization methods rely on examining association patterns in GWAS and eQTL studies for 
similarity; association patterns can differ due to the extent of LD in a region, which can vary by ancestry. 
We further examined LD patterns in cis-eQTLs discovered in Finns for a subset of the BMI GWAS loci 
that were discovered in individuals from Japan  (Table 2.9, Table 2.14, Figure 2.9). We evaluated the LD 
r2 values between the GWAS variant and eSNP in both the Finnish eQTL population and in East Asian 
1000G data. Of the six loci (corresponding to nine eQTL transcripts) that met the GWAS variant-eSNP 
colocalization LD threshold (r2 > 0.8) in Finns, lead variants at four loci had similar pairwise LD in East 
Asians and two had lower LD in East Asians (Table 2.14).  
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As an example of similar LD patterns across populations, the lead BMI-associated variant near 
GON4L in Japanese individuals114, rs860295, was also the lead eSNP for DAP3 (Figure 2.9A). Similar to 
previous examples comparing GWAS and eQTL signals within one ancestry, the similar patterns of 
GWAS and eQTL association signals here suggest DAP3 as a candidate gene for the observed 
association with BMI. DAP3 has been shown to mediate interferon gamma-induced cell death115 and 
IFNG is involved in pro-inflammatory responses related to obesity116. Of note, a GWAS in Europeans102 
also identified BMI-associated variants in this chromosomal region, although the European and Japanese 
GWAS variants exhibited low pairwise LD (r2 = 0.32 in 1000 Genomes East Asians and r2 = 0.35 in Finns) 
and the European signal was not colocalized with any genes (Table 2.9). While further characterization of 
the locus may identify additional candidate genes, the shared LD patterns support cross-ancestry 
conclusions of colocalized GWAS and eQTL signals.  
Two GWAS-eQTL signals we considered to be colocalized showed high LD (r2 ³ 0.8) between 
the lead GWAS and eSNP in Finns but not in East Asians. The lead GWAS variant at the IL27/NUPR1 
East Asian BMI locus, rs62034325, is a cis-eQTL for SULT1A2 (P = 1.03 ´ 10-27; β = 0.67; Figure 2.9B). 
LD between the lead GWAS variant and the eSNP, rs28698667, is high in Finns (r2 = 0.93) but low in 
East Asians (r2 = 0.22). However, LD between the lead GWAS variant and other near-lead eQTL variants 
(e.g. rs62034322, P= 1.02 x 10-27; β = 0.67) is high in both Finns (r2 = 1.0) and East Asians (r2 = 0.89), 
and conditional analyses in the eQTL data (Pcond = 1.61 ´ 10-3) showed that these signals are colocalized. 
The SULT1A2 eQTL signal in Finns consists of more variants than the BMI signal in Japanese, and the 
BMI-associated variants appear to be a subset of the eQTL variants. SULT1A2 catalyzes the sulfate 
conjugation of estrogens, estrogenic alkylphenols, and 17-β-estradiol, to facilitate their removal from the 
body117, and increased levels of 17-β-estradiol are associated with obesity118; in addition, SULT1A1 levels 
were altered in adipose tissue of rats on a high fat diet119. These results are consistent with the 
dependence of all colocalization methods on patterns of association that vary by ancestry and suggest 
that, regardless of GWAS study ancestry, LD-based methods to assess colocalization should focus on 




Cardiometabolic trait association with expression level of eQTL-GWAS colocalized genes  
To further investigate the 287 genes identified based on colocalized primary eQTL-GWAS 
signals, we tested for association of expression level with 20 cardiometabolic traits measured in the same 
434 METSIM individuals. Because BMI is correlated with the expression level of a high percentage (51%) 
of all genes in our study, we performed gene-trait associations with and without adjustment for BMI (Table 
2.15 & 2.16). Without adjustment for BMI, expression levels of 154 genes were associated with at least 
one trait, and with adjustment for BMI, expression levels of 49 genes were associated with a trait. The 
difference between the analysis with and without adjustment for BMI may demonstrate the influence of 
this trait on adipose tissue gene expression levels. This difference also could be due to gene expression 
and cardiometabolic traits influencing BMI (collider bias). We recommend caution interpreting association 
results when a gene’s expression level is associated with BMI (Table 2.15), as collider bias can alter the 
effect size and significance level of the association. The traits associated with expression level of the 
most genes were Matsuda index, WHR, and triglycerides. For example, at a WHRadjBMI locus, EIF4G2, 
also known as DAP5, was significantly associated with fasting free fatty acids (P = 3.0 x 10-5) and with 
Matsuda index, a measure of insulin sensitivity120 (P = 7.2 x 10-5) (Table 2.16), and EIF4G2 was not 
associated with BMI (Table 2.15), suggesting that this gene may affect these traits. EIF4G2 is thought to 
play a role in the interferon gamma-induced cell death pathway121. Association between adipose gene 
expression level and clinical traits provides an additional line of evidence that changes in expression of 
the colocalized genes may influence quantitative traits and disease risk. 
 
Mediation analysis 
We next evaluated colocalized signals for evidence that gene expression mediates the effect of a 
GWAS variant on a cardiometabolic trait. We estimated the mediating effect of a variant on a trait level 
through gene expression level, adjusted for age, relevant covariates, and BMI (except when evaluating 
BMI as an outcome; see Methods for covariates). Of note, observing mediation depends on detecting 
effects of variants on traits in only 434 individuals. Among the colocalized loci, we only tested mediation 
paths at loci for which a trait comparable to the reported GWAS signal had been measured in the 
individuals with gene expression data; this choice resulted in testing the same variant and gene for 
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multiple traits in some cases, leading to more potential mediations than colocalized signals. Of 348 
potential mediations, 90 (25.9%) showed evidence of gene expression mediating the effect of an 
association signal on a trait (the 95% CI of a mediation effect, ME, does not include 0; Table 2.17). We 
focused on signals with nominal evidence of the combined effect of mediation and a direct effect of the 
GWAS variant on the trait (P < 0.05, Table 2.18). Of these, at least four loci have functions relevant to 
cardiometabolic traits. For example, at a well-characterized GWAS locus for adiponectin levels, adipose 
expression level of CDH13, which encodes a receptor for high molecular weight adiponectin multimers122, 
mediates the effect of rs12051272 on plasma adiponectin levels (ME = 0.34; CI [0.086, 0.63]). At another 
GWAS locus, MLXIPL, also known as ChREBP, mediates the variant effect on triglyceride levels (ME = -
0.12; CI [-0.21, -0.40]). In adipose tissue, MLXIPL has been shown to regulate glucose homeostasis and 
fatty acid synthesis123. In addition, RSPO3 mediates the effect of rs72959041 on triglycerides (ME = -
0.12; CI [-0.21, -0.043]), and RSPO3 activates the Wnt/b-catenin pathway which promotes 
angiogenesis124, suggesting a potential role in the expansion of adipose tissue. Finally, JAZF1 mediates 
the effect of rs1708302 on BMI (ME = 0.17; CI [0.059, 0.30]); in adipocytes, overexpression of JAZF1 
inhibits lipid accumulation and regulates lipid metabolism125. In addition to these well characterized loci, 
expression level of CATSPERZ, also known as TEX40, mediates an association with BMI (ME= -0.23; CI 
[-0.44, -0.065]), and expression level of ADH1A mediates an association with WHR (ME= -0.01; CI [-
0.016, -0.005]). CATSPERZ encodes a calcium ion channel and ADH1A encodes a member of the 
alcohol dehydrogenase family; while neither gene has yet been directly linked to body size or fat 
distribution, these mediation results support the eQTL colocalization and suggest that these genes play a 
role in obesity. 
 
Discussion 
We identified primary and secondary cis-eQTLs in subcutaneous adipose from 434 Finnish males 
from the METSIM study and linked their gene expression levels to cardiometabolic GWAS signals and 
measures of 20 cardiometabolic traits. By colocalizing eQTL signals with 262 cardiometabolic trait GWAS 
signals, we identified 318 candidate genes, the highest proportion of which corresponded to traits with 
multiple biological pathways relevant to adipose tissue: WHR (15% of GWAS signals), lipids (14% of 
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GWAS signals), and T2D (8% of GWAS signals). Additional integration of clinical trait information from the 
eQTL study participants through gene-trait association and mediation analysis provided further support of 
a role for these genes in cardiometabolic trait variation. 
While GWAS have successfully identified thousands of genomic regions associated with 
cardiometabolic diseases and complex traits, the genes and mechanisms responsible for many of these 
loci remain unknown. Identifying candidate transcripts for GWAS loci is relatively straightforward when 
one of the lead GWAS variants is predicted to cause a loss of gene function, but identifying candidate 
genes with a testable link to function is more ambiguous when all candidate GWAS variants are 
noncoding. Colocalized eQTL signals provide one of several approaches to identify reasonable candidate 
genes126,127. The value of eQTLs derives from the low prior probability that GWAS variants will by chance 
also be functional variants associated with a gene’s expression level. For our main colocalization 
analysis, we assumed that candidate functional variants would be among those that show the strongest 
association with both a GWAS trait and gene expression level. Consistent with widespread evidence that 
expression levels of most genes are regulated by genetic variants128, 31% of lead GWAS variants in this 
study showed nominal evidence of association (FDR < 1%) with expression levels of at least one 
transcript. Further evaluation of signal colocalization using one or more methods65–69 is critical, because 
here only 1.3% of the associations showed the identical lead variant to be associated with both the 
GWAS and gene expression traits. Interpretation of colocalization can be challenging as comparison of 
signals is affected by sampling heterogeneity, the presence of multiple and/or differing GWAS and eQTL 
signals per locus, and differences in LD patterns between GWAS and eQTL study participants. 
The use of eQTLs to detect candidate genes at GWAS loci is becoming more widespread, but 
colocalizations often only consider primary eQTL signals, which are most easily available via summary 
data. While primary eQTLs identified 90% of the candidate genes detected here, analysis of secondary 
eQTLs detected another 21 genes that would have been missed by summary level analysis. These 
secondary eQTLs may reflect parallel biology with primary eQTL signals or they may derive from a 
different underlying cell type present in bulk tissue samples. As eQTL study sample sizes increase and 
single-cell or in silico cell-type deconvolution technologies improve, studies will have more potential to 
detect multiple regulatory effects per gene.  
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Colocalization methods are imperfect and sensitive to the thresholds applied. In the LD and 
conditional analysis approach, we applied a threshold for LD between the GWAS variant and the eSNP 
as well as a threshold for evidence of association after conditional analysis. These thresholds are 
arbitrary and sensitive to the strength of the original eQTL signal, the use of lead variants subject to 
sampling variability, and a conditional analysis step that requires individual-level data. In comparison, 
coloc2 requires setting prior probabilities and thresholds for interpreting posterior probabilities and is 
sensitive to the presence of multiple signals in either the eQTL or the GWAS data. Further development 
of colocalization methods may improve the use of eQTLs for identifying candidate genes for GWAS loci. 
We provide evidence for cross-ancestry GWAS-eQTL colocalizations and demonstrated the 
importance of evaluating colocalization using the LD structure of the eQTL study population. When the 
lead variants for the GWAS and eQTL studies are the same or in high LD in both populations, 
colocalization is straightforward. At these loci, conditional analysis showed evidence of colocalization. 
However, when the LD structure differs substantially between populations, closer comparison of the 
patterns of association in GWAS and eQTL data is required to ensure that the conclusion of colocalization 
is warranted. The results of colocalization across populations can be influenced especially when the 
pattern of association is broader due to LD in one population than another and the selection of a different 
lead variant within the set of highly associated variants would result in high LD between the GWAS 
variant and eSNP in both ancestries. Although some loci can be compared cleanly across ancestries, as 
eQTL studies in more diverse populations become available, comparing GWAS and eQTL signals within 
ancestries will likely provide stronger evidence of colocalization. 
To further investigate causal relationships between genetic variants and clinical traits, we used 
the extensive phenotypic trait information available for the METSIM eQTL study participants and identified 
49 genes associated with cardiometabolic traits at colocalized GWAS loci. Although Matsuda index, 
WHR, and triglycerides showed the most associations with genes, these traits did not exhibit the most 
variation between individuals, suggesting that even small changes in traits can result in association with 
colocalized genes. Because BMI is associated with nearly half of all genes in our data, the direction of the 
relationship between BMI, related traits, and gene expression is hard to determine; expression level of a 
gene may affect BMI, or BMI may influence expression level of a gene and a trait independently. We 
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further tested for effects of the variants mediated through gene expression on the GWAS trait or a related 
trait. The six highlighted mediations (Table 2) show not only an association between these variant, gene, 
and trait, but also a directional, and potentially causal, path. This mediation analysis method is limited by 
statistical power because it uses only the hundreds of individuals with expression data to detect an effect 
of the genotype on the trait, whereas thousands of samples were used to originally detect these 
associations in GWAS studies. To mitigate this limitation, we confined our analysis to established GWAS 
loci and required the combined effect of the genotype on the trait and the mediation to be significant. The 
results of both gene-trait associations and mediation analysis can be used to guide efforts in functional 
tests of genes for mechanistic effects on cardiometabolic traits.   
 The 318 candidate genes identified here correspond to GWAS loci across a broad range of 
cardiometabolic traits. These genes may act to influence obesity, diabetes, and cardiovascular traits and 
should be prioritized for future functional analysis. As larger subcutaneous adipose data sets become 
available in diverse ancestries, multiple eQTL signals will become easier to identify and colocalize with 
GWAS signals from across populations. 
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Figure 2.1: Percentages of different tissues across 550 samples: Stacked bar plot of estimated tissue 
composition from full set of 550 subcutaneous adipose tissue needle biopsy samples from METSIM 
study. For each individual (x-axis), the estimated percentages of subcutaneous adipose, skeletal muscle, 
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whole blood, and EBV-transformed lymphocytes identified using DESeq2 are shown. 
 
Figure 2.2: Selection and identification of PEER factors: PEER factor curve (A) showing the number 
of PEER factors (x-axis) used to identify genes with a significant eQTL association (FDR <5%, y-axis). 
For panels B & C, samples (n=434) are plotted by their values for PEER factors 1 (x-axis) and 2 (y-axis). 






Figure 2.3: Comparison of primary and secondary eQTL association signals: (A) For each type of 
transcript (x-axis), the number of transcripts associated with at least one nearby variant that met the 
genome-wide FDR <1% is shown (y-axis). (B) Density plot showing the distance from the lead eQTL 
variant to the TSS. Dashed lines represent the median distance to the TSS for primary (purple) and 
secondary (green) eQTLs. (C) Enrichment of primary and secondary eQTLs in chromatin marks from 
Roadmap adipose nuclei chromatin marks and open chromatin ATAC-seq peaks from adipose tissue. 
The horizontal lines represent the logistic regression coefficient for enrichment with vertical lines 
representing the 95% confidence interval around the coefficient. D) Absolute value of the effect sizes of 
eQTL variants that overlap Roadmap adipose nuclei promoters and enhancers. Black horizontal lines 




Figure 2.4: eQTL effect sizes for variants located in adipose tissue ATAC-seq peaks or 
adipose nuclei chromatin marks: Absolute value of the effect sizes for variants from combined primary 
and secondary eQTL signals that overlap promoter or enhancer regions from Roadmap adipose nuclei 
and ATAC-seq adipose tissue. Black lines represent the median effect sizes of primary and secondary 








Figure 2.5: Cardiometabolic GWAS and eQTL colocalizations, stratified by trait: Each point 
represents the lead GWAS variant of a signal colocalized by LD and conditional analysis with an eQTL for 
the named gene. Plots show eQTLs at GWAS loci for (A) T2D, (B) WHRadjBMI, and (C) lipids. The x-axis 
shows chromosomal positions of colocalized signals and the y-axis shows the -log10 P-values of the 
GWAS variant’s association with gene expression level in adipose tissue. After matching the effect allele 
from the eQTL study with the risk allele from the GWAS, risk alleles that are associated with increased 
gene expression level are shown in red and risk alleles that are associated with decreased gene 
expression level are shown in blue. Triangles indicate that more than one gene is colocalized with the 
GWAS variant (other genes would appear at the same x-axis position). Variants colocalized as secondary 
eQTLs are designated by a star after the gene name. Only the strongest associations for the named traits 















Figure 2.6: Extended Cloud City plots of cardiometabolic GWAS and eQTL colocalizations, 
stratified by trait: Each point represents a lead GWAS variant associated with a nearby gene associated 
with various cardiometabolic traits and colocalized by LD and conditional analysis. The x-axis shows 
chromosomal positions of colocalized signals and the y-axis shows the -log10 P-values of the GWAS 
variant’s association with gene expression level in adipose tissue. After matching the effect allele from the 
eQTL study with the risk allele from the GWAS, risk alleles that are associated with increased gene 
expression level are shown in red and risk alleles that are associated with decreased gene expression 
level are shown in blue. Triangles indicate that more than one gene is colocalized with the GWAS variant 
(other genes would appear in columns). Variants colocalized as secondary eQTLs are designated by a 
star after the gene name. Variants associated with BMI are separated into two plots, stratified by 
increased expression (A) or decreased expression (B). Lipid traits were separated by HDL (C), LDL (D), 
Triglycerides (E), Total Cholesterol (F). Additionally, variants from WHR (G), CVD (H) and Adiponectin (I) 









Figure 2.7: A WHRadjBMI signal colocalizes with the secondary eQTL for DGKQ Locus plots for the 
DGKQ locus, colored by two distinct signals present in the METSIM eQTL data. The lead GWAS variant 
associated with WHRadjBMI at this locus, rs11724804 (top) is associated with DGKQ expression, but is 
not in LD with the variant most strongly associated with DGKQ expression, rs11731377 (eSNP; middle). 
After conditional analysis, a second eQTL signal for DGKQ is apparent and is colocalized with the lead 
GWAS variant (bottom). Variants are colored by the strength of their LD with the lead variant for each 





Figure 2.8: Comparison of GWAS and eQTLs found not to be colocalized by coloc2:  
Locus plots showing the regional associations for GWAS (top) and gene expression level (bottom) 
results. (A) The EYA2 eQTL is colocalized with T2D by LD and reciprocal conditional analysis (LD 
r2=0.94, Pcond= 0.058), but the posterior probability that they were colocalized is more marginal 
(PP4=0.67). There are two signals in the both the GWAS and eQTL data, which are not captured well by 
coloc2, according to the assumptions of the software. (B) At the FTO locus, we identify a colocalization 
between the lead T2D GWAS variant and eSNP for AKTIP (LD r2= 0.98, Pcond= 0.065). Results from 
coloc2 suggest that these two signals are not colocalized (PP3=1.0). There are two independent signals 
in the GWAS data, one near FTO and another near AKTIP. In the eQTL data, there is only signal for 






Figure 2.9: Cross-ancestry comparison of colocalized GWAS – eQTL signals: Locus plots showing 
the regional associations for BMI in Japanese individuals, colored by East Asian LD (EAS) (top) and gene 
expression in Finns (bottom), colored by Finnish LD. (A) A DAP3 eQTL signal is colocalized with a BMI 
signal near GON4L. The lead variant is shared between the GWAS and eQTL studies and the patterns of 
association are similar. (B) A SULT1A2 eQTL signal is colocalized with a BMI signal near IL27/NUPR1. 





Abbreviation Metabolic trait Mean± standard deviation Median  (25th, 75th percentile) 
Age Age (years) 54.6 ± 5.3 54.0 (51.0, 58.5)  
BMI Body mass index (kg/m2)  26.6 ± 3.5 26.1 (24.4, 28.4) 
WHR Waist-to-hip ratio 0.96 ± 0.06 0.96 (0.92, 1.00) 
WC Waist circumference (cm)  96.6 ± 10.3 95.0 (90.0, 102.0)  
HIP Hip circumference (cm)  100.8 ± 7.0 100.0 (96.0, 104.0)  
FFMASS Fat-free mass (%)  78.8  ± 5.1 79.2 (76.3, 82.0)  
FFA Fasting plasma free fatty acid (mmol/l)  0.35 ± 0.13 0.33 (0.25, 0.43) 
TG Total triglycerides (mmol/l)  1.37 ± 0.93 1.16 (0.87, 1.59)  
CHOL Total cholesterol (mmol/l) 5.50 ± 0.89 5.40 (4.88, 6.07)  
LDL-C LDL cholesterol (mmol/l) 3.48 ± 0.77 3.42 (2.96, 3.96)  
HDL-C HDL cholesterol (mmol/l)  1.50 ± 0.38 1.45 (1.21, 1.70)  
Adiponectin Plasma adiponectin (ug/ml)  7.44 ± 3.55 6.70 (5.00, 9.00) 
Matsuda Matsuda composite insulin sensitivity index (mg/dl, mU/l)  7.52 ± 3.97 6.81 (4.33, 9.98)  
HOMA-B Insulin resistance index based on homeostasis assessment  66.8 ± 41.3 54.1 (40.7, 80.8)  
Glucose Fasting plasma glucose (mmol/l)  5.71 ± 0.47 5.70 (5.40, 5.95) 
Insulin Fasting plasma insulin (mU/l)  44.1 ± 29.3 34.8 (24.6, 54.6)  
Proinsulin Fasting plasma proinsulin (pmol/l)  12.9 ± 6.38 11.5 (8.70, 15.2)  
HbA1c Blood glycated HbA1c (%) 5.64 ± 0.31 5.60 (5.40, 5.80) 
SBP Systolic blood pressure (mm Hg)  133.3 ± 14.7 132.0 (122.0, 140.7)  
DBP Diastolic blood pressure (mm Hg)  86.9 ± 8.80 86.7 (80.7, 92.7) 
CRP High sensitivity C-reactive protein (mg/l) 2.15 ± 5.20 0.99 (0.46, 2.18) 
IL1RA Interleukin-1 receptor antagonist (pg/ml)  200.4 ± 145.9 167.0 (126.4, 225.5) 
GFR Glomerular filtration rate 0.091 ± 0.01 0.089 (0.082, 0.098) 
TotFA  Total fatty acids (mmol/l)  14.4 ± 3.28 13.7 (12.1, 16.0)  
T2D & IGT Type 2 diabetes & Impaired glucose tolerant (count) 32  







Table 2.1: Characteristics of the METSIM study participants in 434 sample subset This table contains the trait characteristics of 434 samples 
from the METSIM study. An extended version of this table is available in Raulerson CK et al. (AJHG 2019). 
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  n=550, >0% adipose (P < 6.07e-4) n=434, >50% adipose (P < 6.06e-4) n=387, >75% adipose (P < 3.79e-4) 
Number 
of PEER 
factors 20 40 60 80 20 40 60 80 20 40 60 80 
# variant-
gene pairs 2.55M  2.74M  2.82M  2.86M  2.74M  2.95M  3.02M  3.05M  2.30M  2.45M  2.50M  2.50M  
# variants 1.40M  1.48M  1.51M  1.53M  1.49M  1.57M  1.60M  1.61M  1.29M  1.35M  1.38M  1.38M  
# genes 15,999  16,286  16,356  16,393  15,788  16,043  16,135  16,183  14,442  14,600  14,715  14,712  
Table 2.2: Comparison of cis-eQTL discovery between sample subsets cis-eQTL discovery statistics reported for chr 1-22 based on FDR<5% 
calculated from FastQTL permutation test and qvalue package. Analyses were based on 21,735 genes and 7.8M variants (hg19, GENCODE v19 
comprehensive, Haplotype Reference Consortium-imputed genotypes with MAF > 1%). The number of variant-gene pairs and variants are 
displayed in the millions (M).  
 








Table S2.3: Comparison of known adipose cis-eQTLs between sample subsets Results for the same variant-gene pair in the three sample 
subsets. These eQTL genes were identified in Civelek et al. (2017). The named variant (column A) was the lead variant in each subset except for 




n=550, >0% adipose          
(P < 6.07e-4) 
n=434, >50% adipose 
(P < 6.06e-4) 
n=387, >75% adipose 
(P < 3.79e-4) 
variant gene P β P β P β 
rs4731702 KLF14 1.30E-15 0.48 3.29E-16 0.54 4.06E-16 0.56 
rs76786086 ADIPOQ 6.63E-04 -0.71 1.03E-09 -1.69 1.98E-09 -1.66 
rs2239857 CDH13 1.86E-23 0.84 4.35E-26 1.00 7.71E-24 1.00 
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Table 2.4: Replication of lead eQTLs between METSIM and GTEx The number of eQTLs in each discovery study is counted by the number of 
genes with at least one significant eSNP. The numbers of cis-eQTLs observed are shown at various p-value thresholds requiring the same 
direction of effect. The percent of eQTLs that matched the direction of effect from the discovery study is based on the number of SNPs available in 
both studies. Variants in GTEx were only reported at the FDR<5% threshold. 
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(57.1%) 50   
 
 51 
eQTL set Genomic Annotation ! Confidence 
Interval 
P 
First Signals All ATAC peaks 2.53 2.48 2.58 < 2e-308 
Second Signals All ATAC peaks 2.17 2.08 2.27 < 2e-308 
GWAS-Coincident First Signals All ATAC peaks 3.20 2.93 3.49 7.40E-111 
First Signals ATAC peaks in Enhancers 2.01 1.93 2.09 < 2e-308 
Second Signals ATAC peaks in Enhancers 1.84 1.68 1.99 7.40E-119 
GWAS-Coincident First Signals ATAC peaks in Enhancers 2.67 2.31 3.00 1.20E-52 
First Signals ATAC peaks in Promoters 2.83 2.77 2.89 < 2e-308 
Second Signals ATAC peaks in Promoters 2.52 2.41 2.63 < 2e-308 
GWAS-Coincident First Signals ATAC peaks in Promoters 3.47 3.18 3.76 6.80E-124 
First Signals ATAC peaks in Stretch Enhancers  2.12 2.00 2.23 1.90E-271 
Second Signals ATAC peaks in Stretch Enhancers  1.93 1.70 2.14 3.50E-65 
GWAS-Coincident First Signals ATAC peaks in Stretch Enhancers  2.75 2.28 3.17 6.80E-34 
First Signals ATAC peaks in Typical Enhancers 1.82 1.69 1.95 5.00E-161 
Second Signals ATAC peaks in Typical Enhancers 1.72 1.46 1.96 2.90E-42 
GWAS-Coincident First Signals ATAC peaks in Typical Enhancers 2.28 1.69 2.80 4.70E-16 
First Signals Roadmap Enhancers 1.68 1.64 1.73 < 2e-308 
Second Signals Roadmap Enhancers 1.45 1.37 1.53 5.60E-277 
GWAS-Coincident First Signals Roadmap Enhancers 2.81 2.48 3.17 4.50E-59 
First Signals Roadmap Promoters 2.46 2.41 2.51 < 2e-308 
Second Signals Roadmap Promoters 2.11 2.02 2.19 < 2e-308 
GWAS-Coincident First Signals Roadmap Promoters 3.06 2.78 3.35 2.70E-97 
First Signals Stretch Enhancers 1.38 1.31 1.44 < 2e-308 
Second Signals Stretch Enhancers 1.31 1.20 1.41 3.50E-132 
GWAS-Coincident First Signals Stretch Enhancers 2.42 2.14 2.70 1.60E-64 
First Signals Typical Enhancers  1.81 1.75 1.87 < 2e-308 
Second Signals Typical Enhancers  1.58 1.47 1.68 1.50E-197 
GWAS-Coincident First Signals Typical Enhancers  2.51 2.23 2.78 6.90E-70 
Table 2.5: Enrichment in Roadmap adipose nuclei marks and METSIM adipose tissue ATAC-seq 
peaksThe top 2,534 primary signals were selected to match the number of lead variants in the secondary 
signal set. Promoters and enhancers were identified using Roadmap adipose nuclei. ATAC peaks were 





Without adjustment with PEER factors With adjustment for 3 PEER factors 
  trans-eQTL 
eGenes 
(P < 1e-4) 
trans-eQTL 
eGenes 
(P < 5e-8) 
trans-eQTL 
eGenes 
(P < 3.4e-13) 
trans-eQTL 
eGenes 
(P < 1e-4) 
trans-eQTL 
eGenes 
(P < 5e-8) 
trans-eQTL 
eGenes 
(P < 3.4e-13) 
  > 1Mb > 5Mb > 1Mb > 5Mb > 1Mb > 5Mb > 1Mb > 5Mb > 1Mb > 5Mb > 1Mb > 5Mb 
protein-
coding 
            
14,902  
            
14,902  
               
12,138  
          
12,106  
                
3,613  
               
3,575  
           
14,902  
               
14,902  
                  
11,352  
      
11,304  
               
3,691  
                 
3,635  
antisense               
1,734  
              
1,734  
                 
1,306  
            
1,300  
                   
363  
                 
357  
            
1,734  
                 
1,734  
                    
1,216  
        
1,211  
                  
347  
                   
340  
lincRNA               
1,357  
              
1,357  
                 
1,043  
            
1,035  
                   
266  
                 
260  
            
1,357  
                 
1,357  
                       
986  
           
976  
                  
244  
                   
237  
other                  
560  
                 
560  
                    
425  
               
423  
                   
155  
                 
151  
               
560  
                    
560  
                       
399  
           
394  
                  
150  
                   
146  
total             
18,553  
            
18,553  
               
14,912  
          
14,864  
                
4,397  
               
4,343  
           
18,553  
               
18,553  
                  
13,953  
      
13,885  
               
4,432  
                 
4,358  
Table 2.6: Trans-eQTL discovery at three significance thresholds eGenes are reported if at least 1 variant > 1 Mb (or the subset > 5 Mb) away 
from the transcription start site shows significant eQTL association. P < 1e-4 is equivalent to the p-value with and FDR of < 5% using the Storey 
method in Small et al. Nat Gen 2018 (PMID 29632379). P < 5e-8 is an approximate genome-wide threshold. P < 4.66e-9 is equivalent to the p-
value with an FDR < 5% using the Benjamini Hochberg method. Analyses were based on 18,553 genes and 7.8M variants (hg19, GENCODE v19 
comprehensive excluding psuedogenes and genes with low mappability, Haplotype Reference.




Without PEER factors With 3 PEER factors 
  
Gene METSIM β METSIM 
P-value 
METSIM β METSIM 
P-value 
TwinsUK β TwinsUK 
P-value 
PRMT2 -0.277 4.53E-09 -0.264 2.28E-08 -0.233 2.24E-06 
CCDC153 -0.250 1.25E-07 -0.231 1.17E-06 NA NA 
MAP3K4 -0.219 4.33E-06 -0.200 2.75E-05 NA NA 
GNAL -0.218 4.38E-06 -0.205 1.60E-05 NA NA 
UNC13B -0.214 7.14E-06 -0.222 3.07E-06 -0.226 2.55E-07 
PARP6 -0.212 8.71E-06 NA NA NA NA 
FGFR1OP -0.211 8.91E-06 -0.227 1.73E-06 NA NA 
FAM109A -0.209 1.19E-05 -0.194 4.82E-05 -0.145 3.01E-04 
RALGPS1 -0.208 1.28E-05 -0.187 8.99E-05 NA NA 
SMYD4 -0.208 1.31E-05 NA NA NA NA 
LSM11 -0.207 1.43E-05 NA NA NA NA 
ANAPC4 -0.206 1.45E-05 -0.198 3.21E-05 NA NA 
HMBS 0.205 1.69E-05 NA NA NA NA 
RP5-942I16.1 -0.203 2.13E-05 NA NA NA NA 
FAM211B -0.199 3.02E-05 NA NA NA NA 
BBS2 -0.195 4.33E-05 -0.194 4.91E-05 NA NA 
LZTS3 -0.194 4.53E-05 -0.217 4.88E-06 NA NA 
SNX14 -0.194 4.74E-05 -0.271 9.71E-09 NA NA 
DCLK2 -0.194 4.94E-05 NA NA NA NA 
BEAN1 -0.192 5.72E-05 NA NA NA NA 
MPP3 -0.189 7.20E-05 NA NA NA NA 
KIF13B -0.189 7.65E-05 NA NA NA NA 
PDXP 0.188 7.95E-05 NA NA NA NA 
APBA1 -0.188 8.06E-05 NA NA NA NA 
RP1-137D17.2 -0.187 9.15E-05 NA NA NA NA 
USP4 -0.187 9.23E-05 NA NA NA NA 
EPN2 -0.186 9.93E-05 NA NA NA NA 
RBBP7 NA NA -0.264 2.47E-08 NA NA 
MAGED2 NA NA -0.251 1.18E-07 -0.264 3.46E-10 
HSPB11 NA NA -0.237 5.67E-07 NA NA 
TWSG1 NA NA -0.229 1.46E-06 NA NA 
CHCHD7 NA NA -0.222 2.88E-06 NA NA 
URI1 NA NA -0.221 3.47E-06 NA NA 
UBE2Q2 NA NA -0.220 3.60E-06 -0.204 4.51E-06 
MFSD10 NA NA -0.219 4.24E-06 NA NA 
GNB1 NA NA -0.218 4.64E-06 -0.208 2.56E-06 
RAN NA NA -0.218 4.76E-06 NA NA 
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HNRNPU-AS1 NA NA -0.210 9.87E-06 NA NA 
APLF NA NA -0.209 1.09E-05 NA NA 
COX20 NA NA -0.208 1.21E-05 NA NA 
CCBL2 NA NA -0.208 1.24E-05 NA NA 
ANKMY2 NA NA -0.208 1.24E-05 NA NA 
SRI NA NA -0.208 1.29E-05 NA NA 
DUSP1 NA NA -0.207 1.44E-05 NA NA 
DYNLT1 NA NA -0.204 1.93E-05 NA NA 
SAP30 NA NA -0.203 1.96E-05 NA NA 
KPNA5 NA NA -0.203 2.05E-05 NA NA 
ARHGAP12 NA NA -0.201 2.48E-05 NA NA 
TM2D3 NA NA -0.200 2.73E-05 -0.191 9.82E-05 
PLK3 NA NA -0.199 3.00E-05 NA NA 
EIF4E3 NA NA -0.198 3.13E-05 -0.252 5.64E-10 
PNMA1 NA NA -0.197 3.49E-05 -0.292 1.06E-08 
MEAF6 NA NA -0.197 3.65E-05 NA NA 
ADD1 NA NA -0.196 3.86E-05 NA NA 
LSM11 NA NA -0.195 4.21E-05 NA NA 
RNF170 NA NA -0.193 5.06E-05 NA NA 
RHNO1 NA NA -0.193 5.25E-05 NA NA 
PTPLA NA NA -0.192 5.77E-05 NA NA 
MOCS2 NA NA -0.192 5.83E-05 -0.178 6.89E-05 
PPP1R15A NA NA -0.191 6.11E-05 NA NA 
SLC9A6 NA NA -0.191 6.27E-05 NA NA 
C8orf82 NA NA -0.189 7.56E-05 -0.284 6.76E-13 
RRP9 NA NA 0.188 7.97E-05 0.248 9.35E-08 
CYR61 NA NA -0.188 8.38E-05 NA NA 
DNAH11 NA NA -0.187 8.58E-05 NA NA 
TKT NA NA 0.187 8.60E-05 0.214 9.10E-07 
NLRX1 NA NA 0.187 9.16E-05 NA NA 
SUPT3H NA NA -0.187 9.22E-05 NA NA 




Table 2.7: Replication of METSIM trans-eQTL for KLF14 target genes in TwinsUK Genes are listed if 
METSIM eQTL for rs4731702 (chr7:130433384) was significant (P<1e-4) with 3 PEER factors.  Values 
are shown as NA in columns B and C if not reported (P < 0.05) without PEER factors, in columns D and E 
if not reported with 3 PEER factors, and in columns F and G if not reported for Twins UK in Small KS et 
al. Nat Genet 2018. The TwinsUK study consists of 856 female twins with expression level measured 
from subcutaneous adipose tissue punch biopsies (1000 Genomes-imputed genotypes, genes annotated 





Trait Category GWAS Trait 
diabetes Type 2 diabetes 
diabetes Diabetes (gestational) 
diabetes Type 2 diabetes and other traits 
glycemic Fasting glucose-related traits 
glycemic Fasting insulin-related traits 
glycemic Fasting plasma glucose 
glycemic Fasting glucose-related traits (interaction with BMI)  
glycemic Fasting insulin-related traits (interaction with BMI)  
glycemic Glycated hemoglobin levels 
glycemic Glycemic traits 
glycemic Insulin-related traits 
glycemic Proinsulin levels 
glycemic Two-hour glucose challenge 
obesity Adiposity 
obesity BMI 
obesity Body mass index 




obesity Obesity (early onset extreme) 
obesity Obesity (extreme) 
obesity Obesity-related traits 
obesity Visceral fat 
obesity Visceral adipose tissue/subcutaneous adipose tissue ratio  
obesity Waist circumference 
obesity Waist circumference and related phenotypes 
obesity Waist Circumference - Triglycerides (WC-TG)  
obesity Waist-hip ratio 
obesity WCadjBMI 
obesity Weight 
obesity WHR  
obesity WHRadjBMI 
lipids Apolipoprotein Levels 
lipids Cholesterol 
lipids Cholesterol total 
lipids HDL cholesterol 
lipids HDL Cholesterol - Triglycerides (HDLC-TG) 
lipids Hypertriglyceridemia 
lipids LDL cholesterol 
lipids LDL (oxidized) 
lipids Lipid metabolism phenotypes 
lipids Lipid traits 
lipids Lipoprotein-associated phospholipase A2 activity and mass 




lipids Oleic acid (18:1n-9) plasma levels 
lipids Palmitic acid (16:0) plasma levels 
lipids Palmitoleic acid (16:1n-7) plasma levels 
lipids Phospholipid levels (plasma) 
lipids Phytosterol levels 
lipids Plasminogen activator inhibitor type 1 levels (PAI-1) 
lipids Resistin levels 
lipids Sphingolipid levels 
lipids Stearic acid (18:0) plasma levels 
lipids Triglycerides 
lipids Triglycerides-Blood Pressure (TG-BP) 
MetS Metabolic syndrome 
MetS Metabolic syndrome (bivariate traits) 
MetS Metabolic traits 
cardiac Abdominal aortic aneurysm 
cardiac Ankle-brachial index 
cardiac Aortic root size 
cardiac Aortic stiffness 
cardiac Aortic-valve calcification 
cardiac Arterial stiffness 
cardiac Cardiac hypertrophy 
cardiac Cardiac structure and function  
cardiac Cardiac Troponin-T levels 
cardiac Cardiovascular disease risk factors 
cardiac Cardiovascular heart disease in diabetics 
cardiac Carotid atherosclerosis in HIV infection 
cardiac Carotid intima media thickness 
cardiac Coronary arterial lesions in patients with Kawasaki disease  
cardiac Coronary heart disease 
cardiac Hypertension 
cardiac Hypertension risk in short sleep duration 
cardiac Intracranial aneurysm 
cardiac Lp(a) levels 
cardiac Moyamoya disease 
cardiac Myocardial infarction 
cardiac Myocardial infarction (early onset) 
cardiac Pulmonary arterial hypertension (without BMPR2 mutations)  
cardiac Stroke (ischemic) 
cardiac Thiazide-induced adverse metabolic effects in hypertensive patients  
cardiac Vascular dementia 
cardiac Venous thromboembolism 
cardiac Venous thromboembolism (gene x gene interaction)  
cardiac Coronary artery calcification 
cardiac Thoracic aortic aneurysms and dissections 
cardiac Stroke 
other circulating leptin levels adjusted for BMI 
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other circulating leptin levels 
other adiponectin measurement 
Table 2.8: 93 cardiometabolic diseases and quantitative traits key terms for which GWAS Catalog 






GWAS lead variant   GWAS variant association with 
eQTL gene 
Lead eQTL variant (eSNP) 
association with eQTL gene 
Lead eQTL variant 
(eSNP) conditioned 
on GWAS variant 
 













SNX10 2.71E-76 -1.08 rs1534696 A 2.71E-
76 
1.08 9.76E-01 0.00E+00 - 




1.06 9.98E-01 3.09E+11 - 




8.10E-01 3.44E+13 - 
rs56271783 C WHRadjB
MI 






9.91E-01 5.48E+11 - 









rs2243312 A HDL RP11-
217B7.2 
6.20E-35 0.77 rs2243312 A 6.20E-
35 
0.77 4.30E-01 0.00E+00 - 
rs17326656 T WHRadjB
MI 











OPRL1 1.07E-27 -0.71 rs8126001 T 1.07E-
27 
0.71 5.61E-01 0.00E+00 - 


















rs1412444 T Coronary 
heart 
disease 
LIPA 3.50E-20 0.61 rs1412444 T 3.50E-
20 
0.61 9.97E-01 9.88E+11 - 




9.36E-01 2.44E+13 - 






















3.07E-01 0.00E+00 - 
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SSC5D 3.75E-15 0.58 rs8103017 G 3.75E-
15 
0.58 9.94E-01 3.39E+11 - 
rs860295 G BMI DAP3 8.00E-14 0.51 rs860295 G 8.00E-
14 
0.51 9.96E-01 2.58E+11 - 




9.54E-01 1.33E+13 - 
rs638722 C WHRadjB
MI 









CMIP 2.24E-13 0.53 rs2925979 T 2.24E-
13 
0.53 9.61E-01 1.50E+13 - 
rs1979527 A WHRadjB
MI 




















0.44 9.64E-01 1.17E+12 - 
rs603424 A Metabolic 
traits 









CBX3 2.00E-09 -0.41 rs1534696 A 2.00E-
09 
0.41 7.52E-01 0.00E+00 - 
rs603424 A Metabolic 
traits 







rs333947 A HDL CSF1 2.85E-08 0.46 rs333947 A 2.85E-
08 
0.46 1.00E+00 0.00E+00 - 









rs6087685 C Venous 
thromboem
bolism 







rs740157 A BMI RP5-
899E9.1 
3.09E-07 -0.33 rs740157 G 3.09E-
07 
0.33 9.93E-01 6.65E+11 - 


































9.94E-01 4.34E+11 - 
rs11277705
1 




0.51 9.19E-01 3.77E+13 - 





rs8070454 C BMI MED24 5.26E-65 0.99 rs4795412 C 5.14E-
65 
0.99 4.40E-01 2.63E+01 1.00 
rs12489828 T WHRadjB
MI 




8.11E-01 1.10E+13 1.00 




















DISP2 1.27E-32 0.99 rs3803360 T 1.26E-
32 
0.99 7.42E-01 3.46E+01 1.00 
rs7187776 G BMI RP11-
1348G14.4 




9.62E-01 7.07E+12 1.00 











rs211718 T Metabolic 
traits 




0.50 8.94E-02 1.06E+01 1.00 
















rs2652822 C Metabolic 
traits 
LACTB 1.43E-37 0.77 rs1126308 C 1.42E-
37 
0.77 7.90E-01 1.31E+01 1.00 




0.53 1.65E-01 1.58E+02 1.00 




1.00E+00 0.00E+00 1.00 
















rs2049805 T blood urea 
nitrogen 
GBAP1 2.56E-46 0.88 rs2974929 T 1.60E-
46 
0.88 3.04E-01 1.35E+00 1.00 







































































0.48 7.17E-01 3.55E+00 1.00 
rs1549293 C BMI KAT8 1.34E-30 0.71 rs9972727 G 1.32E-
30 
0.71 8.51E-01 1.17E+00 1.00 

























rs8396 C Metabolic 
traits 











1.27E-22 0.94 rs6888037 T 4.11E-
23 
0.95 7.48E-02 2.08E+00 1.00 
rs1045241 C WHRadjB
MI 







rs9846123 T BMI WDR6 8.77E-87 1.12 rs6768433 G 2.95E-
88 
1.12 6.18E-03 1.64E+00 1.00 







rs8070454 C BMI PSMD3 7.62E-08 0.36 rs8081692 A 6.44E-
08 
0.36 3.00E-01 2.18E+00 1.00 







rs12964689 A BMI NPC1 4.95E-18 -0.54 rs6507716 G 4.91E-
18 
0.54 4.20E-01 4.23E+01 1.00 
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rs13391552 A Metabolic 
traits 
ALMS1P 1.49E-09 0.48 rs6736866 G 1.16E-
09 
0.49 7.78E-02 5.91E+00 1.00 




0.78 3.22E-01 6.43E+01 1.00 
rs9435732 C WHRadjB
MI 




0.57 7.97E-02 1.62E+00 1.00 
rs2657879 G Metabolic 
traits 




0.67 3.93E-01 7.93E-01 1.00 











rs823074 T BMI PM20D1 2.65E-46 0.87 rs708727 G 2.50E-
46 
0.87 7.25E-01 7.12E-01 1.00 
rs58749629 A Abdominal 
aortic 
aneurysm 
NEURL2 2.10E-17 0.82 rs7270354 A 2.02E-
17 
0.82 6.72E-01 3.10E+00 1.00 
rs709400 G BMI RP11-
73M18.9 
1.89E-50 0.94 rs7359090 G 1.65E-
50 
0.94 5.67E-01 1.73E+00 1.00 





















rs6684514 G Glycated 
hemoglobin 
levels 




0.76 4.46E-01 6.77E-01 0.99 







rs450231 G BMI ANKS6 2.05E-21 0.65 rs7035722 C 5.95E-
22 
0.65 4.15E-02 1.82E+00 0.99 




0.93 2.92E-02 8.64E-01 0.99 




1.01 1.32E-01 1.35E+00 0.99 







rs7871866 C BMI RP11-
339B21.13 
3.05E-07 0.43 rs4734 G 2.99E-
07 
0.43 7.96E-01 2.61E-01 0.99 


































0.37 8.91E-02 6.67E-01 0.99 
rs17207196 C BMI POM121C 2.88E-20 -0.64 rs794373 C 1.55E-
20 
0.63 2.65E-01 5.54E-01 0.99 
rs6859752 T WHRadjB
MI 
SH3PXD2B 3.04E-19 0.66 rs6866204 A 1.59E-
20 
0.68 1.54E-03 1.88E+00 0.99 









rs2294120 A T2D ZNF34 3.33E-12 0.47 rs7004501 C 2.91E-
12 
0.47 5.91E-01 3.61E-01 0.99 









rs926279 A BMI XXbac-
BPGBPG55
C20.2 
3.72E-44 0.92 rs1970605 G 1.01E-
44 
0.94 3.43E-02 2.66E+00 0.99 





























0.34 2.99E-01 4.99E-01 0.99 




0.55 1.86E-01 8.57E-01 0.99 
rs926279 A BMI XXbac-
BPGBPG55
C20.1 









EYA1 1.97E-16 0.62 rs7843475 G 1.14E-
16 
0.62 2.57E-01 1.05E+00 0.99 
rs6764533 A BMI CTD-
2002J20.1 







rs6558295 G Metabolic 
traits 









rs6558295 G Metabolic 
traits 

































rs17173637 C HDL AOC1 1.76E-20 0.82 rs7787577 G 2.76E-
21 









0.99 2.33E-04 2.11E+00 0.99 
rs73858966 A WHRadjB
MI 




0.65 3.64E-01 2.10E+00 0.98 
rs4281707 G T2D AKTIP 4.11E-12 0.48 rs8055279 T 1.48E-
12 
0.49 6.49E-02 1.36E+00 0.98 
rs4372913 G WHRadjB
MI 




0.39 5.84E-02 9.01E-01 0.98 
rs2513987 G WHR RP11-
690D19.3 











0.58 8.26E-02 1.62E+00 0.98 




0.58 8.26E-02 1.62E+00 0.98 









rs2013208 C HDL RBM6 2.17E-68 -0.99 rs2856234 G 2.73E-
71 
1.00 2.32E-04 1.16E+00 0.98 
rs7122539 G BMI RP11-
867G23.1 











0.78 2.19E-01 1.94E+00 0.98 
rs10463416 A WHRadjB
MI 
ABLIM3 4.59E-17 0.58 rs6889927 A 2.07E-
18 
0.61 5.89E-03 1.07E+00 0.98 
rs6684514 G Glycated 
hemoglobin 
levels 
CCT3 6.44E-20 0.68 rs2075166 G 2.63E-
20 
0.69 1.73E-01 5.65E-01 0.98 




0.81 4.73E-01 4.38E-01 0.98 














0.31 1.30E-01 1.24E+00 0.98 
rs6047259 T WHRadjB
MI 
















rs4281707 G T2D RBL2 4.15E-24 0.69 rs2908797 C 3.68E-
24 
0.68 5.90E-01 4.75E-01 0.98 
rs10832778 G BMI RP1-
239B22.5 
7.01E-11 0.42 rs7928810 A 5.82E-
11 
0.42 5.17E-01 3.09E-01 0.98 


















1.00 1.69E-02 8.82E-01 0.98 




1.00 1.92E-01 8.91E-01 0.98 





























0.55 8.53E-03 9.78E-01 0.97 




0.44 2.59E-01 4.37E-01 0.97 









rs12369009 T BMI RP3-
473L9.4 




























rs272889 A Metabolic 
traits 
AC034220.3 3.31E-48 -0.87 rs272852 A 1.47E-
50 








0.40 2.19E-01 5.43E-01 0.97 




0.86 6.51E-02 9.28E-01 0.97 
rs11600990 C BMI TEX40 3.79E-06 0.46 rs477895 T 5.74E-
07 
0.48 2.58E-02 9.78E-01 0.97 
rs7918400 T T2D RP11-
57H14.2 







rs10268050 C BMI NUDCD3 1.68E-21 0.75 rs6463234 A 1.20E-
21 
0.77 3.29E-01 4.97E-01 0.96 
rs12430764 A WHR GPC6 5.64E-12 0.46 rs1328369 T 2.21E-
13 
0.50 4.79E-03 8.85E-01 0.96 
rs2230590 C BMI MST1R 2.64E-06 0.32 rs9862795 T 1.67E-
06 
0.32 3.50E-01 3.24E-01 0.96 


































rs1801214 T T2D WFS1 1.83E-23 0.64 rs5018648 G 5.59E-
26 
0.67 6.69E-04 7.42E-01 0.96 







rs6980507 A Glycated 
hemoglobin 
levels 
SMIM19 8.02E-62 1.02 rs3099936 T 1.15E-
63 
1.06 2.75E-03 8.52E-01 0.96 







rs516946 C T2D ANK1 3.21E-06 0.39 rs3802315 G 1.85E-
06 
0.40 3.00E-01 4.56E-01 0.95 
rs3825061 T WHR HMBS 2.01E-18 0.68 rs4614 G 5.17E-
19 
0.68 8.69E-02 5.30E-01 0.95 

























0.99 4.98E-01 6.54E-01 0.95 
















rs11602339 T BMI MTCH2 5.82E-31 0.76 rs4752856 A 1.11E-
32 
0.79 4.79E-03 7.09E-01 0.95 
rs3825807 A Coronary 
heart 
disease 




0.38 1.36E-02 6.22E-01 0.95 
rs11123170 G blood urea 
nitrogen 




















1.35 1.65E-03 2.20E+00 0.94 
rs4932265 T T2D C15orf38-
AP3S2 
3.01E-40 0.92 rs4932143 G 2.64E-
43 
0.93 1.26E-04 7.67E-01 0.94 
rs6063048 G T2D EYA2 3.86E-09 0.45 rs1206773 G 6.90E-
10 
0.47 5.85E-02 6.31E-01 0.94 









rs2294120 A T2D RPL8 2.82E-45 -0.87 rs2954654 G 1.62E-
46 
0.87 1.07E-02 6.43E-01 0.93 
























1.27 9.19E-02 8.37E-01 0.93 


















0.69 1.61E-03 9.28E-01 0.93 



















rs2034088 T HIPadjBMI VPS53 3.96E-07 0.34 rs7214241 G 2.23E-
08 
0.38 8.88E-03 6.58E-01 0.92 















0.65 5.06E-04 7.38E-01 0.92 




0.90 8.07E-05 9.19E-01 0.92 
rs7102 C WHRadjB
MI 






















TSEN34 2.05E-12 0.57 rs36623 G 1.94E-
12 
0.56 2.95E-01 2.91E-01 0.92 






















0.62 1.54E-01 6.19E-01 0.91 
rs11917361 C WHRadjB
MI 




0.67 3.34E-03 6.95E-01 0.91 











rs10190332 T BMI RP11-
493E12.2 
1.03E-15 0.55 rs777589 C 7.21E-
17 
0.58 2.05E-02 4.99E-01 0.91 
rs8126001 C WHRadjB
MI 
RGS19 1.35E-16 -0.56 rs6062343 A 6.20E-
17 
0.56 1.58E-01 3.79E-01 0.90 
rs2275426 A BMI MAST2 5.75E-08 0.38 rs4626927 T 4.60E-
08 
0.38 3.40E-01 2.24E-01 0.90 






























0.54 7.90E-02 3.51E-01 0.90 













0.37 2.51E-02 4.53E-01 0.90 




0.91 8.50E-02 5.04E-01 0.90 
rs704 A LDL CTD-
2350C19.1 
2.48E-07 0.36 rs2073867 C 5.61E-
08 
0.37 9.03E-02 3.78E-01 0.89 
















rs6695980 T TG ATP2B4 2.33E-31 -0.71 rs6685593 A 2.21E-
35 
0.75 1.45E-05 8.81E-01 0.89 







rs2854322 T TC EVI2A 8.27E-07 0.35 rs2952994 T 5.71E-
08 
0.38 1.27E-02 6.21E-01 0.89 













0.74 2.90E-04 8.48E-01 0.89 
rs13333747 T WHR PKD1 3.77E-09 0.50 rs35786 T 1.99E-
09 
0.53 1.72E-01 3.45E-01 0.88 
rs10502148 C WHRadjB
MI 



























rs435306 G HDL PLTP 5.83E-25 0.78 rs6104410 G 1.16E-
26 
0.79 4.21E-03 6.46E-01 0.87 
rs2110073 T Glycated 
hemoglobin 
levels 



























0.38 4.59E-02 3.94E-01 0.87 
rs11917361 C WHRadjB
MI 
















rs7025486 A Abdominal 
aortic 
aneurysm 







rs2048327 C Coronary 
heart 
disease 




0.57 3.89E-02 4.61E-01 0.87 
rs6558295 G Metabolic 
traits 













0.46 7.09E-02 3.38E-01 0.86 




0.38 2.26E-03 5.43E-01 0.86 
rs7251505 G WHRadjB
MI 






















0.54 1.79E-03 4.83E-01 0.85 
rs630337 C LDL RHCE 1.78E-24 -0.66 rs665372 C 1.21E-
24 
0.65 3.54E-02 3.49E-01 0.85 


















0.55 1.11E-03 5.75E-01 0.84 
rs709400 G BMI APOPT1 1.40E-09 0.42 rs2274269 A 7.58E-
13 
0.50 4.67E-05 7.27E-01 0.84 




0.32 1.19E-01 2.89E-01 0.84 










rs2836961 C BMI PSMG1 2.21E-16 0.53 rs2836949 A 1.85E-
19 
0.58 1.75E-04 6.36E-01 0.83 
rs998732 A BMI YJEFN3 1.13E-16 0.89 rs7252453 G 7.96E-
21 
0.91 1.34E-05 9.78E-01 0.83 
rs998732 A BMI YJEFN3 1.13E-16 0.89 rs7252453 G 7.96E-
21 
0.91 1.34E-05 9.78E-01 0.83 
rs12369009 T BMI RP3-
462E2.5 
4.13E-13 0.64 rs2233861 A 4.19E-
15 
0.72 2.68E-03 7.02E-01 0.83 
chr10:65318
766 


















rs9988 T WHR MRPS7 3.33E-11 0.73 rs2306217 T 2.50E-
11 
0.78 9.83E-02 4.35E-01 0.83 







rs7187776 G BMI EIF3CL 9.08E-10 0.40 rs6565259 C 8.50E-
13 
0.47 1.49E-04 5.99E-01 0.83 
rs2066938 G Metabolic 
traits 




0.41 1.45E-02 4.07E-01 0.83 


















rs7871866 C BMI RP11-
339B21.15 


















rs6843738 G BMI MANBA 2.29E-15 0.53 rs223492 G 2.30E-
17 
0.56 2.23E-03 4.85E-01 0.82 
rs2633310 G T2D FUT11 8.98E-15 0.50 rs7072988 C 4.89E-
18 
0.56 1.19E-04 5.41E-01 0.82 







rs7184597 T Obesity RP11-
1348G14.1 











1.06 2.58E-02 2.14E+00 0.81 
rs7479183 T WHRadjB
MI 
AP006621.6 3.67E-12 -0.47 rs4963156 T 5.21E-
14 






TMEM60 3.66E-17 0.57 rs1544459 T 7.34E-
20 
0.60 4.31E-04 5.47E-01 0.81 
rs761423 T BMI MST1L 2.43E-13 0.53 rs7517838 C 1.29E-
13 
0.57 1.10E-01 3.39E-01 0.81 
rs12138803 T WHRadjB
MI 
PIGC 7.64E-06 0.36 rs1132148 G 1.08E-
08 
0.49 2.28E-04 6.31E-01 0.81 
rs17154889 C WHRadjB
MI 
PPIP5K2 8.55E-08 0.39 rs187427 C 3.91E-
10 
0.47 8.39E-04 6.02E-01 0.81 
rs6949451 T WHRadjB
MI 
HOXA-AS4 5.67E-20 0.61 rs6461991 C 2.39E-
22 
0.65 4.56E-04 4.99E-01 0.80 
rs12448257 A BMI DNASE1 4.90E-11 0.60 rs7199766 A 7.36E-
13 
0.66 3.51E-03 5.69E-01 0.80 
rs3731861 C WHRadjB
MI 







rs704 A LDL TMEM199 1.28E-08 0.39 rs967645 T 5.13E-
11 
0.45 9.75E-04 5.03E-01 0.80 
rs6499165 A Metabolic 
traits 
PLA2G15 3.37E-12 0.49 rs8056893 C 1.87E-
15 
0.58 1.24E-04 6.05E-01 0.80 
Table 2.9: Primary eQTLs (FDR <1%) colocalized with GWAS variants based on linkage disequilibrium and conditional analysis between 
GWAS and lead eQTL variants Shown above are LD and conditional analysis values for GWAS variants and eQTL variants found to be 
colocalized. We matched the eQTL allele to the GWAS risk increasing. This table is sorted by the LD r2 between the lead eQTL and the GWAS 
variant and then by the initial p-value of the GWAS variant's association with a nearby gene. LD r2 was calculated in 10K Finns from METSIM. An 


















Genes (%) for which 








d genes  
Genes (%) for which 




BMI 310 85 116 60 (52%) 12 11 4 (36%) 
All Lipids 186 56 62 31 (50%) 7 7 3 (43%) 
  HDL 73 25 30 18 (60%) 3 3 2 (67%) 
  LDL 64 16 18 8 (44%) 1 1 0 (0%) 
  Triglycerides 42 18 19 11 (58%) 2 2 1 (50%) 
  Total 
Cholesterol 
47 
13 13 6 (46%) 2 2 1 (50%) 
WHRadjBMI 157 48 57 35 (61%) 9 9 5 (56%) 
WHR 134 40 49 32 (65%) 6 6 3 (50%) 
T2D 115 28 37 20 (54%) 7 8 4 (50%) 
Cardiovascular 
  Disease 
 
28 9 10 6 (60%)  -  -  - 
Adiponectin 11 4 4 2 (50%)  -  -  - 
Any Trait 874 231 287 152 (53%) 31 31 15 (48%) 
Table 2.10: Primary and secondary eQTLs colocalized at GWAS lociColocalized eQTL (FDR < 1%; P < 9.63 ´ 10-6) among 2,843 GWAS 
signals (variants clumped by LD r2 > 0.8) associated with one or more of 93 cardiometabolic traits. Each GWAS variant may colocalize with an 
eQTL for more than one gene. GWAS signals reported for multiple traits are included in counts of colocalized eQTLs for each trait, so signals and 
genes are not unique by row. Percentages expressed as the number of genes for which the GWAS risk allele was associated with decreased 
expression among all colocalized genes for that trait. No secondary eQTL signals were found to be colocalized with GWAS loci for cardiovascular 






   Primary eQTL signals 







Percent (%) of tested 
GWAS variants found 
to be colocalized 
BMI 851 257 69 8% 
All Lipids 79 31 11 14% 
   HDL 29 10 2 7% 
   LDL 17 8 3 18% 
   Triglycerides 19 8 4 21% 
   Total 
Cholesterol 15 7 2 13% 
WHRadjBMI 381 147 45 12% 
WHR 204 107 30 15% 
T2D 263 86 22 8% 
Any Trait 1777 545 177 10% 
Table 2.11: Proportion of tested GWAS signals colocalized Proportions of all GWAS signals (column 
B), by trait, that were colocalized with adipose eQTLs (column E). Signals were determined to be 
colocalized by LD & reciprocal conditional analysis. GWAS signals indicates that the GWAS signal was 
looked up in the eQTL data, but does not indicate whether any gene was associated with it. Colocalized 
signals were required to be a subset of all GWAS signals, from the following papers: Pulit et al. (Hum Mol 
Genet 2019) for WHR & WHRadjBMI, Yengo et al. (Hum Mol Genet 2018) for BMI, Mahajan et al. (Nat. 





GWAS lead variant   GWAS variant association 
with eQTL gene 
Lead eQTL variant (eSNP) 
association with eQTL gene 
Lead eQTL variant 
(eSNP) conditioned 
on GWAS variant 
 












Pcond βcond LD 
r2 









rs4883201 A TC M6PR 6.47E-
15 





rs235374 C HDL PTTG1IP 4.26E-
09 





rs758747 T BMI CLUAP1 5.17E-
08 





rs2240108 C BMI SLC48A1 1.46E-
07 





















































rs1575972 A T2D DMRTA1 6.70E-
06 
















rs3111316 A T2D GCDH 9.79E-
07 























































































rs10876528 A WHR HOXC4 1.36E-
10 





rs7715806 C BMI POC5 2.72E-
06 
















rs7811265 A TG BCL7B 4.12E-
11 




























































rs2307111 T BMI POC5 3.05E-
06 





























rs761423 T BMI NBPF1 7.23E-
06 











Table 2.12: Secondary eQTLs (FDR <1%) colocalized with GWAS variants based on linkage disequilibrium and conditional analysis 
between GWAS and lead eQTL variants Shown above are LD and conditional analysis values for GWAS variants and eQTL variants found to be 
colocalized. We matched the eQTL allele to the GWAS risk increasing allele. This table is sorted by the LD r2 between the lead eQTL and the 
GWAS variant and then by the initial p-value of the GWAS variant's association with a nearby gene. LD r2 was calculated in 10K Finns from 







  coloc2 Posterior Probabilities for 
Four Hypotheses 
Source of GWAS Summary Statistics GWAS-
eSNP 
  












Trait Publication LD r2 Interpretation 
of coloc2 
evidence 
AC018720.10 407 0.00 0.00 0.00 0.00 1.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
NSUN5P1 414 0.00 0.00 0.00 0.00 1.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.987 Strong evidence 
of colocalization; 
PP H4 > .8  




PP H4 > .8  
POM121C 410 0.00 0.00 0.00 0.00 1.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.991 Strong evidence 
of colocalization; 
PP H4 > .8  
GNL3 969 0.00 0.00 0.00 0.00 1.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.955 Strong evidence 
of colocalization; 
PP H4 > .8  




PP H4 > .8  




PP H4 > .8  




PP H4 > .8  
MST1L 1060 0.00 0.00 0.00 0.00 1.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.809 Strong evidence 
of colocalization; 
PP H4 > .8  




PP H4 > .8  




PP H4 > .8  
RP11-1348G14.4 566 0.00 0.00 0.00 0.02 0.98 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Strong evidence 
of colocalization; 




SLC27A4 1140 0.00 0.00 0.00 0.03 0.97 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.992 Strong evidence 
of colocalization; 
PP H4 > .8  
PM20D1 1380 0.00 0.00 0.00 0.03 0.97 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.996 Strong evidence 
of colocalization; 
PP H4 > .8  
TNFAIP8 6220 0.00 0.00 0.00 0.03 0.97 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.998 Strong evidence 
of colocalization; 
PP H4 > .8  
CPED1 4620 0.00 0.00 0.00 0.04 0.96 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
RP1-239B22.5 1560 0.00 0.00 0.00 0.04 0.96 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.977 Strong evidence 
of colocalization; 
PP H4 > .8  
STAB1 835 0.00 0.00 0.00 0.04 0.96 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.977 Strong evidence 
of colocalization; 
PP H4 > .8  
RSPO3 3640 0.00 0.00 0.00 0.04 0.96 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.932 Strong evidence 
of colocalization; 
PP H4 > .8  
ADH1A 6140 0.00 0.00 0.00 0.05 0.95 WHR Pulit et al. (Hum Mol Genet 2019) 0.997 Strong evidence 
of colocalization; 
PP H4 > .8  
YWHAZ 1740 0.00 0.00 0.00 0.05 0.95 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.989 Strong evidence 
of colocalization; 
PP H4 > .8  
RCN1 1300 0.00 0.00 0.00 0.05 0.95 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.848 Strong evidence 
of colocalization; 
PP H4 > .8  
RP11-339B21.13 1130 0.00 0.00 0.00 0.05 0.95 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.992 Strong evidence 
of colocalization; 
PP H4 > .8  




PP H4 > .8  
MRPS6 5090 0.00 0.01 0.00 0.04 0.95 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.833 Strong evidence 
of colocalization; 
PP H4 > .8  
CTD-2002J20.1 780 0.00 0.01 0.00 0.05 0.94 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.988 Strong evidence 
of colocalization; 
PP H4 > .8  
JAZF1 4720 0.00 0.00 0.00 0.06 0.94 T2D Mahajan et al. (Nat. Genet. 2018) 1.000 Strong evidence 
of colocalization; 




NTHL1 922 0.00 0.00 0.00 0.06 0.94 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.837 Strong evidence 
of colocalization; 
PP H4 > .8  
TEX40 910 0.00 0.01 0.00 0.05 0.94 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.965 Strong evidence 
of colocalization; 
PP H4 > .8  
CTC-228N24.3 5350 0.00 0.00 0.00 0.06 0.94 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.998 Strong evidence 
of colocalization; 
PP H4 > .8  
HEY2 1290 0.00 0.00 0.00 0.06 0.94 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
RP1-18D14.7 1300 0.00 0.00 0.00 0.07 0.93 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.996 Strong evidence 
of colocalization; 
PP H4 > .8  
TAL1 1310 0.00 0.00 0.00 0.07 0.93 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.999 Strong evidence 
of colocalization; 
PP H4 > .8  
DHRS11 983 0.00 0.00 0.00 0.07 0.93 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.990 Strong evidence 
of colocalization; 
PP H4 > .8  
C10orf112 2690 0.00 0.00 0.00 0.07 0.93 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.912 Strong evidence 
of colocalization; 
PP H4 > .8  
C17orf82 2970 0.00 0.00 0.00 0.08 0.92 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.999 Strong evidence 
of colocalization; 
PP H4 > .8  
MED24 965 0.00 0.00 0.00 0.08 0.92 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
HMGB1 6270 0.00 0.00 0.00 0.09 0.91 WHR Pulit et al. (Hum Mol Genet 2019) 0.948 Strong evidence 
of colocalization; 
PP H4 > .8  
BEND6 1260 0.00 0.00 0.00 0.09 0.91 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.988 Strong evidence 
of colocalization; 
PP H4 > .8  




PP H4 > .8  
DISP2 4460 0.00 0.00 0.00 0.09 0.91 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
KAT8 498 0.00 0.00 0.00 0.10 0.91 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.999 Strong evidence 
of colocalization; 





TIPARP 5480 0.00 0.00 0.00 0.11 0.89 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 1.000 Strong evidence 
of colocalization; 
PP H4 > .8  
MST1R 640 0.00 0.01 0.00 0.09 0.89 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.964 Strong evidence 
of colocalization; 
PP H4 > .8  
NPC1 1350 0.00 0.00 0.00 0.12 0.88 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.997 Strong evidence 
of colocalization; 
PP H4 > .8  
ZNHIT3 4330 0.00 0.00 0.00 0.12 0.87 WHR Pulit et al. (Hum Mol Genet 2019) 0.993 Strong evidence 
of colocalization; 
PP H4 > .8  






PP H4 > .8  
IPO9 1660 0.00 0.00 0.00 0.14 0.86 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.971 Strong evidence 
of colocalization; 
PP H4 > .8  
CPSF4 853 0.00 0.00 0.00 0.16 0.84 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.982 Strong evidence 
of colocalization; 
PP H4 > .8  
PKD1 5580 0.00 0.00 0.00 0.16 0.84 WHR Pulit et al. (Hum Mol Genet 2019) 0.884 Strong evidence 
of colocalization; 
PP H4 > .8  
MFAP2 5130 0.00 0.00 0.00 0.17 0.83 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.997 Strong evidence 
of colocalization; 
PP H4 > .8  
MTOR 1160 0.00 0.00 0.00 0.17 0.83 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.989 Strong evidence 
of colocalization; 
PP H4 > .8  
AC097724.3 2030 0.00 0.00 0.00 0.19 0.81 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.873 Strong evidence 
of colocalization; 
PP H4 > .8  





PP H4 > .5 
RGS19 4070 0.00 0.00 0.00 0.21 0.79 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.905 Moderate 
evidence of 
colocalization; 
PP H4 > .5 














PP H4 > .5 
AP3S2 4580 0.00 0.00 0.00 0.23 0.78 T2D Mahajan A (biorxiv 2017) 0.921 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
C15orf38-AP3S2 4580 0.00 0.00 0.00 0.23 0.78 T2D Mahajan A (biorxiv 2017) 0.939 Moderate 
evidence of 
colocalization; 
PP H4 > .5 





PP H4 > .5 
LITAF 8230 0.00 0.00 0.00 0.24 0.76 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.920 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
ABLIM3 5300 0.00 0.00 0.00 0.25 0.75 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.980 Moderate 
evidence of 
colocalization; 
PP H4 > .5 





PP H4 > .5 





PP H4 > .5 
TBX18 5430 0.00 0.04 0.00 0.22 0.74 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.998 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
COL8A1 5030 0.00 0.00 0.00 0.31 0.69 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.985 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
EYA2 4280 0.00 0.00 0.10 0.23 0.67 T2D Mahajan et al. (Nat. Genet. 2018) 0.936 Moderate 
evidence of 
colocalization; 




EEF1G 4630 0.00 0.01 0.00 0.33 0.66 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.952 Moderate 
evidence of 
colocalization; 
PP H4 > .5 





PP H4 > .5 
GPC6 5850 0.00 0.00 0.00 0.38 0.62 WHR Pulit et al. (Hum Mol Genet 2019) 0.964 Moderate 
evidence of 
colocalization; 
PP H4 > .5 





PP H4 > .5 





PP H4 > .5 





PP H4 > .5 
CRYAB 4400 0.00 0.00 0.00 0.40 0.60 WHR Pulit et al. (Hum Mol Genet 2019) 0.871 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
ROM1 4610 0.00 0.00 0.00 0.41 0.59 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.842 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
PLK1S1 4030 0.00 0.00 0.00 0.41 0.58 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.980 Moderate 
evidence of 
colocalization; 
PP H4 > .5 
FST 6630 0.00 0.02 0.00 0.41 0.58 WHR Pulit et al. (Hum Mol Genet 2019) 0.968 Moderate 
evidence of 
colocalization; 
PP H4 > .5 














PP H4 > .5 





PP H4 > .5 





PP H4 > .5 





GWAS and eQTL 
signals differ; PP 
H3 > .8 
SNX10 5690 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
AAMP 4340 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.802 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
TRIP4 1040 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.896 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
HEMK1 696 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.913 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
ZNF75A 4880 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.977 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
AC013264.2 1260 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.918 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
NUDCD3 1450 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.964 Evidence that 
GWAS and eQTL 
signals differ; PP 




HOXA11-AS 5470 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.945 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-433P17.3 4950 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-3B7.1 645 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.915 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
ARIH2 598 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.997 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
C1orf213 4240 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
CEBPA-AS1 6320 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.855 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
BRWD1-IT2 2330 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.833 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PSMG1 2290 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.835 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
AP006621.6 5520 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.811 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
CCDC36 636 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.915 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PIDD 5590 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.990 Evidence that 
GWAS and eQTL 
signals differ; PP 




DNASE1 1070 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.803 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP3-462E2.5 748 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.834 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PRDX6 944 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
SCAPER 1110 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.982 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PACS1 701 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.995 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
AKTIP 4330 0.00 0.00 0.00 1.00 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.984 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP1-178F10.3 3000 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.818 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-755F10.1 631 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.885 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
NCKIPSD 594 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.919 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
MANBA 1460 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.818 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 





GWAS and eQTL 
signals differ; PP 




YJEFN3 849 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.834 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
HLA-DRB6 2750 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.986 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
HOXA-AS4 5490 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.804 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RBL2 4180 0.00 0.00 0.00 1.00 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.978 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-57H14.2 3550 0.00 0.00 0.00 1.00 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.964 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
WDR6 607 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.997 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
NDUFAF1 1210 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
1.000 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
CBX3 5810 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-804H8.6 668 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.950 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PIGC 4740 0.00 0.00 0.00 1.00 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.807 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
C11orf49 847 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.999 Evidence that 
GWAS and eQTL 
signals differ; PP 




RP11-493E12.2 1270 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.907 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
TSPY26P 1170 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.971 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
MAST2 1010 0.00 0.00 0.00 1.00 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.904 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
MRPS7 5340 0.00 0.00 0.00 0.99 0.01 WHR Pulit et al. (Hum Mol Genet 2019) 0.833 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
MAST4-AS1 5500 0.00 0.00 0.00 0.99 0.01 WHR Pulit et al. (Hum Mol Genet 2019) 0.886 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
ATXN2L 555 0.00 0.00 0.00 0.99 0.01 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.933 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
ELP6 2920 0.00 0.00 0.00 0.99 0.01 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.868 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
EIF3CL 748 0.00 0.00 0.00 0.99 0.01 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.830 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-380L11.4 5180 0.00 0.02 0.00 0.98 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.946 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
C11orf52 4400 0.00 0.00 0.00 0.98 0.02 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.875 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
NET1 7850 0.00 0.01 0.00 0.97 0.02 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.975 Evidence that 
GWAS and eQTL 
signals differ; PP 




PPIP5K2 5050 0.00 0.00 0.00 0.97 0.03 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.805 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
LAMB1 4960 0.00 0.00 0.00 0.97 0.03 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.924 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
CCDC144B 2710 0.00 0.04 0.00 0.96 0.00 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 1.000 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP3-473L9.4 580 0.00 0.04 0.00 0.96 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.971 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
LMOD1 1660 0.00 0.00 0.00 0.95 0.05 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.987 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-867G23.1 627 0.00 0.08 0.00 0.92 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.980 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
PABPC4 3740 0.00 0.00 0.00 0.91 0.09 T2D Mahajan et al. (Nat. Genet. 2018) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
SH2B1 526 0.00 0.00 0.00 0.90 0.11 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.930 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
FHOD1 694 0.00 0.00 0.12 0.88 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.932 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
MARCH5 4150 0.00 0.00 0.00 0.88 0.12 WHR Pulit et al. (Hum Mol Genet 2019) 0.999 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
AC003090.1 6220 0.00 0.00 0.00 0.87 0.13 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.827 Evidence that 
GWAS and eQTL 
signals differ; PP 




NRBF2 5540 0.00 0.00 0.00 0.87 0.14 WHR Pulit et al. (Hum Mol Genet 2019) 0.833 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 





GWAS and eQTL 
signals differ; PP 
H3 > .8 
SETD2 3450 0.00 0.00 0.00 0.84 0.16 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.870 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
CTC-277H1.7 689 0.01 0.08 0.11 0.81 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.952 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .8 
RP11-95O2.5 4530 0.00 0.00 0.00 0.80 0.20 WHR Pulit et al. (Hum Mol Genet 2019) 0.959 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
LMX1B 1520 0.00 0.21 0.00 0.79 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.956 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
AC017074.2 4710 0.00 0.01 0.00 0.72 0.27 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.983 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
EIF4G2 6990 0.00 0.22 0.00 0.72 0.07 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) same lead 
variant 
Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
CCDC12 3880 0.00 0.00 0.00 0.72 0.28 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.912 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
IRS1 4620 0.00 0.00 0.00 0.72 0.28 T2D Mahajan et al. (Nat. Genet. 2018) 0.925 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
TMEM60 6050 0.00 0.00 0.00 0.69 0.31 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.811 Evidence that 
GWAS and eQTL 
signals differ; PP 




RP11-690D19.3 6430 0.00 0.00 0.00 0.66 0.34 WHR Pulit et al. (Hum Mol Genet 2019) 0.983 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
FBXL18 961 0.00 0.00 0.00 0.65 0.35 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.977 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
UHRF1BP1 1330 0.00 0.00 0.00 0.65 0.35 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.993 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
PLCL1 1220 0.00 0.01 0.00 0.60 0.38 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.935 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
PHC2 1540 0.00 0.00 0.00 0.58 0.42 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.903 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
RP11-339B21.15 1110 0.00 0.00 0.00 0.55 0.45 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.822 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
SH3PXD2B 5660 0.00 0.00 0.00 0.55 0.45 WHRadjBMI Pulit et al. (Hum Mol Genet 2019) 0.991 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 
FARSA 3220 0.00 0.00 0.01 0.54 0.46 T2D Mahajan et al. (Nat. Genet. 2018) 0.962 Evidence that 
GWAS and eQTL 
signals differ; PP 
H3 > .5 







probability > .5  




Evidence that the 
eQTL signal is 
not sufficiently 
strong 
CCND2 4710 0.00 0.73 0.00 0.26 0.00 T2D Mahajan et al. (Nat. Genet. 2018) same lead 
variant 
Evidence that the 






RP11-53O19.3 2490 0.00 0.00 0.92 0.08 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.908 Evidence that the 





433 0.00 0.00 0.95 0.05 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.989 Evidence that the 
GWAS signal is 
not sufficiently 
strong 
LINC00680 400 0.00 0.00 0.95 0.05 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.998 Evidence that the 





400 0.00 0.00 0.95 0.05 0.00 BMI Yengo et al. (Hum Mol Genet 
2018) 
0.990 Evidence that the 
GWAS signal is 
not sufficiently 
strong 
RFT1 3240 0.00 0.00 0.97 0.03 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.995 Evidence that the 
GWAS signal is 
not sufficiently 
strong 
SFMBT1 3140 0.00 0.00 0.97 0.02 0.00 T2D Mahajan et al. (Nat. Genet. 2018) 0.862 Evidence that the 
GWAS signal is 
not sufficiently 
strong 
HSD17B12 4970 0.00 0.00 0.97 0.02 0.01 T2D Mahajan et al. (Nat. Genet. 2018) same lead 
variant 
Evidence that the 
GWAS signal is 
not sufficiently 
strong 
Table 2.13: Coloc2 summaries of 173 genes found to be colocalized by conditional analysis Comparison of colocalization of GWAS and 
eQTL signals based on LD and conditional analysis to coloc. This comparison was limited to GWAS publications reporting more than 10 eGenes 
found to be colocalized based on LD and conditional analysis. Coloc2 hypotheses are: H0: neither trait has a genetic association in the region, H1: 
only trait 1 (GWAS) has a genetic association in the region, H2: only trait 2 (eQTL) has a genetic association in the region, H3: both traits are 
associated, but with different causal variants, and H4: both traits are associated and share a single causal variant. We provide interpretations 
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Table 2.14: Comparison of LD for loci with strongest GWAS signals for BMI identified in East Asians This table shows cis-eQTL results for 
which the GWAS-eQTL lead variant EUR LD r2 > 0.6 and the strongest GWAS p-value came from a study of East Asians (Akiyama M et al. Nat 
Genet 2017). The results are sorted by GWAS-eQTL lead variant LD (r2) in all METSIM (~10k Finnish men) imputed to the Haplotype Reference 
Consortium (HRC), then by the initial eQTL p-value of the GWAS variant. We matched the eQTL allele to the GWAS risk allele. The “Interpretation 
of colocalization” column shows the interpretation of colocalization based on METSIM LD and conditional analysis criteria. LD r2 in East Asians 
presented from 1000 Genomes, phase 3 (1KG) and LD r2 in Finns presented from METSIM 10K HRC imputation. Colocalization is defined as LD 





  BMI Fasting Free Fatty Acids Matsuda Index 
Gene P β FDR P β FDR P β FDR 
AOC1 4.1E-02 9.8E-02 9.7E-02 2.6E-01 -5.4E-02 3.1E-01 2.3E-02 -1.1E-01 6.5E-02 
RBM6 3.9E-01 -4.1E-02 3.9E-01 8.4E-01 9.6E-03 5.7E-01 2.0E-01 -6.2E-02 2.7E-01 
PKD1 3.7E-03 -1.4E-01 1.8E-02 7.2E-02 -8.6E-02 1.4E-01 1.5E-03 1.5E-01 8.5E-03 
MED24 3.3E-02 1.0E-01 8.4E-02 2.1E-01 6.0E-02 2.8E-01 2.3E-03 -1.5E-01 1.2E-02 
MLXIPL 4.8E-01 3.4E-02 4.3E-01 9.1E-01 5.2E-03 5.9E-01 9.7E-01 1.9E-03 6.1E-01 
STAB1 1.6E-04 -1.8E-01 1.4E-03 5.9E-01 2.6E-02 4.8E-01 6.3E-03 1.3E-01 2.6E-02 
NPC1L1 4.5E-02 -9.6E-02 1.0E-01 9.1E-01 5.2E-03 5.9E-01 2.4E-01 5.7E-02 3.0E-01 
NUDCD3 8.0E-03 1.3E-01 3.1E-02 4.3E-01 -3.8E-02 4.1E-01 7.7E-02 -8.5E-02 1.5E-01 
SLC7A9 1.1E-01 7.7E-02 1.9E-01 1.1E-01 7.8E-02 1.8E-01 5.5E-01 -2.8E-02 4.7E-01 
ANK1 1.6E-02 1.2E-01 5.0E-02 3.4E-01 4.6E-02 3.6E-01 8.2E-03 -1.3E-01 3.1E-02 
RCN1 4.2E-19 4.1E-01 2.8E-16 1.6E-01 6.8E-02 2.3E-01 6.8E-25 -4.7E-01 2.8E-21 
ANAPC4 9.6E-09 2.7E-01 3.2E-07 5.7E-03 1.3E-01 2.4E-02 5.1E-14 -3.5E-01 1.0E-11 
ATP2B4 5.4E-01 2.9E-02 4.6E-01 9.7E-01 -1.8E-03 6.1E-01 5.0E-01 -3.3E-02 4.4E-01 
PIGV 2.8E-08 2.6E-01 8.1E-07 6.0E-02 9.0E-02 1.2E-01 4.1E-06 -2.2E-01 6.2E-05 
EYA2 5.8E-02 -9.1E-02 1.2E-01 9.5E-01 -3.1E-03 6.0E-01 1.3E-01 7.4E-02 2.0E-01 
NTHL1 5.0E-01 3.3E-02 4.4E-01 8.0E-01 1.2E-02 5.6E-01 9.5E-01 -3.2E-03 6.0E-01 
UHRF1BP1 1.6E-02 1.2E-01 5.1E-02 1.1E-01 7.7E-02 1.8E-01 1.6E-01 -6.8E-02 2.4E-01 
APOB 5.4E-01 -2.9E-02 4.6E-01 8.1E-01 1.2E-02 5.6E-01 6.9E-01 -1.9E-02 5.2E-01 
MAST2 9.2E-04 1.6E-01 5.9E-03 1.9E-02 1.1E-01 5.7E-02 6.9E-03 -1.3E-01 2.8E-02 
SNX10 5.6E-01 2.8E-02 4.7E-01 3.1E-01 4.9E-02 3.4E-01 3.8E-01 -4.3E-02 3.8E-01 
DOCK3 1.4E-02 1.2E-01 4.7E-02 5.7E-01 2.7E-02 4.8E-01 1.1E-01 -7.7E-02 1.9E-01 
PLK1S1 1.1E-08 2.7E-01 3.6E-07 8.4E-01 9.9E-03 5.7E-01 3.7E-10 -3.0E-01 1.7E-08 
PABPC4 2.1E-14 3.6E-01 4.9E-12 8.8E-02 8.2E-02 1.6E-01 4.0E-15 -3.7E-01 1.2E-12 
CERS4 3.3E-04 1.7E-01 2.5E-03 3.3E-01 4.7E-02 3.6E-01 2.8E-06 -2.2E-01 4.6E-05 
LAMB1 1.7E-02 -1.1E-01 5.3E-02 4.4E-01 -3.7E-02 4.2E-01 1.8E-03 1.5E-01 1.0E-02 
CWF19L1 3.0E-04 -1.7E-01 2.3E-03 8.4E-01 -9.8E-03 5.7E-01 9.5E-04 1.6E-01 6.0E-03 




PLTP 8.7E-01 7.7E-03 5.8E-01 3.2E-01 -4.8E-02 3.5E-01 1.4E-01 -7.1E-02 2.2E-01 
PROCR 2.6E-11 3.1E-01 1.8E-09 5.2E-01 3.1E-02 4.5E-01 1.6E-10 -3.0E-01 9.0E-09 
POLR2C 2.4E-07 2.4E-01 5.3E-06 7.0E-01 1.9E-02 5.3E-01 1.2E-04 -1.8E-01 1.1E-03 
PLA2G15 2.3E-06 -2.2E-01 3.9E-05 6.9E-01 -1.9E-02 5.2E-01 1.1E-04 1.8E-01 1.1E-03 
RBL2 7.1E-01 1.8E-02 5.3E-01 3.1E-01 4.9E-02 3.4E-01 2.5E-01 -5.6E-02 3.0E-01 
KAT8 5.6E-11 3.1E-01 3.5E-09 7.9E-01 -1.3E-02 5.6E-01 1.2E-12 -3.3E-01 1.5E-10 
LACTB 9.4E-01 -3.4E-03 6.0E-01 2.7E-01 -5.3E-02 3.2E-01 7.5E-01 -1.5E-02 5.5E-01 
TRIP4 7.4E-02 -8.6E-02 1.4E-01 4.6E-01 -3.6E-02 4.2E-01 4.4E-02 9.7E-02 1.0E-01 
EYA1 8.3E-01 1.0E-02 5.7E-01 6.7E-01 2.0E-02 5.2E-01 8.4E-01 -9.5E-03 5.7E-01 
CPED1 2.7E-09 -2.8E-01 1.1E-07 2.0E-01 -6.1E-02 2.8E-01 1.0E-11 3.2E-01 8.8E-10 
BCL7B 7.6E-18 4.0E-01 3.4E-15 9.9E-02 7.9E-02 1.7E-01 3.8E-20 -4.2E-01 3.1E-17 
AKNA 4.3E-01 3.8E-02 4.1E-01 4.4E-02 9.7E-02 1.0E-01 1.4E-02 -1.2E-01 4.7E-02 
LIPA 2.8E-01 5.1E-02 3.3E-01 2.8E-01 5.2E-02 3.2E-01 8.7E-01 7.8E-03 5.8E-01 
OBFC1 6.7E-12 3.2E-01 6.7E-10 1.4E-01 7.2E-02 2.2E-01 2.9E-08 -2.6E-01 8.3E-07 
DHRS11 9.3E-04 -1.6E-01 5.9E-03 2.2E-01 -5.9E-02 2.9E-01 4.6E-05 1.9E-01 5.0E-04 
ZNHIT3 1.1E-01 -7.6E-02 1.9E-01 4.9E-01 3.4E-02 4.4E-01 2.7E-01 5.3E-02 3.2E-01 
PSMD3 3.4E-02 1.0E-01 8.4E-02 9.4E-01 3.5E-03 6.0E-01 7.2E-02 -8.7E-02 1.4E-01 
CDK5RAP3 2.2E-01 5.9E-02 2.8E-01 2.7E-01 5.3E-02 3.2E-01 3.5E-01 -4.5E-02 3.7E-01 
MANBA 2.2E-01 -5.9E-02 2.9E-01 3.9E-01 4.1E-02 3.9E-01 3.1E-01 4.9E-02 3.4E-01 
WFS1 5.4E-06 -2.2E-01 7.9E-05 9.7E-01 1.6E-03 6.1E-01 1.2E-07 2.5E-01 2.9E-06 
CRYAB 2.2E-04 1.8E-01 1.8E-03 3.7E-01 4.3E-02 3.8E-01 3.4E-05 -2.0E-01 4.0E-04 
MTCH2 9.2E-01 4.7E-03 5.9E-01 4.8E-01 3.4E-02 4.3E-01 8.3E-01 1.0E-02 5.7E-01 




Table 2.15: Gene expression - trait associations (unadjusted for BMI) for genes colocalized by LD This table shows selected results from 
the gene expression – clinical trait associations. Traits were adjusted for age and genes were adjusted TIN, sequencing batch, and age. Both traits 
and genes were inverse normal transformed prior to linear regression. FDR was calculated using the Storey method. An extended version of this 







  BMI Fasting Free Fatty Acids Matsuda Index 
Gene P β FDR P β FDR P β FDR 
AOC1 8.8E-01 7.6E-03 8.6E-01 1.7E-01 -6.6E-02 5.6E-01 8.1E-02 -8.4E-02 4.4E-01 
RBM6 8.2E-01 1.1E-02 8.5E-01 6.7E-01 2.0E-02 8.1E-01 5.7E-02 -9.1E-02 3.8E-01 
PKD1 5.1E-01 3.1E-02 7.7E-01 1.9E-01 -6.3E-02 5.8E-01 9.6E-03 1.2E-01 1.8E-01 
MED24 8.7E-01 -8.2E-03 8.5E-01 3.5E-01 4.5E-02 6.9E-01 2.5E-02 -1.1E-01 2.8E-01 
MLXIPL 9.1E-01 -5.2E-03 8.6E-01 9.6E-01 2.4E-03 8.7E-01 5.3E-01 3.0E-02 7.8E-01 
STAB1 8.8E-01 -7.1E-03 8.6E-01 2.5E-01 5.5E-02 6.3E-01 4.4E-01 3.7E-02 7.4E-01 
NPC1L1 8.3E-01 -1.1E-02 8.5E-01 6.7E-01 2.0E-02 8.1E-01 8.1E-01 1.2E-02 8.5E-01 
NUDCD3 7.9E-01 1.3E-02 8.4E-01 2.3E-01 -5.8E-02 6.1E-01 4.4E-01 -3.7E-02 7.4E-01 
SLC7A9 9.7E-01 1.5E-03 8.7E-01 1.5E-01 6.9E-02 5.3E-01 8.6E-01 8.2E-03 8.5E-01 
ANK1 6.0E-01 2.5E-02 7.9E-01 5.2E-01 3.1E-02 7.7E-01 3.1E-02 -1.0E-01 3.0E-01 
RCN1 4.2E-01 3.8E-02 7.3E-01 8.5E-01 8.9E-03 8.5E-01 1.6E-13 -3.4E-01 3.1E-10 
ANAPC4 8.0E-01 1.2E-02 8.4E-01 2.9E-02 1.0E-01 3.0E-01 3.4E-08 -2.6E-01 3.9E-05 
ATP2B4 9.0E-01 -5.9E-03 8.6E-01 9.3E-01 -4.4E-03 8.6E-01 8.6E-01 -8.7E-03 8.5E-01 
PIGV 9.7E-01 -1.6E-03 8.7E-01 2.7E-01 5.3E-02 6.4E-01 5.2E-02 -9.3E-02 3.7E-01 
EYA2 7.7E-01 -1.4E-02 8.3E-01 8.2E-01 1.1E-02 8.5E-01 3.2E-01 4.8E-02 6.8E-01 
NTHL1 8.4E-01 -9.5E-03 8.5E-01 8.6E-01 8.6E-03 8.5E-01 4.4E-01 3.7E-02 7.4E-01 
UHRF1BP1 7.3E-01 -1.7E-02 8.2E-01 2.0E-01 6.2E-02 5.8E-01 8.5E-01 -9.3E-03 8.5E-01 
APOB 8.8E-01 7.0E-03 8.6E-01 7.5E-01 1.5E-02 8.3E-01 5.5E-01 -2.9E-02 7.8E-01 
MAST2 8.4E-01 9.5E-03 8.5E-01 4.4E-02 9.7E-02 3.4E-01 1.2E-01 -7.5E-02 4.9E-01 
SNX10 7.1E-01 -1.8E-02 8.2E-01 3.0E-01 5.0E-02 6.6E-01 8.0E-01 -1.3E-02 8.4E-01 
DOCK3 7.7E-01 1.4E-02 8.4E-01 8.1E-01 1.2E-02 8.5E-01 4.3E-01 -3.8E-02 7.3E-01 
PLK1S1 7.1E-01 1.8E-02 8.2E-01 4.7E-01 -3.5E-02 7.5E-01 1.0E-05 -2.1E-01 2.3E-03 
PABPC4 6.5E-01 2.2E-02 8.1E-01 4.9E-01 3.4E-02 7.6E-01 4.0E-07 -2.4E-01 1.9E-04 
CERS4 8.2E-01 1.1E-02 8.5E-01 6.4E-01 2.3E-02 8.0E-01 6.1E-04 -1.6E-01 3.7E-02 
LAMB1 8.2E-01 1.1E-02 8.5E-01 7.0E-01 -1.8E-02 8.2E-01 7.1E-03 1.3E-01 1.5E-01 




SCD 9.7E-01 -1.9E-03 8.7E-01 5.7E-01 -2.7E-02 7.8E-01 3.2E-02 -1.0E-01 3.0E-01 
PLTP 8.3E-01 -1.0E-02 8.5E-01 3.1E-01 -4.9E-02 6.7E-01 1.1E-01 -7.6E-02 4.8E-01 
PROCR 7.8E-01 -1.3E-02 8.4E-01 7.3E-01 -1.7E-02 8.2E-01 8.8E-05 -1.9E-01 1.1E-02 
POLR2C 5.5E-01 2.9E-02 7.8E-01 7.5E-01 -1.5E-02 8.3E-01 3.1E-02 -1.0E-01 3.0E-01 
PLA2G15 8.0E-01 -1.2E-02 8.4E-01 8.0E-01 1.2E-02 8.5E-01 1.5E-02 1.2E-01 2.2E-01 
RBL2 4.8E-01 -3.4E-02 7.5E-01 4.2E-01 3.9E-02 7.3E-01 6.3E-01 -2.3E-02 8.0E-01 
KAT8 5.8E-01 2.6E-02 7.9E-01 1.7E-01 -6.6E-02 5.6E-01 2.2E-06 -2.2E-01 7.9E-04 
LACTB 9.1E-01 5.7E-03 8.6E-01 2.9E-01 -5.1E-02 6.5E-01 4.2E-01 -3.9E-02 7.3E-01 
TRIP4 7.4E-01 -1.6E-02 8.3E-01 6.3E-01 -2.3E-02 8.0E-01 5.9E-02 9.1E-02 3.8E-01 
EYA1 5.0E-01 -3.2E-02 7.6E-01 6.9E-01 1.9E-02 8.1E-01 8.0E-01 1.2E-02 8.4E-01 
CPED1 6.1E-01 -2.5E-02 7.9E-01 6.9E-01 -1.9E-02 8.1E-01 5.8E-08 2.6E-01 5.6E-05 
BCL7B 5.7E-01 2.7E-02 7.8E-01 5.7E-01 2.7E-02 7.8E-01 8.7E-11 -3.1E-01 1.3E-07 
AKNA 4.5E-01 3.7E-02 7.4E-01 4.3E-02 9.7E-02 3.4E-01 9.4E-03 -1.2E-01 1.8E-01 
LIPA 9.7E-01 -1.6E-03 8.7E-01 3.0E-01 5.0E-02 6.6E-01 5.7E-01 2.7E-02 7.8E-01 
OBFC1 9.3E-01 -4.0E-03 8.6E-01 4.3E-01 3.8E-02 7.3E-01 1.0E-02 -1.2E-01 1.9E-01 
DHRS11 2.7E-01 -5.3E-02 6.4E-01 4.0E-01 -4.1E-02 7.2E-01 4.9E-04 1.7E-01 3.2E-02 
ZNHIT3 8.7E-01 -8.0E-03 8.5E-01 2.8E-01 5.2E-02 6.5E-01 7.6E-01 1.5E-02 8.3E-01 
PSMD3 9.0E-01 -6.0E-03 8.6E-01 8.3E-01 -1.0E-02 8.5E-01 4.8E-01 -3.4E-02 7.5E-01 
CDK5RAP3 6.0E-01 -2.5E-02 7.9E-01 3.7E-01 4.3E-02 7.0E-01 7.5E-01 -1.5E-02 8.3E-01 
MANBA 6.4E-01 -2.2E-02 8.1E-01 2.8E-01 5.2E-02 6.5E-01 4.1E-01 4.0E-02 7.2E-01 
WFS1 6.6E-01 -2.1E-02 8.1E-01 5.1E-01 3.1E-02 7.7E-01 3.4E-06 2.2E-01 1.1E-03 
CRYAB 6.7E-01 2.0E-02 8.1E-01 7.4E-01 1.6E-02 8.2E-01 5.4E-03 -1.3E-01 1.3E-01 
MTCH2 7.3E-01 -1.6E-02 8.2E-01 4.6E-01 3.6E-02 7.4E-01 7.5E-01 1.6E-02 8.3E-01 







Table 2.16: Gene expression - trait associations (adjusted for BMI) for genes colocalized by LD This table shows selected results from the 
gene expression – clinical trait associations. Traits were adjusted for age and BMI and genes were adjusted TIN, sequencing batch, age, and BMI. 
Both traits and genes were inverse normal transformed prior to linear regression. FDR was calculated using the Storey method. An extended 
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rs12051272 CDH13 Adiponectin -1.75 0.36 1.3E-06 -1.41 0.34 3.2E-05 0.34 0.09 0.63 yes 
rs11600990 TEX40 BMI -0.87 0.36 1.5E-02 -1.10 0.35 1.8E-03 -0.23 -0.44 -0.07 yes 
rs7811265 MLXIPL Triglycerides -0.10 0.09 2.5E-01 -0.22 0.08 6.4E-03 -0.12 -0.21 -0.04 yes 
rs1789882 ADH1A WHR 0.00 0.00 8.6E-01 -0.01 0.00 2.4E-02 -0.01 -0.02 0.00 yes 
rs72959041 RSPO3 Triglycerides 0.40 0.14 4.2E-03 0.28 0.14 3.9E-02 -0.12 -0.21 -0.04 yes 
rs1708302 JAZF1 BMI 0.31 0.24 1.9E-01 0.48 0.24 4.6E-02 0.17 0.06 0.30 yes 
rs11602339 MTCH2 BMI 0.02 0.24 9.5E-01 0.48 0.25 5.5E-02 0.46 0.27 0.69 yes 
rs9435732 MFAP2 WHR 0.00 0.00 3.1E-01 -0.01 0.00 6.1E-02 0.00 0.00 0.00 yes 
rs2972144 IRS1 Adiponectin -0.17 0.24 4.7E-01 -0.42 0.24 7.8E-02 -0.25 -0.41 -0.12 yes 
rs76895963 CCND2 Matsuda 
Index 
2.37 0.77 2.3E-03 1.39 0.82 9.1E-02 -0.97 -1.65 -0.35 yes 
rs10502148 C11orf52 WHR -0.01 0.00 4.1E-02 -0.01 0.00 9.7E-02 0.00 0.00 0.00 yes 
rs9931407 CTC-277H1.7 BMI -0.80 0.40 4.4E-02 -0.62 0.39 1.1E-01 0.18 0.02 0.39 yes 
rs4897182 CENPW Matsuda 
Index 
-0.54 0.24 2.4E-02 -0.36 0.23 1.2E-01 0.18 0.06 0.33 yes 
rs2820311 LMOD1 BMI 0.97 0.26 2.4E-04 0.40 0.26 1.3E-01 -0.57 -0.81 -0.35 yes 
rs3825061 HMBS WHR -0.01 0.00 5.4E-02 -0.01 0.00 1.3E-01 0.00 0.00 0.00 yes 
rs17145738 BCL7B BMI 0.37 0.37 3.1E-01 0.55 0.36 1.3E-01 0.17 0.02 0.36 yes 
rs12489828 NT5DC2 WHR 0.01 0.00 1.1E-02 0.00 0.00 1.4E-01 0.00 -0.01 0.00 yes 
rs6843738 MANBA BMI 0.45 0.25 7.1E-02 0.36 0.24 1.4E-01 -0.09 -0.20 -0.01 yes 
rs7798002 AC003090.1 WHR 0.01 0.00 6.0E-02 0.01 0.00 1.4E-01 0.00 0.00 0.00 yes 
rs950732 MARCH5 WHR 0.00 0.00 3.6E-01 0.00 0.00 1.5E-01 0.00 0.00 0.00 yes 
rs8070454 MED24 BMI 0.25 0.26 3.5E-01 -0.34 0.24 1.5E-01 -0.59 -0.87 -0.33 yes 
rs6063048 EYA2 HOMA beta 5.54 2.89 5.6E-02 3.89 2.80 1.6E-01 -1.65 -3.42 -0.13 yes 





rs4731702 AC016831.7 BMI 0.54 0.24 2.3E-02 0.32 0.24 1.8E-01 -0.22 -0.37 -0.09 yes 
rs4731702 KLF14 BMI 0.05 0.25 8.4E-01 0.32 0.24 1.8E-01 0.27 0.07 0.48 yes 
rs6047259 PLK1S1 WHR 0.00 0.00 4.4E-01 0.00 0.00 1.9E-01 0.00 0.00 0.00 yes 
rs6700838 RP1-18D14.7 BMI -0.13 0.25 6.2E-01 -0.34 0.26 1.9E-01 -0.21 -0.38 -0.07 yes 
rs6700838 TAL1 BMI -0.05 0.27 8.5E-01 -0.34 0.26 1.9E-01 -0.29 -0.48 -0.13 yes 
rs2276390 CRYAB WHR -0.01 0.00 7.6E-02 0.00 0.00 1.9E-01 0.00 0.00 0.00 yes 
rs7871866 SLC27A4 BMI -0.13 0.29 6.6E-01 -0.38 0.30 2.0E-01 -0.25 -0.45 -0.09 yes 
rs1308362 MRAS BMI 0.51 0.29 7.4E-02 0.36 0.28 2.1E-01 -0.16 -0.31 -0.04 yes 
rs740157 RP5-899E9.1 BMI -0.57 0.22 1.1E-02 -0.28 0.23 2.2E-01 0.28 0.14 0.46 yes 
rs1544474 LAMB1 WHR -0.01 0.00 4.9E-02 0.00 0.00 2.3E-01 0.00 0.00 0.00 yes 
rs2972144 IRS1 BMI -0.53 0.25 3.2E-02 -0.29 0.25 2.4E-01 0.24 0.11 0.40 yes 
rs10779751 MTOR BMI -0.16 0.27 5.4E-01 -0.30 0.26 2.6E-01 -0.14 -0.27 -0.04 yes 
rs9846123 WDR6 BMI -0.71 0.32 2.5E-02 -0.27 0.24 2.6E-01 0.43 0.04 0.84 yes 
rs223051 RCN1 BMI -0.08 0.25 7.6E-01 -0.28 0.25 2.7E-01 -0.20 -0.36 -0.07 yes 
rs1708302 JAZF1 Matsuda 
Index 
-0.11 0.23 6.5E-01 -0.26 0.23 2.7E-01 -0.15 -0.28 -0.05 yes 
rs926279 LINC00680 BMI 0.86 0.35 1.5E-02 0.26 0.25 3.0E-01 -0.60 -1.09 -0.11 yes 
rs174547 FADS1 Triglycerides 0.04 0.06 5.5E-01 0.06 0.06 3.2E-01 0.02 0.00 0.05 yes 
rs4253772 CDPF1 Total 
Cholesterol 
-0.16 0.12 1.7E-01 -0.11 0.11 3.5E-01 0.05 0.01 0.11 yes 
rs2710323 STAB1 BMI 0.01 0.24 9.8E-01 -0.23 0.25 3.6E-01 -0.24 -0.41 -0.09 yes 
rs2710323 GNL3 BMI 0.02 0.26 9.4E-01 -0.23 0.25 3.6E-01 -0.25 -0.43 -0.10 yes 
rs2925979 CMIP Adiponectin 0.09 0.26 7.3E-01 0.22 0.25 3.8E-01 0.13 0.02 0.27 yes 
rs12679556 EYA1 WHR 0.01 0.00 4.5E-02 0.00 0.00 3.9E-01 0.00 -0.01 0.00 yes 
rs17326656 LHCGR WHR 0.01 0.00 1.1E-01 0.00 0.00 3.9E-01 0.00 -0.01 0.00 yes 
rs2972144 IRS1 Matsuda 
Index 
0.17 0.24 4.8E-01 -0.20 0.24 4.1E-01 -0.37 -0.56 -0.20 yes 
rs2972144 IRS1 Triglycerides -0.01 0.06 9.1E-01 0.05 0.06 4.3E-01 0.06 0.02 0.10 yes 
rs17145738 BCL7B HDL 0.04 0.04 2.5E-01 0.03 0.04 4.5E-01 -0.02 -0.03 0.00 yes 





rs7187776 SH2B1 WHR 0.00 0.00 8.1E-01 0.00 0.00 4.6E-01 0.00 0.00 0.00 yes 
rs2294120 ZNF251 Matsuda 
Index 
0.07 0.24 7.7E-01 0.17 0.23 4.6E-01 0.10 0.02 0.22 yes 
rs1700137 MMP16 BMI -0.09 0.26 7.3E-01 0.19 0.26 4.8E-01 0.28 0.13 0.46 yes 
rs1075901 ADORA2B BMI 0.74 0.28 8.2E-03 0.16 0.24 5.0E-01 -0.58 -0.91 -0.28 yes 
rs2581787 SFMBT1 Matsuda 
Index 
-0.22 0.23 3.3E-01 -0.15 0.23 5.1E-01 0.07 0.00 0.17 yes 
rs2581787 RFT1 Matsuda 
Index 
-0.33 0.25 1.8E-01 -0.15 0.23 5.1E-01 0.18 0.02 0.36 yes 
rs3768321 PABPC4 HDL 0.01 0.03 8.2E-01 0.02 0.03 5.2E-01 0.01 0.00 0.03 yes 
rs7134375 PDE3A BMI -0.31 0.25 2.1E-01 -0.15 0.25 5.5E-01 0.16 0.06 0.30 yes 
rs1549293 KAT8 BMI -0.01 0.24 9.6E-01 0.12 0.23 6.0E-01 0.13 0.00 0.28 yes 
rs9988 MRPS7 WHR 0.00 0.01 4.0E-01 0.00 0.01 6.0E-01 0.00 0.00 0.00 yes 
rs12145743 HDGF HDL 0.00 0.03 9.2E-01 0.01 0.03 6.3E-01 0.01 0.00 0.02 yes 
rs12574668 C11orf49 BMI 0.23 0.38 5.5E-01 -0.19 0.40 6.3E-01 -0.42 -0.71 -0.17 yes 
rs2972144 IRS1 WHR 0.00 0.00 1.8E-01 0.00 0.00 7.2E-01 0.00 0.00 0.01 yes 
rs59774409 RCN3 Triglycerides 0.07 0.17 7.0E-01 -0.06 0.17 7.4E-01 -0.12 -0.23 -0.04 yes 
rs7251505 CEBPA-AS1 WHR 0.00 0.01 7.5E-01 0.00 0.01 7.4E-01 -0.01 -0.01 0.00 yes 
rs11688682 INHBB Matsuda 
Index 
-0.13 0.25 6.0E-01 0.08 0.26 7.6E-01 0.21 0.08 0.37 yes 
rs76895963 CCND2 HOMA beta -9.08 8.58 2.9E-01 -2.57 8.72 7.7E-01 6.51 2.17 11.76 yes 
rs8126001 OPRL1 WHR 0.00 0.00 4.2E-01 0.00 0.00 7.8E-01 0.00 0.00 0.01 yes 
rs8126001 RGS19 WHR 0.00 0.00 8.3E-01 0.00 0.00 7.8E-01 0.00 0.00 0.00 yes 
rs2657879 SPRYD4 Triglycerides 0.01 0.08 8.6E-01 -0.02 0.07 7.8E-01 -0.03 -0.07 0.00 yes 
rs12369009 RP3-462E2.5 BMI -0.13 0.33 6.9E-01 0.09 0.32 7.8E-01 0.22 0.01 0.46 yes 
rs10832778 RP1-239B22.5 BMI -0.15 0.23 5.1E-01 0.06 0.23 7.8E-01 0.22 0.10 0.37 yes 
rs6063048 EYA2 Matsuda 
Index 
-0.24 0.27 3.9E-01 -0.06 0.27 8.2E-01 0.18 0.03 0.35 yes 
rs2972144 IRS1 HOMA beta -1.67 2.59 5.2E-01 0.56 2.55 8.3E-01 2.23 0.90 3.85 yes 
rs9838283 RP11-804H8.6 BMI -0.16 0.39 6.8E-01 0.08 0.38 8.4E-01 0.23 0.07 0.45 yes 
rs357438 TRIM24 WHR 0.00 0.00 5.0E-01 0.00 0.00 8.5E-01 0.00 0.00 0.00 yes 





rs7187776 SH2B1 Waist 0.14 0.31 6.5E-01 -0.05 0.31 8.6E-01 -0.19 -0.37 -0.05 yes 
rs435306 PLTP HDL -0.03 0.03 4.0E-01 0.00 0.03 8.7E-01 0.02 0.00 0.04 yes 
rs1063355 HLA-DQA1 Matsuda 
Index 
-1.02 0.37 6.1E-03 -0.04 0.24 8.7E-01 0.98 0.43 1.54 yes 
rs7187776 RP11-1348G14.4 BMI 0.14 0.25 5.7E-01 -0.04 0.23 8.8E-01 -0.18 -0.37 0.00 yes 
rs7102 LITAF WHR -0.01 0.00 1.4E-01 0.00 0.00 8.8E-01 0.01 0.00 0.01 yes 
rs13209968 HEY2 BMI -0.70 0.24 3.7E-03 0.03 0.24 9.0E-01 0.73 0.49 0.99 yes 
rs62034325 SULT1A2 BMI -0.46 0.24 5.1E-02 -0.03 0.23 9.1E-01 0.44 0.26 0.64 yes 
rs2972144 IRS1 Waist -0.17 0.33 6.2E-01 0.03 0.33 9.4E-01 0.19 0.04 0.39 yes 
rs757608 C17orf82 BMI -0.11 0.26 6.8E-01 -0.02 0.26 9.4E-01 0.09 0.01 0.20 yes 
rs524281 PACS1 BMI -0.16 0.29 5.9E-01 0.02 0.28 9.4E-01 0.18 0.02 0.36 yes 
rs1020548 BEND6 BMI -0.62 0.30 4.1E-02 -0.01 0.30 9.8E-01 0.61 0.37 0.88 yes 
rs4281707 AKTIP Matsuda 
Index 
-0.08 0.25 7.5E-01 -0.01 0.24 9.8E-01 0.07 0.01 0.17 yes 
rs13095652 DOCK3 BMI 0.35 0.26 1.7E-01 0.00 0.26 1.0E+00 -0.35 -0.55 -0.19 yes 
rs2928148 INO80 GFR 0.00 0.00 6.2E-03 0.00 0.00 3.6E-03 0.00 0.00 0.00 no 
rs17145738 BCL7B Triglycerides -0.24 0.09 9.3E-03 -0.23 0.09 1.2E-02 0.01 -0.02 0.06 no 
rs73858966 COL8A1 WHR -0.01 0.01 2.3E-02 -0.01 0.01 1.3E-02 0.00 0.00 0.00 no 
rs7932891 EIF4G2 WHR 0.01 0.00 1.4E-02 0.01 0.00 1.4E-02 0.00 0.00 0.00 no 
rs7918400 RP11-57H14.2 HOMA beta -4.04 2.76 1.4E-01 -5.89 2.46 1.7E-02 -1.85 -4.41 0.58 no 
rs754523 APOB LDL 0.13 0.06 4.5E-02 0.12 0.06 3.8E-02 -0.01 -0.06 0.04 no 
rs13391552 ALMS1P GFR 0.00 0.00 1.4E-02 0.00 0.00 4.0E-02 0.00 0.00 0.00 no 
rs12776880 C10orf112 BMI -0.48 0.25 5.3E-02 -0.47 0.24 4.6E-02 0.00 -0.13 0.14 no 
rs2925979 CMIP Matsuda 
Index 
0.42 0.26 1.0E-01 0.49 0.25 5.7E-02 0.06 -0.05 0.19 no 
rs3111316 FARSA HOMA beta 5.32 2.74 5.3E-02 4.97 2.71 6.7E-02 -0.35 -1.27 0.45 no 
rs35565646 DISP2 WHR -0.01 0.00 2.1E-01 -0.01 0.00 6.8E-02 0.00 -0.01 0.00 no 
rs7918400 RP11-57H14.2 Matsuda 
Index 
0.57 0.26 2.9E-02 0.42 0.23 7.3E-02 -0.15 -0.39 0.08 no 
rs3814883 INO80E BMI -0.51 0.25 4.1E-02 -0.43 0.24 7.4E-02 0.08 -0.05 0.23 no 





rs2222543 CPED1 WHR -0.01 0.00 3.7E-02 -0.01 0.00 8.7E-02 0.00 0.00 0.00 no 
rs761423 MST1L BMI 0.39 0.28 1.6E-01 0.45 0.26 9.0E-02 0.05 -0.14 0.25 no 
rs4846914 GALNT2 HDL 0.05 0.02 5.0E-02 0.04 0.02 9.4E-02 -0.01 -0.02 0.00 no 
rs10164099 RP11-95O2.5 WHR 0.01 0.00 8.9E-02 0.01 0.00 9.5E-02 0.00 0.00 0.00 no 
rs672356 CCDC144B WHR -0.01 0.00 1.2E-01 -0.01 0.00 9.9E-02 0.00 0.00 0.00 no 
rs12680842 RP11-267M23.4 BMI -0.34 0.27 2.0E-01 -0.41 0.25 9.9E-02 -0.07 -0.26 0.11 no 
rs6463489 FBXL18 BMI -0.88 0.50 8.0E-02 -0.78 0.49 1.1E-01 0.10 -0.12 0.34 no 
rs9931407 FHOD1 BMI -0.60 0.40 1.3E-01 -0.62 0.39 1.1E-01 -0.03 -0.16 0.10 no 
rs8103017 SSC5D WHR 0.00 0.00 2.3E-01 0.01 0.00 1.1E-01 0.00 0.00 0.00 no 
rs1979527 ABTB1 WHR 0.01 0.00 6.5E-02 0.01 0.00 1.2E-01 0.00 0.00 0.00 no 
rs6494481 TRIP4 BMI 0.63 0.37 8.9E-02 0.54 0.35 1.2E-01 -0.08 -0.31 0.14 no 
rs4500751 NPIPA2 BMI -0.38 0.26 1.6E-01 -0.38 0.24 1.2E-01 0.00 -0.20 0.20 no 
rs2820311 IPO9 BMI 0.43 0.26 1.0E-01 0.40 0.26 1.3E-01 -0.03 -0.12 0.04 no 
rs11917361 SETD2 WHR -0.01 0.00 1.2E-01 0.00 0.00 1.4E-01 0.00 0.00 0.00 no 
rs11917361 CCDC12 WHR 0.00 0.00 1.8E-01 0.00 0.00 1.4E-01 0.00 0.00 0.00 no 
rs41279633 NPC1L1 LDL 0.11 0.08 1.6E-01 0.09 0.06 1.4E-01 -0.02 -0.11 0.07 no 
rs7350438 NET1 WHR 0.00 0.00 2.9E-01 0.00 0.00 1.5E-01 0.00 0.00 0.00 no 
rs3731861 AAMP WHR -0.01 0.00 1.6E-01 -0.01 0.00 1.5E-01 0.00 0.00 0.00 no 
rs8070454 PSMD3 BMI -0.28 0.24 2.4E-01 -0.34 0.24 1.5E-01 -0.06 -0.15 0.00 no 
rs1801214 WFS1 HOMA beta -3.57 2.53 1.6E-01 -3.42 2.44 1.6E-01 0.15 -1.17 1.43 no 
rs7811265 MLXIPL WHR 0.01 0.00 6.4E-02 0.01 0.00 1.6E-01 0.00 -0.01 0.00 no 
rs450231 ANKS6 BMI 0.43 0.27 1.1E-01 0.35 0.25 1.6E-01 -0.08 -0.26 0.10 no 
rs4731702 RP11-138A9.1 BMI 0.33 0.24 1.8E-01 0.32 0.24 1.8E-01 -0.01 -0.12 0.10 no 
rs1045411 HMGB1 Matsuda 
Index 
0.32 0.25 2.0E-01 0.32 0.24 1.8E-01 0.00 -0.13 0.14 no 
rs9299 HOXB7 WHR 0.00 0.00 2.8E-01 0.00 0.00 1.8E-01 0.00 0.00 0.00 no 
rs7479183 PIDD WHR -0.01 0.00 7.5E-02 0.00 0.00 1.9E-01 0.00 0.00 0.00 no 
rs7479183 AP006621.6 WHR 0.00 0.00 2.9E-01 0.00 0.00 1.9E-01 0.00 0.00 0.00 no 





rs7871866 RP11-339B21.15 BMI -0.33 0.32 3.0E-01 -0.38 0.30 2.0E-01 -0.05 -0.26 0.14 no 
rs7871866 RP11-339B21.13 BMI -0.37 0.31 2.3E-01 -0.38 0.30 2.0E-01 -0.02 -0.14 0.09 no 
rs79598313 ZDHHC18 LDL 0.18 0.13 1.8E-01 0.16 0.13 2.1E-01 -0.01 -0.05 0.01 no 
rs7122539 RP11-867G23.1 BMI 0.36 0.25 1.6E-01 0.30 0.25 2.2E-01 -0.05 -0.17 0.05 no 
rs886444 CDK5RAP3 BMI 0.27 0.24 2.7E-01 0.29 0.24 2.3E-01 0.02 -0.06 0.10 no 
rs3768321 PABPC4 HOMA beta -3.97 3.37 2.4E-01 -3.94 3.30 2.3E-01 0.03 -1.30 1.41 no 
rs2275426 MAST2 BMI 0.25 0.25 3.2E-01 0.29 0.25 2.4E-01 0.04 -0.08 0.17 no 
rs2836961 BRWD1-IT2 BMI 0.21 0.25 3.9E-01 0.28 0.24 2.4E-01 0.07 -0.07 0.22 no 
rs10268050 NUDCD3 BMI -0.29 0.29 3.2E-01 -0.34 0.29 2.4E-01 -0.05 -0.15 0.02 no 
rs2854322 EVI2A Total 
Cholesterol 
-0.06 0.06 3.7E-01 -0.07 0.06 2.5E-01 -0.02 -0.04 0.01 no 
rs17154889 PPIP5K2 WHR 0.00 0.00 2.6E-01 0.00 0.00 2.5E-01 0.00 0.00 0.00 no 
rs67536243 ROM1 WHR 0.00 0.00 2.5E-01 0.00 0.00 2.6E-01 0.00 0.00 0.00 no 
rs67536243 EEF1G WHR 0.00 0.00 2.5E-01 0.00 0.00 2.6E-01 0.00 0.00 0.00 no 
rs9846123 RP11-3B7.1 BMI -0.37 0.25 1.4E-01 -0.27 0.24 2.6E-01 0.10 -0.01 0.22 no 
rs9846123 ARIH2 BMI -0.26 0.25 2.8E-01 -0.27 0.24 2.6E-01 -0.01 -0.07 0.05 no 
rs7307277 RP11-380L11.4 Matsuda 
Index 
-0.28 0.27 3.0E-01 -0.30 0.27 2.7E-01 -0.02 -0.11 0.07 no 
rs5112 APOC1P1 Triglycerides 0.08 0.06 2.2E-01 0.06 0.06 2.7E-01 -0.01 -0.06 0.03 no 
rs11591741 CWF19L1 Total 
Cholesterol 
0.11 0.07 1.0E-01 0.07 0.07 2.7E-01 -0.04 -0.09 0.00 no 
rs8017377 NYNRIN LDL -0.07 0.05 1.8E-01 -0.06 0.05 2.8E-01 0.01 0.00 0.04 no 
rs78058190 WNT6 HDL 0.01 0.06 9.1E-01 -0.05 0.05 2.9E-01 -0.06 -0.12 0.01 no 








BMI 0.11 0.33 7.3E-01 0.26 0.25 3.0E-01 0.15 -0.26 0.56 no 
rs12448257 DNASE1 BMI 0.39 0.33 2.3E-01 0.33 0.32 3.0E-01 -0.06 -0.20 0.06 no 





rs10049088 TIPARP WHR 0.00 0.00 7.5E-01 0.00 0.00 3.1E-01 0.00 -0.01 0.00 no 
rs4886506 SCAPER BMI 0.30 0.26 2.5E-01 0.25 0.25 3.1E-01 -0.05 -0.21 0.10 no 
rs4372913 AC017074.2 WHR 0.00 0.00 2.7E-01 0.00 0.00 3.3E-01 0.00 0.00 0.00 no 
rs174547 FADS1 HDL -0.02 0.02 3.6E-01 -0.02 0.02 3.3E-01 0.00 -0.01 0.01 no 
rs74551598 AKNA Total 
Cholesterol 
0.07 0.06 2.6E-01 0.06 0.06 3.3E-01 -0.01 -0.04 0.01 no 
rs3768321 PABPC4 Matsuda 
Index 
0.30 0.32 3.5E-01 0.30 0.31 3.3E-01 0.01 -0.12 0.14 no 
rs333947 CSF1 HDL -0.02 0.03 4.4E-01 -0.03 0.03 3.3E-01 -0.01 -0.02 0.00 no 
rs2448 FST Adiponectin -0.35 0.29 2.3E-01 -0.28 0.29 3.4E-01 0.07 0.00 0.17 no 
rs1549293 KAT8 Waist -0.18 0.32 5.8E-01 -0.29 0.31 3.4E-01 -0.12 -0.30 0.06 no 
rs11591741 CWF19L1 Matsuda 
Index 
-0.23 0.27 4.1E-01 -0.23 0.25 3.6E-01 -0.01 -0.20 0.18 no 
rs7134375 PDE3A HDL -0.02 0.03 3.9E-01 -0.02 0.03 3.6E-01 0.00 -0.01 0.01 no 
rs12325187 ZNF75A WHR 0.00 0.00 2.2E-01 0.00 0.00 3.6E-01 0.00 -0.01 0.00 no 
rs12325187 RP11-433P17.3 WHR 0.00 0.00 3.2E-01 0.00 0.00 3.6E-01 0.00 0.00 0.00 no 
rs7902274 C10orf88 LDL 0.04 0.05 4.4E-01 0.05 0.05 3.6E-01 0.01 -0.01 0.02 no 
rs4660293 OXCT2 HDL 0.03 0.03 2.7E-01 0.03 0.03 3.7E-01 -0.01 -0.03 0.01 no 
rs11784833 GRINA LDL 0.04 0.05 4.0E-01 0.04 0.05 3.9E-01 0.00 -0.01 0.01 no 
rs7941030 UBASH3B BMI -0.28 0.24 2.4E-01 -0.21 0.24 3.9E-01 0.08 -0.01 0.19 no 
rs1933182 SYPL2 GFR 0.00 0.00 6.1E-01 0.00 0.00 4.0E-01 0.00 0.00 0.00 no 
rs11672254 FPR3 LDL -0.06 0.05 3.0E-01 -0.05 0.05 4.0E-01 0.01 0.00 0.03 no 
rs11715915 APEH Fasting 
glucose 
-0.03 0.03 3.9E-01 -0.03 0.03 4.0E-01 0.00 -0.01 0.02 no 
rs919433 AC013264.2 BMI 0.28 0.25 2.5E-01 0.20 0.24 4.1E-01 -0.09 -0.22 0.03 no 
rs316611 NDUFAF1 BMI -0.20 0.28 4.8E-01 -0.21 0.26 4.2E-01 -0.01 -0.24 0.22 no 
rs3111316 FARSA Matsuda 
Index 
0.18 0.26 4.9E-01 0.21 0.26 4.2E-01 0.03 -0.05 0.12 no 
rs6684514 C1orf85 HbA1c -0.01 0.02 5.9E-01 -0.02 0.02 4.3E-01 -0.01 -0.02 0.00 no 
rs6684514 CCT3 HbA1c -0.01 0.02 5.7E-01 -0.02 0.02 4.3E-01 0.00 -0.02 0.01 no 
rs10190332 RP11-493E12.2 BMI -0.29 0.26 2.7E-01 -0.19 0.25 4.3E-01 0.09 -0.06 0.26 no 





rs4731702 RP11-138A9.1 HOMA beta 1.32 2.51 6.0E-01 1.88 2.45 4.4E-01 0.56 -0.59 1.79 no 
rs4731702 AC016831.7 HOMA beta 2.32 2.51 3.6E-01 1.88 2.45 4.4E-01 -0.43 -1.58 0.63 no 
rs3814883 INO80E Matsuda 
Index 
0.10 0.25 6.8E-01 0.18 0.24 4.5E-01 0.08 -0.06 0.23 no 
rs3814883 HIRIP3 Matsuda 
Index 
0.15 0.24 5.4E-01 0.18 0.24 4.5E-01 0.03 -0.06 0.14 no 
rs4731702 AC016831.7 Matsuda 
Index 
-0.27 0.24 2.6E-01 -0.17 0.23 4.5E-01 0.09 -0.01 0.21 no 
rs4731702 KLF14 Matsuda 
Index 
-0.28 0.25 2.6E-01 -0.17 0.23 4.5E-01 0.11 -0.08 0.30 no 
rs4731702 RP11-138A9.1 Matsuda 
Index 
-0.12 0.24 6.1E-01 -0.17 0.23 4.5E-01 -0.05 -0.17 0.05 no 
rs4253772 CDPF1 LDL -0.10 0.10 3.4E-01 -0.07 0.10 4.6E-01 0.02 -0.02 0.07 no 
rs516946 ANK1 HOMA beta -2.34 3.17 4.6E-01 -2.30 3.10 4.6E-01 0.04 -1.32 1.40 no 
rs7187776 RP11-1348G14.4 WHR 0.00 0.00 7.6E-01 0.00 0.00 4.6E-01 0.00 0.00 0.00 no 
rs6980507 SMIM19 HbA1c 0.01 0.02 7.3E-01 0.02 0.02 4.6E-01 0.01 -0.01 0.03 no 
rs1045411 HMGB1 BMI -0.12 0.26 6.4E-01 -0.18 0.25 4.6E-01 -0.06 -0.21 0.07 no 
rs2294120 ZNF34 Matsuda 
Index 
0.25 0.24 2.9E-01 0.17 0.23 4.6E-01 -0.08 -0.20 0.02 no 
rs2294120 RPL8 Matsuda 
Index 
0.08 0.25 7.4E-01 0.17 0.23 4.6E-01 0.09 -0.08 0.26 no 
rs3814883 INO80E HOMA beta 2.02 2.59 4.4E-01 1.82 2.48 4.6E-01 -0.20 -1.70 1.28 no 
rs3814883 HIRIP3 HOMA beta 1.78 2.53 4.8E-01 1.82 2.48 4.6E-01 0.04 -0.90 1.02 no 
rs12748152 PIGV Triglycerides -0.03 0.12 7.8E-01 -0.08 0.11 4.6E-01 -0.05 -0.11 0.00 no 
rs12748152 RP5-968P14.2 Triglycerides -0.09 0.12 4.4E-01 -0.08 0.11 4.6E-01 0.01 -0.07 0.09 no 
rs2814992 SNRPC BMI 0.26 0.26 3.1E-01 0.18 0.25 4.7E-01 -0.08 -0.20 0.03 no 
rs2814992 UHRF1BP1 BMI 0.18 0.27 5.2E-01 0.18 0.25 4.7E-01 0.01 -0.22 0.23 no 
rs709400 TRMT61A BMI -0.22 0.25 3.7E-01 -0.18 0.25 4.7E-01 0.04 -0.01 0.13 no 
rs709400 AL049840.1 BMI -0.35 0.27 2.0E-01 -0.18 0.25 4.7E-01 0.17 -0.05 0.38 no 
rs709400 RP11-73M18.9 BMI -0.36 0.28 2.0E-01 -0.18 0.25 4.7E-01 0.18 -0.09 0.46 no 
rs2243312 RP11-217B7.2 HDL 0.00 0.03 8.9E-01 -0.02 0.02 4.7E-01 -0.02 -0.05 0.01 no 





rs174547 FADS1 Total 
Cholesterol 
-0.06 0.06 3.6E-01 -0.04 0.06 4.7E-01 0.01 -0.01 0.03 no 
rs6884702 RP11-53O19.3 HOMA beta 1.24 2.39 6.0E-01 1.71 2.38 4.7E-01 0.47 -0.14 1.33 no 
rs1730859 PRMT6 WHR 0.00 0.00 4.0E-01 0.00 0.00 4.7E-01 0.00 0.00 0.00 no 
rs823074 PM20D1 BMI -0.43 0.30 1.5E-01 -0.17 0.24 4.8E-01 0.26 -0.10 0.62 no 
rs75584603 HOXA11-AS WHR 0.01 0.01 6.5E-01 0.01 0.01 4.8E-01 0.00 0.00 0.01 no 
rs8017377 NYNRIN Total 
Cholesterol 
-0.05 0.06 4.5E-01 -0.04 0.06 4.9E-01 0.00 -0.02 0.03 no 
rs13139571 RP11-588K22.2 dbp 0.47 0.67 4.8E-01 0.45 0.66 4.9E-01 -0.01 -0.23 0.19 no 
rs11926707 PTH1R Matsuda 
Index 
-0.11 0.26 6.8E-01 -0.17 0.25 5.0E-01 -0.06 -0.20 0.07 no 
rs2453580 SLC47A1 GFR 0.00 0.00 4.3E-01 0.00 0.00 5.0E-01 0.00 0.00 0.00 no 
rs1075901 ZSWIM7 BMI -0.10 0.36 7.8E-01 0.16 0.24 5.0E-01 0.26 -0.27 0.81 no 
rs3134353 YWHAZ BMI 0.22 0.23 3.5E-01 0.15 0.23 5.1E-01 -0.06 -0.16 0.00 no 
rs12964689 NPC1 BMI 0.10 0.24 6.7E-01 0.14 0.23 5.3E-01 0.04 -0.08 0.18 no 
rs12964689 C18orf8 BMI 0.13 0.23 5.7E-01 0.14 0.23 5.3E-01 0.01 -0.06 0.09 no 
rs2898290 FAM85A sbp -0.94 1.03 3.6E-01 -0.63 1.00 5.3E-01 0.31 -0.22 0.87 no 
rs2898290 RP11-419I17.1 sbp -0.66 1.02 5.2E-01 -0.63 1.00 5.3E-01 0.03 -0.38 0.46 no 
rs17764730 CTC-228N24.3 WHR 0.01 0.01 2.4E-01 0.00 0.00 5.3E-01 0.00 -0.01 0.00 no 
rs2925979 CMIP HOMA beta -1.59 2.75 5.6E-01 -1.67 2.68 5.3E-01 -0.08 -1.30 1.13 no 
rs2925979 CMIP HDL 0.02 0.03 4.5E-01 0.02 0.03 5.3E-01 0.00 -0.02 0.01 no 
rs1061810 HSD17B12 Matsuda 
Index 
0.36 0.28 1.9E-01 0.16 0.25 5.4E-01 -0.21 -0.46 0.03 no 
rs2034088 VPS53 BMI 0.13 0.25 6.0E-01 0.14 0.24 5.5E-01 0.01 -0.08 0.12 no 
rs174547 FADS1 Fasting 
glucose 
-0.02 0.03 5.4E-01 -0.02 0.03 5.6E-01 0.00 -0.01 0.01 no 
rs1045411 HMGB1 WHR 0.00 0.00 4.7E-01 0.00 0.00 5.6E-01 0.00 0.00 0.00 no 
rs7184597 RP11-1348G14.1 WHR 0.00 0.00 4.1E-01 0.00 0.00 5.7E-01 0.00 0.00 0.00 no 
rs7184597 NPIPB6 WHR 0.00 0.00 7.0E-01 0.00 0.00 5.7E-01 0.00 0.00 0.00 no 
rs2516739 NTHL1 BMI -0.22 0.28 4.5E-01 -0.16 0.28 5.7E-01 0.06 -0.01 0.15 no 
rs4653017 PHC2 BMI 0.06 0.26 8.1E-01 0.15 0.26 5.7E-01 0.09 0.00 0.20 no 





rs1045241 TNFAIP8 WHR 0.00 0.00 7.3E-01 0.00 0.00 5.8E-01 0.00 0.00 0.00 no 
rs11869286 PGAP3 HDL 0.01 0.03 7.4E-01 0.01 0.03 5.8E-01 0.01 0.00 0.02 no 
rs6764533 CTD-2002J20.1 BMI 0.17 0.27 5.3E-01 0.14 0.26 5.9E-01 -0.02 -0.13 0.08 no 
rs56271783 VEGFB Triglycerides 0.05 0.13 7.1E-01 0.06 0.11 5.9E-01 0.01 -0.09 0.12 no 
rs1045241 TNFAIP8 Triglycerides 0.05 0.06 4.3E-01 0.04 0.07 5.9E-01 -0.02 -0.04 0.01 no 
rs912768 PRDX6 BMI -0.35 0.23 1.3E-01 -0.14 0.26 5.9E-01 0.21 -0.01 0.44 no 
rs2448 FST WHR 0.00 0.00 6.8E-01 0.00 0.00 5.9E-01 0.00 0.00 0.00 no 
rs516946 ANK1 Matsuda 
Index 
0.10 0.30 7.4E-01 0.16 0.29 5.9E-01 0.06 -0.07 0.20 no 
rs174547 FADS1 LDL -0.03 0.05 5.3E-01 -0.03 0.05 5.9E-01 0.01 -0.01 0.02 no 
rs12748152 PIGV LDL -0.07 0.10 4.6E-01 -0.05 0.10 6.0E-01 0.02 -0.02 0.07 no 
rs12748152 RP5-968P14.2 LDL -0.03 0.10 7.5E-01 -0.05 0.10 6.0E-01 -0.02 -0.09 0.05 no 
rs13134327 RP11-673E1.1 HbA1c 0.02 0.02 3.8E-01 0.01 0.02 6.0E-01 -0.01 -0.03 0.01 no 
rs13240600 CPSF4 BMI 0.13 0.30 6.7E-01 0.15 0.29 6.1E-01 0.02 -0.11 0.16 no 
rs860295 DAP3 BMI 0.18 0.25 4.8E-01 0.12 0.25 6.2E-01 -0.06 -0.16 0.03 no 
rs1063355 HLA-DQA1 HOMA beta 5.42 3.96 1.7E-01 1.26 2.57 6.2E-01 -4.16 -10.06 1.61 no 
rs12145743 RRNAD1 HDL 0.01 0.03 6.0E-01 0.01 0.03 6.3E-01 0.00 -0.01 0.01 no 
rs2581787 SFMBT1 HOMA beta 1.57 2.45 5.2E-01 1.17 2.44 6.3E-01 -0.40 -1.18 0.12 no 
rs2581787 RFT1 HOMA beta 1.80 2.60 4.9E-01 1.17 2.44 6.3E-01 -0.63 -2.47 1.12 no 
rs3829849 LMX1B BMI -0.17 0.25 5.0E-01 -0.11 0.24 6.4E-01 0.05 -0.05 0.17 no 
rs72875462 ABCG5 Total 
Cholesterol 
-0.06 0.10 5.9E-01 -0.05 0.10 6.4E-01 0.01 -0.05 0.07 no 
rs6859752 SH3PXD2B WHR 0.00 0.00 6.6E-01 0.00 0.00 6.5E-01 0.00 0.00 0.00 no 
rs7307277 RP11-380L11.4 Triglycerides 0.04 0.07 5.8E-01 0.03 0.07 6.5E-01 -0.01 -0.03 0.01 no 
rs4500751 NPIPA2 Hip -0.04 0.32 9.1E-01 -0.13 0.30 6.5E-01 -0.10 -0.35 0.15 no 
rs704 TMEM199 LDL 0.03 0.05 5.3E-01 0.02 0.05 6.6E-01 -0.01 -0.03 0.00 no 
rs704 CTD-2350C19.1 LDL 0.03 0.05 5.7E-01 0.02 0.05 6.6E-01 -0.01 -0.02 0.01 no 
rs6884702 RP11-53O19.3 Matsuda 
Index 
0.09 0.23 6.9E-01 0.10 0.23 6.6E-01 0.01 -0.06 0.08 no 





rs630337 RHCE Total 
Cholesterol 
0.03 0.07 6.3E-01 0.02 0.06 6.7E-01 -0.01 -0.06 0.05 no 
rs2230590 MST1R BMI 0.07 0.24 7.7E-01 0.10 0.24 6.8E-01 0.03 -0.05 0.12 no 
rs7739232 KLHL31 Hip 0.11 0.57 8.5E-01 -0.22 0.53 6.8E-01 -0.33 -0.79 0.10 no 
rs12748152 RP5-968P14.2 HDL 0.00 0.05 9.5E-01 0.02 0.05 6.8E-01 0.02 -0.02 0.05 no 
rs12748152 PIGV HDL 0.02 0.05 7.3E-01 0.02 0.05 6.8E-01 0.00 -0.02 0.02 no 
rs4897182 CENPW HOMA beta 2.02 2.51 4.2E-01 0.98 2.44 6.9E-01 -1.04 -2.40 0.13 no 
rs6738445 AC068039.4 BMI 0.10 0.32 7.6E-01 -0.11 0.27 7.0E-01 -0.20 -0.54 0.12 no 
rs10948059 PEX6 HDL -0.03 0.03 4.0E-01 -0.01 0.02 7.0E-01 0.02 -0.03 0.06 no 
rs4660293 OXCT2 Triglycerides 0.05 0.07 5.2E-01 0.03 0.07 7.0E-01 -0.02 -0.06 0.02 no 
rs1708302 JAZF1 HOMA beta 0.28 2.49 9.1E-01 0.96 2.47 7.0E-01 0.68 -0.03 1.66 no 
rs1045411 HMGB1 HOMA beta -1.06 2.64 6.9E-01 -0.97 2.54 7.0E-01 0.09 -1.30 1.53 no 
rs6671166 TPM3 Triglycerides 0.03 0.06 6.4E-01 0.02 0.06 7.1E-01 -0.01 -0.02 0.01 no 
rs11102965 CELSR2 LDL 0.03 0.05 5.6E-01 0.02 0.05 7.2E-01 -0.01 -0.04 0.01 no 
rs7941030 UBASH3B HDL -0.01 0.03 7.0E-01 -0.01 0.02 7.2E-01 0.00 -0.01 0.01 no 
rs524281 PACS1 WHR 0.00 0.00 9.6E-01 0.00 0.00 7.3E-01 0.00 0.00 0.00 no 
rs2306589 ZNHIT3 WHR 0.00 0.00 5.9E-01 0.00 0.00 7.4E-01 0.00 0.00 0.00 no 
rs4372836 AC097724.3 BMI 0.17 0.27 5.2E-01 0.08 0.26 7.4E-01 -0.09 -0.25 0.06 no 
rs181362 CCDC116 HDL 0.02 0.03 3.7E-01 0.01 0.02 7.4E-01 -0.02 -0.04 0.00 no 
rs1534696 SNX10 WHR 0.00 0.00 4.2E-01 0.00 0.00 7.4E-01 0.00 0.00 0.01 no 
rs1534696 CBX3 WHR 0.00 0.00 7.1E-01 0.00 0.00 7.4E-01 0.00 0.00 0.00 no 
rs11926707 PTH1R HOMA beta 0.31 2.70 9.1E-01 0.84 2.60 7.5E-01 0.52 -0.85 2.00 no 
rs56271783 VEGFB WHR 0.00 0.01 7.9E-01 0.00 0.01 7.6E-01 0.00 -0.01 0.00 no 
rs7307277 RP11-380L11.4 HOMA beta -0.68 2.88 8.1E-01 -0.88 2.84 7.6E-01 -0.20 -1.21 0.75 no 
rs7307277 RP11-380L11.4 HDL 0.01 0.03 6.1E-01 0.01 0.03 7.6E-01 -0.01 -0.02 0.00 no 
rs2034088 VPS53 Hip 0.19 0.29 5.1E-01 0.09 0.29 7.6E-01 -0.11 -0.25 0.01 no 
rs4731702 AC016831.7 Hip -0.19 0.29 5.2E-01 -0.09 0.29 7.6E-01 0.10 -0.02 0.25 no 
rs4731702 RP11-138A9.1 Hip -0.12 0.29 6.8E-01 -0.09 0.29 7.6E-01 0.04 -0.10 0.17 no 





rs4846914 GALNT2 Triglycerides -0.02 0.06 8.0E-01 -0.02 0.06 7.6E-01 0.00 -0.03 0.03 no 
rs630337 RHCE LDL -0.02 0.06 7.2E-01 -0.01 0.05 7.7E-01 0.01 -0.04 0.05 no 
rs498240 NELFE BMI -0.04 0.62 9.5E-01 -0.18 0.61 7.7E-01 -0.14 -0.38 0.05 no 
rs12430764 GPC6 WHR 0.00 0.00 7.8E-01 0.00 0.00 7.8E-01 0.00 0.00 0.00 no 
rs12369009 RP3-473L9.4 BMI 0.17 0.33 6.0E-01 0.09 0.32 7.8E-01 -0.08 -0.24 0.05 no 
rs9341990 TBX18 WHR 0.00 0.00 9.8E-01 0.00 0.00 7.8E-01 0.00 0.00 0.00 no 
rs10463416 ABLIM3 WHR 0.00 0.00 9.3E-01 0.00 0.00 7.8E-01 0.00 0.00 0.00 no 
rs1106908 DHRS11 BMI -0.10 0.26 7.1E-01 -0.07 0.24 7.8E-01 0.03 -0.16 0.22 no 
rs638722 C1orf213 WHR 0.00 0.00 6.4E-01 0.00 0.00 7.9E-01 0.00 0.00 0.00 no 
rs4281707 AKTIP HOMA beta -0.81 2.60 7.6E-01 -0.65 2.58 8.0E-01 0.16 -0.53 0.95 no 
rs4281707 RBL2 HOMA beta -0.59 2.68 8.3E-01 -0.65 2.58 8.0E-01 -0.07 -1.49 1.34 no 
rs12946454 HEXIM1 sbp 0.35 1.10 7.5E-01 0.28 1.10 8.0E-01 -0.07 -0.34 0.12 no 
rs9931407 FHOD1 HDL -0.02 0.04 6.7E-01 -0.01 0.04 8.0E-01 0.01 0.00 0.02 no 
rs9931407 CTC-277H1.7 HDL -0.02 0.04 6.5E-01 -0.01 0.04 8.0E-01 0.01 -0.01 0.03 no 
rs4731702 KLF14 HDL 0.01 0.03 8.2E-01 -0.01 0.02 8.3E-01 -0.01 -0.03 0.01 no 
rs4731702 RP11-138A9.1 HDL 0.00 0.02 1.0E+00 -0.01 0.02 8.3E-01 -0.01 -0.02 0.01 no 
rs4731702 AC016831.7 HDL -0.01 0.02 7.7E-01 -0.01 0.02 8.3E-01 0.00 -0.01 0.01 no 
rs2513987 RP11-690D19.3 WHR 0.00 0.00 9.5E-01 0.00 0.00 8.4E-01 0.00 0.00 0.00 no 
rs9838283 HEMK1 BMI 0.14 0.39 7.1E-01 0.08 0.38 8.4E-01 -0.07 -0.24 0.09 no 
rs12681990 ZNF703 Matsuda 
Index 
0.16 0.36 6.7E-01 0.07 0.34 8.5E-01 -0.09 -0.33 0.14 no 
rs72959041 RSPO3 WHR 0.01 0.01 4.9E-01 0.00 0.01 8.6E-01 0.00 -0.01 0.00 no 
rs17173637 AOC1 HDL 0.00 0.04 9.8E-01 -0.01 0.03 8.6E-01 -0.01 -0.03 0.02 no 
rs1801214 WFS1 Matsuda 
Index 
0.02 0.24 9.2E-01 0.04 0.23 8.6E-01 0.02 -0.10 0.14 no 
rs72875462 ABCG5 LDL -0.01 0.09 9.0E-01 -0.02 0.09 8.6E-01 0.00 -0.06 0.05 no 
rs7187776 RP11-1348G14.4 Waist 0.11 0.33 7.3E-01 -0.05 0.31 8.6E-01 -0.17 -0.43 0.06 no 
rs28451064 MRPS6 WHR 0.00 0.00 7.5E-01 0.00 0.00 8.8E-01 0.00 0.00 0.00 no 
rs28451064 LINC00310 WHR 0.00 0.00 9.9E-01 0.00 0.00 8.8E-01 0.00 0.00 0.00 no 





rs7184597 RP11-1348G14.1 Matsuda 
Index 
0.09 0.25 7.2E-01 0.04 0.24 8.8E-01 -0.05 -0.17 0.05 no 
rs7184597 NPIPB6 Matsuda 
Index 
0.08 0.25 7.5E-01 0.04 0.24 8.8E-01 -0.04 -0.20 0.10 no 
rs17826219 AC005562.1 BMI 0.17 0.46 7.2E-01 0.06 0.45 8.9E-01 -0.10 -0.32 0.09 no 
rs3814883 HIRIP3 WHR 0.00 0.00 7.2E-01 0.00 0.00 9.0E-01 0.00 0.00 0.00 no 
rs3814883 INO80E WHR 0.00 0.00 9.6E-01 0.00 0.00 9.0E-01 0.00 0.00 0.00 no 
rs2448 FST HDL 0.00 0.03 9.9E-01 0.00 0.03 9.1E-01 0.00 0.00 0.01 no 
rs7184597 RP11-1348G14.1 HOMA beta 0.78 2.61 7.6E-01 0.28 2.55 9.1E-01 -0.51 -1.71 0.55 no 
rs7184597 NPIPB6 HOMA beta -0.01 2.67 1.0E+00 0.28 2.55 9.1E-01 0.29 -1.24 1.85 no 
rs1061810 HSD17B12 HOMA beta -0.41 2.96 8.9E-01 0.28 2.65 9.1E-01 0.69 -1.89 3.31 no 
rs17207196 STAG3L1 BMI 0.08 0.25 7.7E-01 0.02 0.25 9.2E-01 -0.05 -0.18 0.07 no 
rs17207196 AC018720.10 BMI -0.05 0.26 8.6E-01 0.02 0.25 9.2E-01 0.07 -0.10 0.25 no 
rs17207196 POM121C BMI 0.04 0.25 8.7E-01 0.02 0.25 9.2E-01 -0.02 -0.10 0.07 no 
rs17207196 NSUN5P1 BMI 0.03 0.25 9.2E-01 0.02 0.25 9.2E-01 0.00 -0.09 0.09 no 
rs2110073 U47924.30 HbA1c 0.01 0.04 8.7E-01 0.00 0.04 9.3E-01 0.00 -0.02 0.02 no 
rs7941030 UBASH3B Total 
Cholesterol 
0.00 0.06 9.4E-01 0.01 0.06 9.3E-01 0.00 -0.02 0.02 no 
rs4660293 OXCT2 WHR 0.00 0.00 6.8E-01 0.00 0.00 9.3E-01 0.00 0.00 0.00 no 
rs2294120 ZNF34 HOMA beta -0.97 2.53 7.0E-01 -0.21 2.48 9.3E-01 0.76 -0.26 2.02 no 
rs2294120 ZNF251 HOMA beta 0.26 2.51 9.2E-01 -0.21 2.48 9.3E-01 -0.47 -1.51 0.37 no 
rs2294120 RPL8 HOMA beta 0.37 2.63 8.9E-01 -0.21 2.48 9.3E-01 -0.58 -2.39 1.14 no 
rs1730859 PRMT6 BMI -0.06 0.29 8.4E-01 0.02 0.27 9.3E-01 0.08 -0.11 0.28 no 
rs12681990 ZNF703 HOMA beta -0.25 3.84 9.5E-01 0.22 3.63 9.5E-01 0.47 -2.03 2.96 no 
rs757608 C17orf82 WHR 0.00 0.00 8.7E-01 0.00 0.00 9.6E-01 0.00 0.00 0.00 no 
rs11277705
1 
POLR2C HDL 0.00 0.04 9.5E-01 0.00 0.04 9.7E-01 0.00 -0.02 0.00 no 
rs11591741 CWF19L1 HOMA beta 0.91 2.87 7.5E-01 -0.09 2.69 9.7E-01 -1.00 -3.07 0.95 no 
rs1730859 PRMT6 LDL 0.02 0.06 7.1E-01 0.00 0.06 9.8E-01 -0.02 -0.06 0.02 no 
rs4281707 RBL2 Matsuda 
Index 
0.06 0.25 8.1E-01 -0.01 0.24 9.8E-01 -0.07 -0.21 0.06 no 





rs2925979 CMIP WHR 0.00 0.00 9.5E-01 0.00 0.00 9.9E-01 0.00 0.00 0.00 no 
rs6063048 EYA2 Triglycerides 0.01 0.07 8.6E-01 0.00 0.07 1.0E+00 -0.01 -0.05 0.03 no 
Table 2.17: Mediation of cardiometabolic traits through gene expression We tested the effect of the variant through gene expression level on 
the GWAS trait, or an equivalent trait measured in METSIM. We estimated the 95% confidence interval of the mediation effect to assess 
significance. This table is sorted first on whether the mediation effect CI does not include 0, and then on the total effect p-value. Abbreviations 






Table 2.18: Mediation analysis of GWAS variants Mediation by adipose gene expression level on the effect of a GWAS variant on a 
cardiometabolic trait in 434 samples from the METSIM study. Results are shown when the combined effect of the direct and mediation effects 
were nominally significant (p < 0.05) 
 
   
Direct Effect                                                 
of GWAS variant on Trait 
Combined Effect                                          
of Direct and Mediation 
Effects Mediation Effect 
GWAS 
variant Gene Trait  
Effect 
Size SE P-value 
Effect 
Size SE  P-value 
Effect 
size  (95% CI) 
rs12051272 CDH13 Adiponectin -1.75 0.36 1.25E-6 -1.41 0.34 3.20E-5 0.34 (0.086, 0.63) 
rs11600990 CATSPERZ BMI -0.87 0.36 0.01 -1.10 0.35 1.80E-3 -0.23 (-0.44, -0.065) 
rs7811265 MLXIPL Triglycerides -0.10 0.09 0.25 -0.22 0.08 6.41E-3 -0.12 (-0.20, -0.040) 
rs1789882 ADH1A WHR 0.001 0.005 0.86 -0.009 0.004 0.024 -0.010 (-0.016, -0.005) 
rs72959041 RSPO3 Triglycerides 0.40 0.14 4.22E-3 0.28 0.14 0.039 -0.12 (-0.21, -0.043) 
rs1708302 JAZF1 BMI 0.31 0.24 0.19 0.48 0.24 0.046 0.17 (0.059, 0.30) 









 mRNA can be spliced differently to produce isoforms and greatly expand the transcriptional 
diversity of cells. An estimated 92-94% of genes in the human genome are subject to alternative 
splicing129 and as many as 20-30% of disease causing mutations may affect mRNA splicing130. In mice, 
high fat diet has been shown to alter adipose tissue splicing profiles, altering adipose tissue 
thermogenesis and white adipose browning28. Alternative splicing has been associated with type 2 
diabetes (T2D) variants at the TCF7L2 GWAS locus in a tissue-specific manner131. In human adipose 
tissue, differential splicing has been observed between different fat depots and during weight loss132. 
RNA-sequencing offers the opportunity to examine different quantifications of the same pool of 
data to identify the presence genes, exons, and splices in the sample transcriptome, potentially 
highlighting differential isoform usage. Reads can be used to quantify genes or exons, from which gene 
and exon-level eQTLs detected. Splices can be quantified by examining the reads that span the junctions 
of exons, excluding certain introns and potentially exons34. Both exon and splice detection provide the 
opportunity to detect changes in the composition of the transcript, such as removal of an exon. 
Depending on the detection method, novel splice junctions or exons may also be identified even if they 
were not previously annotated. The quantity of reads at splice junctions can then be used as outcomes in 
eQTL detection, resulting in splice eQTLs (sQTLs).  
Previous studies have examined sQTLs in several different tissues, including whole blood, brain, 
and fetal retinal pigment epithelium35,37,40. Despite the hypothesis that variants within canonical splice 
sites themselves may be common sQTL variants, Saferali et al. noted that the distribution of eQTLs and 




and intergenically, suggesting that variants may influence splice expression not merely by disrupting 
consensus splice sites and potentially implicating splice silencers and enhancers. Prior studies have 
shown sQTL colocalizations with GWAS loci for traits including chronic obstructive pulmonary disease 
(COPD), Alzheimer’s disease, age-related macular degeneration (AMD), and Parkinson’s disease in 
relevant tissues35,37,39,40. In several studies, sQTLs were able to provide a plausible mechanisms for the 
function of known candidate genes35,40.  
 Here, we present the analysis of subcutaneous adipose tissue expression level from 426 subjects 
from the METabolic Syndrome in Men (METSIM study). We differentiated between the splice, exon, and 
previously described gene-level eQTLs by identifying genes that were detected by sQTL but not by gene-
level and exon-level eQTLs and then pathways enriched with those genes. We further identified the sQTL 
signals that colocalize with GWAS signals for BMI, WHRadjBMI, lipid traits, T2D, and cardiovascular 
disease. At the gene dense MADD-NR1H3 locus, we describe a novel splice junction of NR1H3, which 
encodes LXRa, a transcription factor involved in cholesterol homeostasis, and show that alternative 
splicing may be responsible for an HDL cholesterol GWAS signal.  
 
Methods 
METSIM study participants, genotypes and sequencing 
METSIM is a population-based cohort composed of 10,197 males of Finnish ancestry from 
Kuopio, Finland74. For this analysis, we examined a subset of 426 participants with subcutaneous adipose 
tissue collected from near the umbilicus via needle biopsy. The METSIM study was approved by the 
Ethics Committee of the University of Eastern Finland and Kuopio University Hospital in Kuopio, Finland 
and carried out in accordance with the Helsinki Declaration. Written informed consent was obtained from 
all participants. 
We measured genotypes using the Illumina OmniExpress BeadChip array and the Illumina 
HumanCoreExome at the Center for Inherited Disease Research (Baltimore, MD). Genotyping quality 
control (QC) and imputation to the Haplotype Reference Consortium (HRC) panel85 have been previously 
described52. For this study, we filtered HRC-imputed genotypes to retain ~7.8 million variants with minor 
allele frequency (MAF)>0.01 and imputation quality r2>0.5. 
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Total mRNA was isolated using the prepared for using the Qiagen miRNeasy kit (Qiagen, Hilden, 
Germany) and was polyA+ selected using Illumina TruSeq RNA Sample Preparation Kit v2 at the 
University of California Los Angeles Neuroscience Genomics Core (UNGC). RNA-sequencing and quality 
control of 434 samples from the METSIM study have been previously described133; here, we used a 
subset of 426 samples to avoid sample overlap with the FUSION study for future meta-analysis. The 
average sequencing depth was 45 million paired-end 50 bp reads. 
Gene, exon, and splice junction quantification 
 We mapped reads using STAR (version 2.4.2a)86 and GENCODE v19 annotation (July 2013 
freeze)29, employing a two-pass method which uses splice sites observed from the first pass as 
annotation for the second pass. This method allows for discovery of novel splice junctions from the 
sequencing data itself. We then quantified the reads into genes, exons, and two metrics for splices using 
distinct methods (Figure S3.1). (1) For genes, we quantified reads using Salmon (version 0.7.2)90 and 
collapsed   isoforms to genes using tximport (version 1.0.3)91. We retained 25,623 genes with at least 5 
reads in 25% of samples. We then calculated counts per million (CPM) adjusted for trimmed means of M 
values (CPMadjTMM)134. (2) For exons, we quantified reads using QTLtools (version 1.1)32, retained 
160,899 exons with at least 5 reads in 25% of samples, and calculated CPMadjTMM. (3) For splice 
junctions, we quantified reads using Leafcutter (version 2.17.4.)34, which does not use annotation for 
splice junction quantification, potentially allowing for novel junctions to be discovered alongside previously 
annotated splices. Leafcutter produces raw read counts and read counts per cluster, suitable for 
transformation into a percent spliced in (PSI) metric, which accounts for gene-level variability by adjusting 
for the prevalence of other nearby splicing events that share a start or stop position. We filtered both read 
metrics requiring 5 reads in 25% of samples, resulting in a set of 61,833 splice junctions. 
 
Gene eQTL, exon eQTL, and sQTL detection 
 For gene, exon, and both splice quantifications, we performed a separate nominal eQTL pass 
using QTLtools32, providing both BMI and different numbers of PEER factors as covariates to the 
analysis. We explicitly included BMI as a covariate, because ~51% of genes are correlated with BMI. To 
determine the number of PEER factors to serve as covariates, we generated factors from 0 to 100, by 
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10s. We then determined the point at which adding ten more PEER factors did not increase the number 
of unique transcripts found to have at least one eQTL or sQTL association by at least 1%. For genes and 
exons, we included 40 PEER factors, and for splices measured as PSI, we included 20 PEER factors 
(Table 3.1).  
 After identifying the number of PEER factors to include for each analysis, we performed 
eQTL detections for genes, exons, and splices, including BMI and the number of PEER factors (k = 40, 
40, 20, respectively) as covariates to QTLtools. We calculated the false discovery rate (FDR) < 1% for 
each type of eQTL detection using the Storey and Tibshirani method135. The equivalent p-value for FDR < 
1% for gene-level eQTL detection was P < 2.2 ´ 10-3 and the equivalent p-value for the exon-level eQTL 
detection was P < 7.1 ´ 10-4. The equivalent p-value for FDR < 1% for splice junctions was P < 2.03 ´ 10-
5. 
To obtain the gene names of transcripts to which splice junctions belong, we used the 
get_intron_meta() and map_clusters_to_genes() utilities from Leafcutter along with GENCODE v19 
annotation. Splices that did not map to genes in the annotation provided were retained but marked with 
an “unknown” tag, since they might represent novel junctions.  
 
Pathway analysis 
 To assess whether genes detected by sQTLs were in any relevant biological pathways, we used 
SIGORA (version 3.0.5)136. Rather than treating all genes as equally informative for identifying 
corresponding pathways, SIGORA uses genes or gene-pairs that are only found in specific pathways to 
test whether the pathway is overrepresented. We ran SIGORA using recommended settings of the 
Reactome Pathways and 4 levels, because the database is hierarchical. We reported results for which 
pathways were significant (Bonferroni-corrected P < 0.05).  
 
Colocalization with cardiometabolic GWAS loci 
 We tested for colocalization between splice QTLs from the PSI set and 2,843 cardiometabolic 
GWAS variants representing 93 traits that have been previously described133. To test for colocalization, 
we first identified GWAS variants associated with the expression level of a splice junction (FDR < 1%). 
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We then identified the most significant sQTL variant for each splice junction and calculated LD (in 
METSIM, n~ 10,000) between the GWAS variant and lead sQTL variant. We then conditioned the lead 
sQTL variant on the GWAS variant by including the latter as a covariate in the QTLtools analysis, 
alongside BMI and PEER factors. We considered the signals to be colocalized if: (i) the LD between the 
GWAS and sQTL variant was strong (r2  ³ 0.8) and (ii) the sQTL variant is no longer associated with the 
splice after conditioning on the GWAS variant (FDR > 1%).  
 
Validation of a novel NR1H3 splice junction 
RNA was isolated from adipose tissue samples of individuals with each genotype of rs1449626 
(Fatty Tissue RNA Purification Kit, Norgen Biotek). First strand cDNA was reverse transcribed according 
to manufacturer’s instructions (SuperScript III, Invitrogen) and amplified with primers located in exons 3 
and 5 of NR1H3 (AGCAGCTGCATCCTCAGAGA/GAAGCCGGTCAGAAAAGGAG; hg19 chr11: 
47281404 – 47282992). PCR products were run on a 1% agarose gel and isoform-specific band intensity 
was quantified using ImageJ137. 
 
Results 
sQTL identification and characterization 
 We performed genome-wide sQTL analysis between 7.8M variants (MAF > 0.01) and 61,834 
splice junctions detected in 426 individuals from the METSIM study. We found 294,361 variants 
associated with level of at least one splice junction (FDR <1%, P < 2.03 ´ 10-5; Table 3.2).  We found 
6,077 (9.8%) splice junctions to be associated with at least one variant within 1 Mb of the splice start 
(FDR <1%, P < 2.03 ´ 10-5; Table 3.1). These 6,077 splice junctions correspond to 3,198 unique genes. 
Among these genes, 1,874 (59%) were identified by an sQTL for a single junction and 27 (0.4%) genes 
were associated with 10 or more junctions (Figure 3.1). The largest number of unique splice junctions in 
the same gene that have at least one sQTL association was 15 and found for members of the SAA gene 
family (SAA1, SAA2, SAA2-SAA4, SAA4), encoding serum amyloid A apolipoproteins. This family of 
proteins is involved in pro-inflammatory response138 and HDL cholesterol homeostasis139. It is possible 
that the high volume of splices in this region is due difficulty differentiating between similar gene products, 
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but this chance is mitigated by our use of 50 base pair paired end reads and low tolerance for 
mismatches during alignment (m < 2). The abundance in this region may also reflect residual gene-level 
eQTL association that was not removed by the percent spliced in method of sQTL detection.  
The most significant sQTL identified was the association between rs7216 and a novel splice 
junction in the 3’ UTR of ALDH3A2 (chr17:19,578,812:19,578,875; P = 2.17 ´ 10-104). Notably, rs7216 is 
an A/T variant located in the consensus splice acceptor site itself, disrupting the intronic AG site, creating 
TG. This splice is present in a predicted isoform of ALDH3A2 with a much shorter 3’ UTR compared with 
other isoforms of the gene. ALDH3A2 is an aldehyde dehydrogenase involved mitigating lipid 
peroxidation by detoxifying aldehyde products; in mice, decreased aldehyde dehydrogenase activity was 
associated with insulin resistance140. Mysore et al. showed that mi-192* targets ALDH3A2 in adipose 
tissue, suggesting a potential functional consequence to changes in the 3’ UTR of this gene141.  Taken 
together, these results show that sQTL detection highlighted genes involved in important adipose tissue 
biological processes. 
To identify differences between the new sQTL and exon eQTL datasets and our previously 
described gene-level eQTL detection133, we compared the genes found uniquely by each of these 
different quantification methods. To more directly compare these discovery methods, we summarized the 
exon eQTLs and sQTLs to the gene level and compared them with eQTL genes. We identified 2,280 
genes found exclusively as sQTLs, exon eQTLs, or both but not as gene-level eQTLs (FDR < 1% in each 
analysis; Figure 3.2).  
To find the biological processes corresponding to genes identified by genes found as only as 
sQTLs, we performed pathway analysis. Among the 112 genes identified only as sQTLs and not detected 
as exon or gene-level eQTLs, we found three significant pathways (Table 3.3). One of the pathways 
identified was “COPI-mediated anterograde transport” (R-HSA-6807878). COPI-mediated trafficking has 
been implicated in lipid droplet formation and regulation of lipid homeostasis in adipose tissue142. This 
analysis also identified “Regulation of HSF1-mediated heat shock response” (R-HSA-3371453; Table 
3.3). Changes in heat shock response proteins have been linked with inflammation in human adipose 





Colocalization of sQTLs and cardiometabolic GWAS loci 
 To identify splices that are associated with GWAS signals and potential mechanisms underlying 
them, we tested for colocalization between 2,843 cardiometabolic GWAS signals (variants clumped LD r2 
³ 0.8) and the sQTLs. We first identified GWAS lead variants associated with splice junctions; GWAS 
lead variants were associated (FDR <1%) with levels of 479 splice junctions from 256 transcripts. After 
performing colocalization analyses using LD and conditional analysis, we found that 104 GWAS signals 
were colocalized with 132 splice junction QTLs. Each GWAS signal can be colocalized with sQTL signals 
from multiple splice junctions. These splice junctions represented 74 unique genes (Table 3.4). Each 
gene can be found colocalized via association from multiple, unique splice junctions, possibly indicating 
the presence of a gene- or isoform-level association. Among the splice junctions, we identified 39 at BMI 
loci, 26 at WHRadjBMI loci, 20 at lipid loci, three at T2D loci and two at CVD loci.  
 For example, we identified a colocalization between an HDL-cholesterol GWAS signal and a 
sQTL for a splice junction (chr11:47281530-47282792) in NR1H3, which removes exon 4 (Figure 3.2). 
This splice junction shared the annotated edges of exons three and five, which matched a predicted 
isoform with only one supporting expressed sequence tag (EST), and our splicing analysis in adipose 
provided novel sequence-based support. We validated this novel splice junction by PCR amplification 
from cDNA derived from subcutaneous adipose tissue from individuals of differing genotypes. We found 
that a fragment matching the predicted length lacking exon 4 was detectable in adipose tissue, together 
with the isoform that includes exon 4 (Figure 3.3A and 3.3B), indicating that this splice is present in 
adipose tissue. Additionally, we found that the amount of the fragment differed according to the genotype 
of   rs74948330, a proxy variant for the lead sQTL variant, rs1449626 (LD r2 =0.95; Figure 3.3C). NR1H3 
encodes Liver X Receptor Alpha (LXRa), a transcription factor that binds to retinoid response elements 
along with its cofactor retinoid X receptor (RXR) and regulates lipid homeostasis144. Exon 4 encodes the 
zinc-finger binding domain needed for motif recognition, suggesting that isoforms lacking exon 4 lead to 




Colocalizations at MADD-NR1H3 locus, by trait and quantification 
 The NR1H3 splice junction is located in a gene-dense region of extensive LD on chromosome 11 
(chr11:46,720,000-47,700,000). To better understand the complex relationships between genetic variants 
at this locus, we evaluated all GWAS signals reported in this region, including extended data sets not 
included in the GWAS Catalog145. We calculated the pairwise LD between reported GWAS variants 
regardless of trait. Using this method, we identified nine distinct signals (LD r2 <0.8 between lead 
variants) for HDL-C, proinsulin, BMI, and WHRadjBMI, which we denote by the letters A-I (Table 3.5, 3.6). 
Two of these signals, rs10838686 (HDL signal C) and rs10838687 (proinsulin signal F), are in moderate 
LD with each other (r2 =0.82 in Finns and 0.77 in Europeans). We retained these signals as separate 
because they represent different traits and because Finnish LD differs from broader European LD for 
these variants. All other signals exhibit low or moderate pairwise LD between lead variants (r2<.0.7). 
Using these nine GWAS signals, we further performed colocalization analyses on the gene-level 
and identified two gene-level eQTL colocalizations in addition to the splice colocalization already 
described (Figures 3.4; Table 3.7, Table 3.4). The primary eQTL signal for NR1H3 (lead variant 
rs75393320) colocalized with HDL signal C (rs10838686; LD r2 = 0.93). The secondary eQTL signal for 
NR1H3 (lead variant rs11039149) colocalized with proinsulin GWAS signal D (rs10501320; LD r2 = 1.0). 
The sQTL signal for the lack of exon 4 of NR1H3 (lead variant rs1449626) colocalized with HDL signal C 
(rs10838686; LD r2 = 1.0). The lead variant of the splice eQTL is non-coding and is located in the 
intergenic region 3’ of NR1H3. Among the proxy variants (r2 > 0.8), none were located in the splice donor 
or acceptor site, but one is a synonymous mutation located in exon 4 of NR1H3 (rs2279238; Table 3.8; 
Figure 3.5). Xiong et al. found that exonic mutations that are not themselves disease-causing are five 
times more likely to affect splicing than other variants146, suggesting that rs2279238 may be the most 
likely variant responsible for the sQTL. Interestingly, the colocalization with HDL signal C is shared 
between the primary gene-level eQTL and the splice eQTL. This variant (rs10838686) is associated with 
increased expression of the gene and increased expression of the aberrant splice product. Taken 
together, these colocalizations, suggest a role for NR1H3 adipose expression in both HDL-cholesterol 





 We identified splice QTLs in subcutaneous adipose tissue from 426 Finnish men enrolled in the 
METSIM study. We found that 9.8% of expressed splice junctions were associated with at least one 
nearby variant. By examining the genes found to have an eQTL only on the splice or exon level, we 
identified 46 pathways that potentially affect the transcriptional program of adipose tissue. We colocalized 
these sQTLs with cardiometabolic GWAS signals and identified 104 variants associated with 132 splice 
junctions, found in 74 genes. One sQTL for a novel splice junction, which affects NR1H3, is colocalized 
with an HDL cholesterol GWAS signal, suggesting a splicing mechanism at this locus. 
 Splicing analysis found noteworthy genes, biological pathways, and novel splice junctions in 
adipose tissue. Our sQTL detection and subsequent pathway analysis of eQTL associated transcripts not 
identified on the gene-level found several pathways with links to important adipose tissue processes such 
as lipid droplet formation, inflammation, and cholesterol homeostasis. Further, we highlighted two novel 
splices (ALDH3A2 and NR1H3) with plausible mechanisms for altering the function of these genes. 
Splice-based analysis was critical to identifying these genes for potential functional testing.  
 Colocalization with sQTLs provides an opportunity to explore isoform differences at GWAS loci. In 
the same way that gene-level eQTLs can mark transcripts that are colocalized with GWAS traits, and may 
act to influence diseases and phenotypes, splice eQTLs can be used to identify transcripts that were not 
identified on the gene-level. However, sQTLs have the added benefit of potentially identifying exon 
inclusion or exclusions that are unique to specific isoforms. Since changes in isoform abundance can 
indicate the pathways at work in tissue37 and some isoform changes can lead to changes in the activity of 
the gene, these sQTLs may indicate the mechanisms by which these genes impact the GWAS trait.  
 At the MADD-NR1H3 locus, we identified a novel splice junction that removes exon 4 and 
remains in frame. This splice was colocalized with a GWAS signal for HDL-cholesterol, suggesting some 
role for this isoform in lipid traits. Exon 4 encodes the only zinc-finger binding domain of LXRa, the 
transcription factor that NR1H3 encodes. Since the transcript remains in frame, it is not likely that the 
mRNA is subject to nonsense mediated decay. The loss of this exon may render the protein unable to 
bind retinoid response elements in DNA alongside its binding partner RXR. We hypothesize that, if 
translated, the protein produced cannot fulfill its role of regulating cholesterol homeostasis. This sQTL 
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colocalized provides evidence of a potential mechanism for the effect of NR1H3 adipose expression on 
HDL levels. 
 Splicing analysis offers the opportunity to explore isoform differences based on the exclusion of 
certain exons. The analyses presented here show that splice QTLs can highlight pathways of interest in 
adipose tissue and identify potential mechanisms at colocalized cardiometabolic GWAS loci. As future 
studies explore splicing in adipose tissue, splice QTLs may help to uncover changes in the transcriptional 
program that influence human disease.   
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Figure 3.1: The number of significant splice QTLs observed per gene: A histogram of the number of 





Figure 3.2: Overlap between genes identified by eQTLs on the gene-, exon- and splice-level:  
Here, the counts of genes for which at least one variant was associated with the level of a gene, an exon 
of the gene, or a splice junction of the gene, significant at FDR <1%. This Venn Diagram shows the 


















Figure 3.3: Novel splice junction that removes exon 4 of NR1H3 (A) The gene model of NR1H3 is 
shown with exons 3-5 marked. (B) PCR product of amplification from cDNA shows the presence of both 
the 3 exon product (top) and the 2 exon product (bottom). (C) PCR product of amplification from cDNA 
shows a change in the intensity of the 2 exon product according to genotype of rs74948330, which is in 
high LD with the lead variant at this locus, rs1449626 (LD r2= 0.95). rs74948330(A) allele is correlated 
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Figure 3.4: Colocalization of multiple GWAS and eQTL signals at MADD-NR1H3:Lead variants of the 
associations for HDL cholesterol (top left), Proinsulin (top right), NR1H3 splice (bottom left), and NR1H3 
gene eQTL (bottom right) are shown as diamonds in the above LocusZoom plots; for all other variants, 
LD with the lead variant is indicated by the intensity of the color and the shape of the point plotted. 
Variants without strong association with one or more lead variants are shown in grey. HDL cholesterol 
association is plotted with data from Teslovich et al (Nature 2010); HDL signal B is shown in blue 
triangles and signal C is shown in red circles. Proinsulin association is plotted using Strawbridge et al 
(Diabetes 2011) and is shown in purple squares. The splice in NR1H3 is plotted in red circles to show its 
colocalization with HDL signal C. The gene-level eQTLs for NR1H3 are shown in red circles (primary 
eQTL, colocalized with HDL signal C) and purple squares (secondary eQTL, colocalized with proinsulin 
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Figure 3.5: Proxy variants for rs1449626 in Finns Here are the variants in high LD (r2 > 0.8) with the 
lead sQTL variant (rs1449626). This region encompasses all known isoforms of NR1H3, and specifically 
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Number of Unique 
Splice Junctions 
k10 15,814  54,037  6,056 
k20 16,703  57,980  6,077 
k30 17,133  59,241  6,074 
k40 17,370  60,486  6,030 
k50 17,524  61,170  5,943 
Table 3.1: Gene, exon, and splice eQTL discovery for PSI quantification with various PEER factors 
The number of QTL genes detected by including BMI and a number of PEER factors for gene-level, exon-






features tested  
Number of features 
significantly associated 





value (FDR 1%) 
Gene-level  25,623 17,370 68% 2.2 x 10-3  
Exon-level  160,899 60,486  38% 7.1 x 10-4 
Splice junction-
level  
61,833 6,077  10% 2.03 x 10-5. 
Table 3.2: A summary of gene-, exon-, and splice junction eQTL discovery This table shows the 
number of genes, exons, and splices tested for eQTLs and the number of these features found to have 




Table 3.3: Pathway analysis of sQTL-specific genes 
The Reactome pathway analysis of genes found only by sQTL analysis but not found in the gene- or exon-level eQTL analysis. Pathway size 
indicates the number of genes annotated with that pathway. The genes unique to each pathway from Sigora are listed (far right). Adjusted p-
values are corrected using the Bonferroni method. 
Reactome 
Pathway 





R-HSA-83936 Transport of nucleosides and free 
purine and pyrimidine bases across 
the plasma membrane 
2.05E-08 2.05E-05 62.6 ARL2BP; ARL2 
R-HSA-6807878 COPI-mediated anterograde 
transport 
6.40E-06 6.40E-03 3153.1 ARFGAP3;ARFGAP2;TUBA1B;TUBA1A 
R-HSA-3371453 Regulation of HSF1-mediated heat 
shock response 














Variant Trait Splice Splice Gene P Variant Eff 
All 
P β P LD 
r2 
rs2222543 WHRadjBMI chr7:120884392:120901686 CPED1 1.75E-19 rs10953934 A 1.75E-19 -0.60 1.00E+00 1.00 
rs211718 Metabolic 
traits 
chr1:76190502:76198329 ACADM 9.65E-17 rs138493988 C 9.37E-17 -0.61 9.98E-01 1.00 
rs1783541 T2D chr11:65307352:65307716 LTBP3 1.76E-16 rs1783541 T 1.76E-16 0.95 1.00E+00 1.00 
rs2222543 WHRadjBMI chr7:120884392:120906281 CPED1 2.73E-16 rs10953934 A 2.73E-16 0.55 1.00E+00 1.00 
rs17154889 WHRadjBMI chr5:102296933:102325976 PAM 1.37E-12 rs17154889 A 1.37E-12 -0.52 1.00E+00 1.00 
rs4883201 TC chr12:9099001:9102084 M6PR 1.90E-11 rs4883201 G 1.90E-11 -0.74 1.00E+00 1.00 
rs435306 HDL 
cholesterol 
chr20:44536543:44538581 PLTP 3.70E-11 rs378114 C 3.70E-11 -0.52 1.00E+00 1.00 
rs1783541 T2D chr11:65307624:65307716 LTBP3 1.06E-08 rs1144928 G 1.04E-08 -0.68 9.92E-01 1.00 
rs3746429 BMI chr20:33596550:33597990 TRPC4AP 1.68E-06 rs3746429 T 1.68E-06 -0.41 1.00E+00 1.00 
rs4938303 Triglycerides chr11:117090474:117093924 PCSK7 2.39E-06 rs4938303 T 2.39E-06 0.33 1.00E+00 1.00 
rs12692738 WHRadjBMI chr2:165557266:165560954 COBLL1 7.93E-06 rs12692738 C 7.93E-06 -0.37 1.00E+00 1.00 
rs6606686 BMI chr12:110874009:110874470 ARPC3 1.74E-05 rs6606686 C 1.74E-05 0.31 1.00E+00 1.00 
rs10838686 HDL-C chr11:47282226:47282792 NR1H3 2.63E-15 rs753992 A 2.56E-15 -0.56 9.97E-01 1.00 
rs10138217 HDL chr14:92516880:92524663 RP11-
529H20.6, 
ATXN3 
2.88E-41 rs910368 A 2.85E-41 0.97 1.00E+00 1.00 
rs62034325 BMI chr16:28604889:28606688 SULT1A2, 
SULT1A1 
5.31E-28 rs62034322 A 5.29E-28 0.68 1.00E+00 1.00 
rs17207196 BMI chr7:75039743:75044163 NSUN5P1 4.55E-08 rs236671 G 3.87E-08 0.40 9.76E-01 1.00 
rs757608 WHRadjBMI chr17:59479312:59480422 TBX2 6.81E-07 rs9905385 G 6.23E-07 0.37 9.82E-01 1.00 
rs314311 TC chr7:100480711:100481691 SRRT 1.09E-05 rs314316 G 1.01E-05 0.34 9.84E-01 1.00 
rs6767619 BMI chr3:156867174:156867274 CCNL1 3.53E-07 rs10451916 T 3.50E-07 -0.39 9.99E-01 1.00 
rs10838686 HDL-C chr11:47281530:47282792 NR1H3 8.34E-44 rs1449626 C 1.76E-44 0.93 9.07E-01 1.00 
rs6700838 BMI chr1:47694194:47694868 TAL1 1.40E-06 rs61782665 G 1.34E-06 0.36 9.93E-01 1.00 
rs62034325 BMI chr16:28549476:28550117 NUPR1 6.18E-18 rs4787458 G 5.71E-18 0.55 9.92E-01 1.00 





rs11220462 LDL-C chr11:126225737:126275991 ST3GAL4 1.75E-16 rs10893500 C 1.36E-16 -0.68 9.72E-01 1.00 
rs9435732 WHRadjBMI chr1:17313127:17313300 ATP13A2 3.61E-09 rs56265117 T 2.68E-09 -0.42 9.50E-01 1.00 
rs2277862 TC chr20:34130690:34135163 ERGIC3 7.00E-25 rs12625762 A 6.95E-25 -1.11 9.99E-01 1.00 
rs2277862 TC chr20:34130690:34131410 ERGIC3 3.48E-18 rs12625762 A 3.46E-18 0.95 9.99E-01 1.00 
rs2277862 TC chr20:34144519:34144744 ERGIC3 4.12E-13 rs12625762 A 4.10E-13 0.80 9.99E-01 1.00 
rs2277862 TC chr20:34144042:34144744 ERGIC3 7.29E-13 rs12625762 A 7.24E-13 -0.79 9.99E-01 1.00 
rs34312154 WHRadjBMI chr11:47288029:47289464 NR1H3 1.19E-07 rs113459934 A 1.09E-07 0.43 9.84E-01 1.00 
rs9435732 WHRadjBMI chr1:17312853:17312958 ATP13A2 1.80E-07 rs2311528 A 1.23E-07 0.38 9.46E-01 0.99 
rs3825061 WHR chr11:118952024:118952169 VPS11 2.26E-22 rs1168570 C 2.13E-22 -0.75 9.95E-01 0.99 
rs17207196 BMI chr7:75044076:75044163 NSUN5P1 2.54E-25 rs809439 A 4.85E-26 -0.71 8.17E-01 0.99 
rs62034325 BMI chr16:28603802:28604573 SULT1A2, 
SULT1A1 
6.75E-23 rs56209193 T 2.00E-23 0.62 8.75E-01 0.99 
rs17207196 BMI chr7:75042210:75044163 NSUN5P1 2.37E-39 rs794373 C 1.39E-40 0.88 7.41E-01 0.99 
rs1075901 BMI chr17:15881227:15881358 ZSWIM7 1.89E-79 rs2302415 T 1.32E-79 -1.07 9.77E-01 0.99 
rs1075901 BMI chr17:15880406:15880893 ZSWIM7 7.51E-60 rs2302415 T 6.80E-60 0.97 9.87E-01 0.99 
rs1075901 BMI chr17:15881014:15881114 ZSWIM7 4.95E-38 rs2302415 T 3.33E-38 0.81 9.75E-01 0.99 
rs9905991 BMI chr17:80052063:80053196 FASN 9.46E-28 rs62078747 G 2.01E-28 -0.72 8.72E-01 0.99 
rs9905991 BMI chr17:80051647:80053196 FASN 9.46E-28 rs62078747 G 2.01E-28 0.72 8.72E-01 0.99 
rs1308362 BMI chr3:138091918:138116166 MRAS 1.10E-07 rs166195 C 4.00E-08 0.44 8.28E-01 0.99 
rs7479183 WHRadjBMI chr11:802396:802543 PIDD 2.50E-15 rs11246314 A 8.97E-16 0.55 8.53E-01 0.99 
rs8070454 BMI chr17:38184199:38185079 MED24 8.99E-06 rs3826331 C 5.14E-06 -0.31 8.89E-01 0.99 
rs2291542 WHR chr3:49738142:49738924 RNF123 2.27E-09 rs2276864 C 1.34E-09 -0.47 9.07E-01 0.99 
rs62034325 BMI chr16:28606996:28607104 SULT1A2, 
SULT1A1 
2.19E-82 rs743590 A 6.44E-85 1.05 7.32E-01 0.99 
rs1997243 TC chr7:1095119:1095740 GPR146 2.48E-12 rs117800627 C 1.97E-12 0.72 9.32E-01 0.99 
rs35576166 WHRadjBMI chr12:124144629:124144713 GTF2H3 1.83E-05 rs4759370 A 1.79E-05 -0.58 9.95E-01 0.99 
rs10838686 HDL-C chr11:47281530:47281960 NR1H3 1.26E-14 rs4647725 C 4.60E-15 -0.56 8.07E-01 0.99 
rs10138217 HDL chr14:92530758:92537279 RP11-
529H20.6, 
ATXN3 








chr16:15138264:15141299 NTAN1 2.15E-15 rs3803573 T 3.66E-16 -0.56 8.10E-01 0.99 
rs12024554 WHR chr1:19943830:19948594 MINOS1-NBL1 
,MINOS1 
2.38E-06 rs10429880 A 6.87E-07 -0.40 7.86E-01 0.99 
rs78429050 HDL chr3:122135097:122139833 RP11-299J3.8 1.81E-13 rs9843165 C 1.23E-13 -0.72 9.00E-01 0.98 
rs1057452 BMI chr16:29845387:29847025 MVP 1.71E-12 rs12932691 A 1.55E-12 -0.75 9.52E-01 0.98 
rs1057452 BMI chr16:29845758:29847025 MVP 1.71E-12 rs12932691 A 1.55E-12 0.75 9.52E-01 0.98 
rs17154889 WHRadjBMI chr5:102310140:102325976 PAM 1.20E-08 rs12659870 C 3.64E-09 0.43 8.17E-01 0.98 
rs17145738 Triglycerides chr7:73010299:73010483 MLXIPL 3.22E-15 rs13244268 C 2.11E-15 -0.81 9.45E-01 0.98 
rs17145738 Triglycerides chr7:73010245:73010483 MLXIPL 1.15E-13 rs13244268 C 7.13E-14 0.77 9.39E-01 0.98 
rs1075901 BMI chr17:15897092:15902833 ZSWIM7 3.27E-06 rs2779207 A 2.82E-06 -0.32 9.65E-01 0.98 
rs2814992 BMI chr6:34664774:34664936 RP11-140K17.3 5.87E-06 rs4513788 T 2.17E-06 0.34 7.91E-01 0.98 
rs10138217 HDL chr14:92516158:92516685 RP11-
529H20.6, 
ATXN3 
1.31E-37 rs58339937 C 1.24E-38 0.93 6.86E-01 0.97 
rs10138217 HDL chr14:92514433:92515947 RP11-529H20.6 4.16E-13 rs58339937 C 1.01E-13 -0.57 7.46E-01 0.97 
rs905938 WHRadjBMI chr1:154938993:154940147 SHC1 3.73E-06 rs1870940 A 1.73E-06 -0.38 8.00E-01 0.97 
rs3803042 WHRadjBMI chr12:54393051:54393493 HOXC-AS1 1.66E-05 rs11614913 T 6.28E-06 -0.30 8.09E-01 0.97 
rs7222 WHR chr12:2055452:2058252 DCP1B 2.04E-19 rs1860047 A 9.12E-20 0.59 8.10E-01 0.97 
rs4969387 BMI chr17:79084759:79089570 BAIAP2 8.20E-08 rs4072589 A 4.46E-08 0.39 8.90E-01 0.97 
rs1019503 2hGlu chr5:96245468:96248341 ERAP2 2.15E-12 rs2617434 G 5.45E-13 0.50 7.77E-01 0.97 
rs10176176 Myocardial 
infarction 
chr2:85806290:85808934 VAMP8 4.52E-10 rs6705839 T 1.32E-10 0.44 7.70E-01 0.97 








chr11:61557462:61557847 TMEM258 9.58E-08 rs174592 G 5.14E-08 0.37 8.27E-01 0.96 
rs2814992 BMI chr6:34725328:34730372 SNRPC 4.01E-27 rs1201874 C 1.56E-27 -0.73 6.26E-01 0.95 
rs4969387 BMI chr17:79082309:79089570 BAIAP2 1.57E-08 rs4969248 T 1.04E-08 -0.41 8.83E-01 0.95 





rs62034325 BMI chr16:28603764:28606688 SULT1A2, 
SULT1A1 
2.35E-18 rs149271 G 4.49E-20 0.58 5.17E-01 0.94 
rs62034325 BMI chr16:28604667:28604763 SULT1A2, 
SULT1A1 
2.86E-07 rs149271 G 4.15E-09 0.38 3.86E-01 0.94 
rs62034325 BMI chr16:28620180:28621252 SULT1A2, 
SULT1A1 
4.45E-11 rs56272201 G 1.57E-11 0.43 6.91E-01 0.94 
rs1048775 BMI chr17:79213743:79214787 C17orf89 2.20E-72 rs2255166 C 5.11E-77 -1.10 3.44E-01 0.94 
rs1048775 BMI chr17:79213478:79214787 C17orf89 1.85E-53 rs2255166 C 7.13E-59 1.00 3.16E-01 0.94 
rs7187776 BMI chr16:28846720:28846870 ATXN2L 2.26E-58 rs11863370 G 4.72E-63 0.97 2.81E-01 0.93 
rs7187776 BMI chr16:28846720:28846867 ATXN2L 7.66E-58 rs11863370 G 9.22E-63 -0.96 2.75E-01 0.93 
rs9931407 BMI chr16:67264694:67265333 FHOD1 6.56E-14 rs72798032 A 1.14E-14 0.81 4.82E-01 0.93 
rs8396 Metabolic 
traits 
chr4:159620282:159624575 ETFDH 2.03E-22 rs17843919 G 4.82E-23 -0.76 6.34E-01 0.93 
rs62034325 BMI chr16:28606785:28606871 SULT1A2, 
SULT1A1 
4.99E-21 rs28698667 T 1.62E-23 0.62 4.38E-01 0.93 
rs10176176 Myocardial 
infarction 
chr2:85806290:85808699 VAMP8 6.56E-16 rs2366639 G 1.48E-16 -0.55 5.21E-01 0.93 
rs12631248 BMI chr3:49722815:49722904 MST1 1.88E-05 rs75729494 A 2.69E-06 -0.70 6.25E-01 0.93 
rs3783347 FGlu chr14:100835595:100841620 WARS 1.56E-18 rs4905957 T 7.64E-19 0.75 6.28E-01 0.93 
rs10838686 HDL-C chr11:47279680:47281342 NR1H3 1.08E-21 rs11039155 A 1.27E-23 0.70 4.13E-01 0.92 
rs10105606 Triglycerides chr8:19777483:19824493 UNKNOWN 1.60E-27 rs13702 C 1.28E-30 0.80 2.99E-01 0.92 
rs1019503 2hGlu chr5:96235893:96237210 ERAP2 2.15E-14 rs2927608 A 2.24E-15 0.55 7.17E-01 0.92 
rs1019503 2hGlu chr5:96232567:96235825 ERAP2 8.39E-13 rs2927608 A 1.41E-14 0.53 4.92E-01 0.92 
rs1019503 2hGlu chr5:96232208:96232436 ERAP2 3.56E-10 rs2927608 A 8.53E-11 0.45 6.94E-01 0.92 
rs1019503 2hGlu chr5:96238057:96239081 ERAP2 5.83E-07 rs2927608 A 1.04E-08 0.40 2.96E-01 0.92 
rs1019503 2hGlu chr5:96237385:96237978 ERAP2 7.97E-07 rs2927608 A 5.20E-07 0.35 7.09E-01 0.92 
rs7479183 WHRadjBMI chr11:778218:783530 AP006621.5 5.49E-20 rs28633403 A 8.91E-23 -0.66 3.06E-01 0.92 
rs62034325 BMI chr16:28619924:28620029 SULT1A2, 
SULT1A1 
1.85E-78 rs11074907 G 1.29E-81 -1.04 3.45E-01 0.92 
rs114031082 WHR chr6:31237862:31237987 HLA-C,HLA-B 3.08E-37 rs115114271 C 2.19E-42 -0.94 2.32E-01 0.91 
rs1105881 WHRadjBMI chr15:42134789:42135874 JMJD7-
PLA2G4B, 
PLA2G4B 
9.22E-14 rs4924580 A 5.85E-15 -0.52 4.92E-01 0.91 
rs6738445 BMI chr2:172586363:172600559 DYNC1I2 4.03E-18 rs12692973 T 2.84E-20 -0.70 1.62E-01 0.91 





rs11715915 FGlu chr3:49721622:49721747 MST1 6.90E-49 rs9858213 T 1.04E-58 -0.96 2.70E-02 0.90 
rs211718 Metabolic 
traits 
chr1:76216231:76226807 ACADM 1.85E-05 rs1251075 G 8.54E-06 0.33 6.67E-01 0.89 
rs62034325 BMI chr16:28726755:28734485 EIF3C 1.44E-17 rs378421 A 6.03E-21 0.59 2.46E-01 0.88 
rs62034325 BMI chr16:28732353:28734485 EIF3C 5.31E-12 rs378421 A 1.65E-14 -0.49 2.77E-01 0.88 
rs62034325 BMI chr16:28617557:28618082 SULT1A2, 
SULT1A1 
8.66E-92 rs3176926 G 1.46E-95 -1.10 9.90E-02 0.88 
rs62034325 BMI chr16:28603764:28604573 SULT1A2, 
SULT1A1 
1.05E-85 rs3176926 G 8.02E-91 1.08 9.95E-02 0.88 
rs9435732 WHRadjBMI chr1:17301518:17301764 MFAP2 3.19E-06 rs55779591 T 8.83E-08 -0.38 3.30E-01 0.87 
rs3814883 BMI chr16:30012361:30012735 INO80E 2.17E-12 rs4787491 G 7.32E-15 0.51 2.48E-01 0.87 
rs3814883 BMI chr16:30014847:30014971 INO80E 8.46E-10 rs4787491 G 1.87E-10 -0.43 5.51E-01 0.87 
rs3814883 BMI chr16:30014991:30015889 INO80E 1.66E-09 rs4787491 G 1.47E-12 -0.47 1.73E-01 0.87 
rs3814883 BMI chr16:30015978:30016542 INO80E 3.55E-09 rs4787491 G 5.56E-12 -0.46 1.99E-01 0.87 
rs3814883 BMI chr16:30012851:30016542 INO80E 5.44E-09 rs4787491 G 2.47E-11 0.45 2.66E-01 0.87 
rs3814883 BMI chr16:30015978:30016071 INO80E 1.00E-06 rs4787491 G 2.92E-08 -0.37 3.46E-01 0.87 
rs524281 BMI chr11:66052437:66053172 YIF1A 3.04E-15 rs7951079 T 9.68E-17 0.66 3.50E-01 0.87 
rs1105881 WHRadjBMI chr15:42135421:42135874 JMJD7-
PLA2G4B, 
PLA2G4B 
3.70E-17 rs9672671 T 4.53E-21 0.63 1.20E-01 0.87 
rs17826219 BMI chr17:29226624:29227431 TEFM 7.08E-06 rs55811708 T 8.40E-07 -0.66 4.02E-01 0.86 
rs4329 Metabolic 
traits 
chr17:61574346:61574498 ACE 7.66E-08 rs4968651 T 9.77E-09 0.40 7.76E-01 0.85 
chr6:32448398 WHRadjBMI chr6:32548633:32549334 HLA-DRB5, 
HLA-DRB1 
7.90E-43 chr6:32448561 G 1.85E-50 -0.98 3.82E-02 0.84 
chr6:32448398 WHRadjBMI chr6:32548047:32548523 HLA-DRB5, 
HLA-DRB1 
3.26E-40 chr6:32448561 G 6.77E-46 0.95 6.68E-02 0.84 
rs709400 BMI chr14:104040507:104053611 RP11-73M18.2, 
APOPT1 
3.35E-14 rs28513222 T 1.36E-17 -0.59 1.19E-01 0.84 
rs2034088 HIPadjBMI chr17:424978:436082 VPS53 2.06E-11 rs2289620 C 3.81E-14 0.51 1.11E-01 0.83 
rs9905991 BMI chr17:80115824:80121076 CCDC57 2.18E-08 rs4789678 T 1.60E-11 0.45 5.54E-02 0.83 
rs386000 HDL-C chr19:54802229:54802483 LILRB5, 
LILRB2, 
LILRA3 
7.16E-16 rs434124 G 2.49E-18 -0.64 1.96E-01 0.83 
rs7479183 WHRadjBMI chr11:780381:783530 AP006621.5 2.85E-24 rs7104929 G 5.62E-31 0.74 1.44E-02 0.83 





rs2034088 HIPadjBMI chr17:424978:425234 VPS53 1.27E-10 rs4968124 C 4.99E-14 -0.51 6.83E-02 0.82 
rs672356 WHRadjBMI chr17:18236602:18243357 SHMT1 1.52E-47 rs2273028 A 2.66E-71 -1.11 2.09E-06 0.81 
rs672356 WHRadjBMI chr17:18236602:18238873 SHMT1 9.16E-23 rs3794772 T 8.65E-31 0.79 4.93E-03 0.81 
rs7795371 WHRadjBMI chr7:77313568:77314519 RSBN1L-AS1 5.51E-13 rs34160426 C 2.61E-15 -0.52 1.95E-01 0.80 
rs672356 WHRadjBMI chr17:18238989:18243357 SHMT1 1.20E-18 rs12946058 T 6.00E-26 0.73 5.26E-03 0.80 
rs672356 WHRadjBMI chr17:18233985:18243357 SHMT1 3.14E-14 rs12946058 T 1.68E-17 -0.61 6.57E-02 0.80 
rs3772071 T2D chr2:161114557:161126713 ITGB6 1.69E-10 rs764729 C 1.70E-13 -0.67 3.58E-02 0.80 
rs12631248 BMI chr3:49722317:49722445 MST1 4.02E-06 rs62260813 G 1.28E-06 0.74 4.95E-01 0.80 
rs4307732 LDL 
cholesterol 
chr11:126225737:126275991 ST3GAL4 3.67E-13 rs10893500 C 1.36E-16 -0.68 7.72E-02 0.80 
Table 3.4: sQTL colocalizations with cardiometabolic traits This table shows the results of the LD and conditional analysis method that met 
the criteria for colocalization (LD r2 > 0.8 and PcondonGWAS > 2.03 ´ 10-5). LD r2 for this table was calculated using 10K Finnish men from the wider 
METSIM study imputed to HRC. The allele corresponding to the effect size (b) of the sQTL is shown in the “Eff All” column. Abbreviations include 







Table:3.5: Distinct GWAS signals around the MADD-NR1H3 locus A summary of the cardiometabolic GWAS signals in the MADD-NR1H3 




rsID-allele Locus Name or 
Nearest Gene 
MAF GWAS          
P-value 
GWAS β GWAS trait GWAS publication 
A rs3136441-T F2 0.12 2.00E-08 -0.03 HDL-C Hoffmann 2018 
B rs10838692-T MADD 0.31 6.00E-20 -0.03 HDL-C Hoffmann 2018 
C rs10838686-T MADD 0.17 1.00E-22 -0.04 HDL-C Hoffmann 2018 
D rs10501320-G  MADD 0.28 1.10E-88 0.08 proinsulin Strawbridge 2011 
E rs35233100-T MADD 0.04 8.00E-15 -0.10 proinsulin Huyghe 2013 
F rs10838687-T  MADD 0.20 7.00E-12 0.03 proinsulin Strawbridge 2011 
G rs11039014-A MTCH2 0.23 3.28E-12 0.02 BMI Yengo 2018 
H rs7124681-A MTCH2 0.41 2.61E-87 0.04 BMI Yengo 2018 














Table 3.6: Pairwise LD between nine GWAS signals in the MADD-NR1H3 region  Pairwise LD between the cardiometabolic GWAS variants in 
the MADD-NR1H3 region was calculated using Finnish LD in 1000G, phase 3 data. The numbers below the diagonal are the pairwise LD r2 
between the variants, and those above the diagonal are the pairwise D’ values. 
 
 
HDL-C HDL-C HDL-C proinsulin proinsulin proinsulin BMI BMI WHRadjBMI  
rs3136441 rs10838692 rs10838686 rs10501320 rs35233100 rs10838687 rs11039014 rs7124681 rs34312154  
A B C D E F G H I 
A 
 
0.92 0.93 0.71 1.00 0.93 1.00 0.88 0.81 
B 0.33 
 
1.00 1.00 1.00 1.00 0.35 0.81 0.90 
C 0.59 0.58 
 
1.00 1.00 1.00 0.57 0.82 0.91 
D 0.03 0.13 0.08 
 
1.00 1.00 0.63 0.40 0.88 
E 0.01 0.02 0.01 0.13 
 
1.00 0.38 0.51 1.00 
F 0.48 0.70 0.82 0.09 0.01 
 
0.44 0.76 0.91 
G 0.55 0.09 0.26 0.04 0.00 0.19 
 
0.91 0.60 
H 0.14 0.30 0.18 0.02 0.00 0.18 0.57 
 
1.00 






Table 3.7: Gene-level colocalizations at NR1H3 This table includes the conditional analysis of two significant eQTLs at NR1H3, which are the 
primary and secondary gene-level signals. The initial association between the GWAS variant and NR1H3 is shown, followed by the association of 
the lead eQTL variant before and after conditioning on the GWAS variant. LD r2 was calculated in 10K Finnish males from the larger METSIM 
study.  
 












P β P β LD r2 
rs10838686 HDL-C NR1H3 4.58E-25 0.72 rs75393320 Primary 2.80E-29 0.78 2.19E-01 0.09 0.93 






rsID chr:pos Alleles MAF R2 Correlated_Alleles RegulomeDB Function 
rs1449626 chr11:47290759 (A/C) 0.28 1.00 A=A,C=C 4 
 
rs59567949 chr11:47300155 (G/A) 0.28 1.00 A=G,C=A 5 
 
rs4752977 chr11:47300429 (T/C) 0.28 1.00 A=T,C=C 6 
 
rs10838685 chr11:47305176 (G/A) 0.28 1.00 A=G,C=A 7 
 
rs1051006 chr11:47306585 (G/A) 0.28 1.00 A=G,C=A 1f miss 
rs10838686 chr11:47311367 (G/T) 0.28 1.00 A=G,C=T 2b 
 
rs58023804 chr11:47312374 (A/G) 0.28 1.00 A=A,C=G 5 
 
rs5791755 chr11:47317625 (AAAAG/-) 0.28 1.00 A=AAAAG,C=- . 
 
rs11493249 chr11:47323821 (G/C) 0.28 1.00 A=G,C=C 6 
 
rs4752978 chr11:47324862 (G/A) 0.28 1.00 A=G,C=A 5 
 
rs74236439 chr11:47333786 (T/G) 0.28 1.00 A=T,C=G 6 
 
rs10838689 chr11:47334524 (G/A) 0.28 1.00 A=G,C=A 1f 
 
rs2290148 chr11:47346145 (G/A) 0.28 1.00 A=G,C=A 1f 
 
rs7124958 chr11:47347260 (C/T) 0.28 1.00 A=C,C=T 1f 
 
rs11341424 chr11:47347688 (G/-) 0.28 1.00 A=G,C=- 5 
 
rs753992 chr11:47349846 (G/A) 0.28 1.00 A=G,C=A 1f 
 
rs11570124 chr11:47352082 (CT/-) 0.28 1.00 A=CT,C=- . 
 
rs4752983 chr11:47352138 (C/T) 0.28 1.00 A=C,C=T 1b 
 
rs3729805 chr11:47352757 (C/T) 0.28 1.00 A=C,C=T 6 
 
rs3729804 chr11:47352862 (G/A) 0.28 1.00 A=G,C=A 5 
 
rs2290146 chr11:47353498 (G/A) 0.28 1.00 A=G,C=A 2b 
 
rs3729802 chr11:47354068 (G/A) 0.28 1.00 A=G,C=A 4 
 
rs2254240 chr11:47357170 (G/A) 0.28 1.00 A=G,C=A 7 
 
rs11039189 chr11:47358035 (C/T) 0.28 1.00 A=C,C=T 6 
 






rs10769253 chr11:47362339 (G/A) 0.28 1.00 A=G,C=A 1f 
 
rs10769255 chr11:47367371 (C/T) 0.28 1.00 A=C,C=T 1f 
 
rs113681661 chr11:47289065 (-/T) 0.28 0.95 A=-,C=T . 
 
rs12574081 chr11:47286414 (G/A) 0.28 0.95 A=G,C=A 3a 
 
rs77532017 chr11:47284317 (C/T) 0.28 0.95 A=C,C=T 6 
 
rs6144337 chr11:47284302 (CCATGTGCCTCA/-) 0.28 0.95 A=CCATGTGCCTCA,C=- . 
 
rs2279238 chr11:47282024 (C/T) 0.28 0.95 A=C,C=T 6 syn 
rs11039148 chr11:47274126 (T/A) 0.28 0.95 A=T,C=A 6 
 
rs3758670 chr11:47272665 (G/A) 0.28 0.95 A=G,C=A 7 
 
rs16938581 chr11:47271039 (G/A) 0.28 0.95 A=G,C=A 2b 
 
rs7118396 chr11:47269936 (C/T) 0.28 0.95 A=C,C=T 1b 
 
rs2242261 chr11:47266808 (T/G) 0.28 0.95 A=T,C=G 1f 
 
rs2242262 chr11:47266540 (G/T) 0.28 0.95 A=G,C=T 1f 
 
rs74948330 chr11:47265745 (C/A) 0.28 0.95 A=C,C=A 7 
 
rs7120158 chr11:47265194 (G/C) 0.28 0.95 A=G,C=C 1b 
 
rs11039144 chr11:47264044 (G/A) 0.28 0.95 A=G,C=A 4 
 
rs4752972 chr11:47263060 (C/T) 0.28 0.95 A=C,C=T 6 
 
rs7933246 chr11:47262648 (G/C) 0.28 0.95 A=G,C=C 4 
 
rs3781620 chr11:47259264 (G/C) 0.28 0.95 A=G,C=C 6 
 
rs3824866 chr11:47258853 (C/T) 0.28 0.95 A=C,C=T 1f 
 
rs4647754 chr11:47257340 (C/T) 0.28 0.95 A=C,C=T 5 
 
rs3781619 chr11:47255317 (G/A) 0.28 0.95 A=G,C=A 1f 
 
rs830083 chr11:47254051 (G/C) 0.28 0.95 A=C,C=G 6 
 
rs4647741 chr11:47254010 (T/C) 0.28 0.95 A=T,C=C 7 
 
rs4647737 chr11:47253244 (T/G) 0.28 0.95 A=T,C=G 6 
 
rs830084 chr11:47251652 (T/C) 0.28 0.95 A=C,C=T 6 
 






rs2633083 chr11:47249420 (T/C) 0.28 0.95 A=C,C=T 7 
 
rs2633080 chr11:47247560 (A/C) 0.28 0.95 A=C,C=A 5 
 
rs76832686 chr11:47247287 (C/T) 0.28 0.95 A=C,C=T 2b 
 
rs7395496 chr11:47245803 (A/G) 0.28 0.95 A=G,C=A 6 
 
rs4647726 chr11:47245494 (A/T) 0.28 0.95 A=A,C=T 6 
 
rs4647725 chr11:47245389 (T/C) 0.28 0.95 A=T,C=C 6 
 
rs10769254 chr11:47362465 (G/C) 0.29 0.93 A=G,C=C 1f 
 
rs2306353 chr11:47256708 (C/T) 0.28 0.93 A=C,C=T 2b 
 
rs11039155 chr11:47280762 (G/A) 0.26 0.93 A=G,C=A 4 
 
rs75393320 chr11:47266471 (G/C) 0.26 0.93 A=G,C=C 5 
 
rs326224 chr11:47255598 (T/C) 0.27 0.90 A=C,C=T 4 
 
rs59002769 chr11:47278205 (-/A) 0.26 0.88 A=-,C=A . 
 
rs11305920 chr11:47339325 (T/-) 0.31 0.84 A=T,C=- . 
 
rs10838687 chr11:47312892 (T/G) 0.32 0.82 A=T,C=G 1b 
 
rs11530166 chr11:47321966 (C/T) 0.32 0.82 A=C,C=T 6 
 
rs60562402 chr11:47322007 (G/-) 0.32 0.82 A=G,C=- . 
 
rs6485751 chr11:47336442 (G/C) 0.32 0.82 A=G,C=C 6 
 
rs4752979 chr11:47339180 (A/G) 0.32 0.82 A=A,C=G 1a 
 
rs753993 chr11:47349969 (C/A) 0.32 0.82 A=C,C=A 1f 
 
Table 3.8: Proxy variants for the lead sQTL variant at NR1H3 (rs1449626): This table shows the proxy variants for rs1449626 in Finns (r2>0.8). 





CHAPTER 4: DISCUSSION 
 One of the main challenges in the genetic analysis of complex traits is identifying the target genes 
affected by variants, especially noncoding variants, detected by genetic association studies. In this 
dissertation, I address this challenge for cardiometabolic traits through use of genotypes, adipose gene 
expression data, and clinical traits measurements from the same individuals. After discovering and 
addressing cell-type heterogeneity in adipose tissue, I investigated two types of molecular mechanisms 
through which variants may affect genes and explored statistical approaches to colocalization with GWAS 
signals and association with clinical traits. 
In previous chapters, I have described the analysis of subcutaneous adipose tissue expression 
levels from 434 Finnish men from the METSIM cohort. In Chapter 2, I first examined the distinctions 
between primary and secondary cis-eQTLs, showing that primary eQTLs are nearer to transcription start 
sites of genes and are more enriched in both promoters and enhancers than secondary eQTLs. I then 
described the results of colocalization between adipose eQTLs and cardiometabolic GWAS signals, 
including the identification of 318 candidate genes. When I examined these eQTLs to determine whether 
gene expression was more commonly increased or decreased when associated with stronger 
cardiometabolic risk in GWAS, I found that gene expression was decreased with risk approximately 53% 
of the time, but that the strongest eQTLs by significance level were gene expression lowering. I identified 
49 associations between genes and clinical traits measured within the same samples and evidence of six 
genes mediating the relationship between variant and trait at GWAS loci. In Chapter 3, I compared sQTL 
discovery with that of gene and exon-level eQTLs, and found expression differences that indicate the 
activity of pathways related to lipid homeostasis and inflammation. I identified 104 variants associated 
with 132 splice junctions in 74 genes as colocalized with cardiometabolic GWAS signals. At the complex 
MADD-NR1H3 locus, I described a novel splice junction that removes the zinc-finger domain of NR1H3, 
potentially rendering it incapable of binding DNA, suggesting a specific mechanism underlying a variant 




One challenge I addressed through this work is the unexpectedly high cell-type heterogeneity of 
adipose tissue samples collected by needle biopsy. When compared with tissue from GTEx, some of the 
samples contained a high proportion of whole blood-like expression. Initially, I attempted to diminish the 
effect of this variation by using high numbers of covariates from PEER (k > 100), but found that this was 
insufficient to address the problem of expression level differences between tissues. When I removed 
samples with a high percentage of blood-like expression (>50%), the cis-eQTLs identified were more 
numerous, stronger, and matched known adipose eQTLs better with a lower number of covariates 
included in the model. In the future, studies may address differences in cell-type by using single-cell 
sequencing to identify expression profiles for the many cell types native to adipose tissue. These data 
may then be used to more cleanly identify eQTLs for the tissue at large, and for specific cell-types within, 
such as infiltrating macrophages.  
As GWAS studies continue to increase in sample size, many more loci, some with multiple 
distinct signals, are reported to be associated with clinical traits and diseases. However, the genes and 
mechanisms at hundreds of these signals remain unknown. One of several approaches to identifying the 
genes that may influence trait risk at GWAS loci is colocalization with eQTLs in tissues relevant to clinical 
traits and disease16,126,127. The utility of eQTLs to associate genes with GWAS loci originates from the 
hypothesis that variants are unlikely to be associated with GWAS trait risk and functionally impact 
expression of nearby genes by chance. However, it is not sufficient to simply verify that the GWAS variant 
is associated with the expression of a gene. The GWAS variant may be significantly associated with the 
eQTL gene due to moderate LD with the lead eQTL variant and still not be among the variants with the 
most significant effects on gene expression. Colocalization methods formally test for evidence that the 
GWAS and eQTL signals are part of the same association. These analyses offer the opportunity to 
identify the gene or genes associated with multiple GWAS signals by using conditional eQTLs and to 
identify potential mechanisms based on the inclusion or exclusion of different exons via sQTL analysis.  
There are a number of potential obstacles to successful colocalization analyses. One difficulty is 
the differences in LD patterns across populations. Even within Europeans, allele frequencies differ 
between countries. The linkage patterns between our eQTL data in Finns and broader European or even 
cross-ancestry meta-analysis can differ substantially, but the eQTL population LD has been shown to 
 
 149 
impact the colocalization more than that of the GWAS data133. One potential explanation for this is that 
most GWAS studies are meta-analyses with differences in sample size between variants, whereas most 
eQTL studies are conducted within one study population, causing LD estimation to be comparatively 
cleaner. Another barrier to colocalization analyses is the presence of multiple signals, either in the GWAS 
data or the eQTL data or both. Many colocalization methods are not equipped to detect multiple signals65. 
Using conditional analysis in primary data or joint conditional analysis methods like GCTA17 can separate 
these signals to better assess the distinct association signals.  
Colocalization has been a very active area in methods development for several years. Some 
methods, such as conditional analysis and RTC67, require access to primary data for either the eQTL 
data, the GWAS data. The LD and conditional analysis method determines whether signals are 
colocalized using the LD between the lead variants from the GWAS and eQTL data and the significance 
of remaining association of the lead eQTL variant after conditioning on the lead GWAS variant. This 
method is sensitive to the identification of the lead variants in the GWAS and the eQTL study, which can 
vary according to allele frequency and sample size133. The RTC method assesses the change in 
significance of the eQTL after including the GWAS SNP in the model, accounting for LD using 
recombination hotspots67.  
Because it is not always possible to obtain the primary data or conduct conditional analysis, 
especially when the GWAS data are from a large-scale meta-analysis, several methods have been 
developed to conduct colocalization analysis using only summary data65,66,68–70. COLOC is a method that 
uses summary statistics to test five hypotheses, of which the most important for colocalization are 
(Hypothesis 3) that the eQTL and GWAS signals both exist, but are not colocalized and (Hypothesis 4) 
that both signals exist and are colocalized. COLOC has been shown to be sensitive the initial Bayesian 
priors72 and the authors note that COLOC is not designed for the presence of multiple signals in either the 
GWAS or the eQTL data66. eCAVIAR is a Bayesian method that attempts to find the causal variant(s) 
shared between GWAS and eQTL summary statistics, which can reportedly detect up to six signals at a 
given locus; however, the model assumes that the casual variant will not be in high LD with a block of 
variants with similar p-value65, which may not reflect the linkage patterns of complex loci. All of these 
methods are sensitive to the thresholds or priors that are used.  
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Due to the ever-growing catalogue of GWAS signals and the expanding set of tissues assayed for 
eQTLs, colocalization method and analyses will continue to make important contributions to identifying 
candidate genes for functional testing and potentially pharmaceutical intervention. When primary data is 
accessible, assessment of LD between the eQTL and GWAS variants and conditional analysis provides 
very strong evidence of colocalization. This method fast to implement and provides a clear way to 
wrangle multiple signals in both the GWAS and eQTL data. When only summary statistics are available, 
COLOC using GCTA-conditioned statistics provides the best chance of success in teasing out the often-
complex relationships between variants at loci with multiple identified signals147.  
Chapters 2 and 3 focus on eQTLs for different aspects of adipose expression data. Notably, I 
found fewer sQTLs than gene-level eQTLs and consequently, fewer colocalizations with GWAS signals. 
While it is possible that fewer of these types of regulations exist on the splicing-level compared with the 
promoter and enhancer level, the change in observed eQTLs could be explained by differences in power 
to detect expression changes. Due to the use of only reads which span splice junctions between exons, 
the number of available reads in the splice analysis is greatly reduced compared with the gene-level, 
resulting in a large difference in power. With greater sample size or greater sequencing depth, it is likely 
that more sQTLs would be detected and proportionally more sQTL-GWAS colocalizations would be 
discovered.  
The analyses presented in this dissertation have limitations. Associations are not necessarily 
causal. I attempted to address this in chapter 2 through use of mediation analyses, which test for the 
effect of a genetic variant through gene expression on clinical traits. Mediation analyses are a more direct 
test of the influence of gene expression on traits, and provide further support for the role of colocalized 
genes in changes in clinical trait values. These analyses were valuable to include, but will benefit in the 
future from increased sample size. Another potential limitation is that eQTLs might not always point to a 
true target gene. Since enhancers can be shared among multiple genes in a region, eQTL variants that 
fall in enhancers may affect multiple genes, which does not necessarily implicate all of these genes in the 
colocalization. It is also important to consider other factors at multi-gene loci, such as the biological 
functions of those genes, if known, and any evidence of mediation. Future methods development and 
improved understanding of mediation will allow for wider usage of this method to support colocalization 
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efforts in implicating genes in GWAS traits. Strategies for interpretation of biological function and 
annotation of eQTL variants by additional methods, such as open chromatin, will enable eQTL data to be 
most useful for interpretation of genetic studies. 
 As eQTL studies swell in sample size, both primary and conditional signals will grow more 
numerous and potentially lead to more complete annotation of candidate genes and mechanisms at 
GWAS signals through colocalization. Additionally, eQTL studies in more diverse ancestry groups will 
prove invaluable to connect genes with GWAS signals that are rare or non-existent in European ancestry 
data. Integration of multiple -omics strategies, such as open chromatin and chromatin conformation 
capture, will enhance the utility of eQTLs further by narrowing the candidate functional variants. In the 
future, eQTL studies will continue to provide evidence for association between genes and GWAS signals 
across many tissues and many disease states, prioritizing candidates for functional study and potentially, 
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